dacarbazine profile

Dacarbazine, also known as DTIC, is an alkylating agent used in the treatment of certain types of cancer, including Hodgkin's lymphoma, melanoma, and soft tissue sarcoma. Its synthesis involves the reaction of 5-aminoimidazole-4-carboxamide with 1-methyl-1-nitrosourea. Dacarbazine exerts its anti-cancer effects by inhibiting DNA synthesis and repair, leading to cell death. The compound is studied extensively due to its effectiveness in treating various cancers and its unique mechanism of action, which differs from other chemotherapy drugs. Its importance lies in its role as a valuable treatment option for patients with certain types of cancer, offering a chance for remission or extended survival.'

(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	135398738
CHEMBL ID	476
CHEBI ID	177836
CHEBI ID	94587
SCHEMBL ID	1014331
SCHEMBL ID	5561
SCHEMBL ID	5560
MeSH ID	M0005636
PubMed CID	2942
CHEMBL ID	1574179
CHEBI ID	4305

Synonym
4-[(e)-dimethylaminodiazenyl]-1h-imidazole-5-carboxamide
CHEBI:177836
(e)-dacarbazine
BRD-K35520305-001-07-8
imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-
nsc-45388
NSC45388 ,
4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide
dtie
5-(3,3-dimethyltriazeno)imidazole-4-carboxamide
5-(dimethyltriazeno)imidazole-4-carboxamide
5-(dimethyltriazeno)imidazole-4-carboximide
dimethyltriazenoimidazolecarboxamide
4-(or 5)-(3,3-dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
carboxamide,3-dimethyl-1-triazeno)imidazole-4-
icdmt
deticene
dtic-dome
nci-c04717
dtic
imidazole-4-carboxamide,3-dimethyl-1-triazeno)-
(dimethyltriazeno)imidazolecarboxamide
4-(dimethyltriazeno)imidazole-5-carboxamide
imidazole-4(or 5)-carboxamide,3-dimethyl-1-triazeno)-
di-me-triazenoimidazolecarboxamide
4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide
4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide
1h-imidazole-4-carboxamide,3-dimethyl-1-triazenyl)-
5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide
icdt
nsc 45388
wln: t5m cnj dvz enunn1&1
dacarbazinum
dacarbazina
hsdb 3219
5-(3,3-dimethyltriaz-1-en-1-yl)-1h-imidazole-4-carboxamide
biocarbazine r
ai3-52825
dacarbazinum [inn-latin]
ccris 190
4(5)-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide
dimethyl triazeno imidazole carboxamide
1h-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-
dacatic
einecs 224-396-1
carboxamide, 5-(3,3-dimethyl-1-triazeno)imidazole-4-
5-(3,3-dimethyl-1-triazenyl)-1h-imidazole-4-carboxamide
dacarbazino [inn-spanish]
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
decarbazine
imidazole-4(or 5)-carboxamide, 5(or 4)-(3,3-dimethyl-1-triazeno)-
imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-
carboxamide, dimethyl imidazole
imidazole carboxamide, dimethyl
4-[(e)-dimethylaminoazo]-1h-imidazole-5-carboxamide
imidazole carboxamide
4-[(1e)-3,3-dimethyltriaz-1-en-1-yl]-1h-imidazole-5-carboxamide
NCGC00091861-01
DACARBAZINE ,
C06936
4342-03-4
DB00851
biocarbazine
D00288
dacarbazine (jan/usp/inn)
dtic-dome (tn)
NCGC00091861-02
SPECTRUM1500218
NCGC00091861-04
NCGC00091861-03
HMS2090A20
HMS2091I20
dacarbasine
nci c04717
CHEMBL476
dicarbazine
HMS501A08
(5e)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
NCGC00091861-05
NCGC00188955-01
NCGC00258563-01
tox21_201010
A826278
(5e)-5-(dimethylaminohydrazinylidene)-4-imidazolecarboxamide
AKOS005220502
pharmakon1600-01500218
nsc-759610
nsc759610
dtxcid20369
tox21_111171
dtxsid0020369 ,
cas-4342-03-4
750512-03-9
CCG-40272
CCG-36068
CCG-35381
dacarbazine [usan:usp:inn:ban:jan]
dacarbazino
4-(or 5)-(3,3-dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
unii-7gr28w0fji
7gr28w0fji ,
dacarbazine [usan]
dacarbazine [jan]
dacarbazine [who-dd]
dacarbazine [usp monograph]
dacarbazine [orange book]
dacarbazine [ep monograph]
dacarbazinum [who-ip latin]
dacarbazine [iarc]
dacarbazine [hsdb]
dacarbazine [who-ip]
dacarbazine [mi]
dacarbazine [usp-rs]
dacarbazine [inn]
dacarbazine [mart.]
dacarbazine [vandf]
S1221
AKOS015850745
SCHEMBL1014331
CS-1772
HY-B0078
SCHEMBL5561
SCHEMBL5560
tox21_111171_1
NCGC00091861-07
KS-5186
W-106228
5-(3,3-dimethyl-1-triazenyl)imidazole-4-carboxamide
FDKXTQMXEQVLRF-ZHACJKMWSA-N
(5z)-5-(dimethylaminohydrazono)imidazole-4-carboxamide
(5e)-5-(dimethylaminohydrazono)imidazole-4-carboxamide
mfcd00057167
5- (3,3-dimethyl-1-triazenyl) imidazole-4-carboxamide
AKOS026750028
sr-05000001598
SR-05000001598-3
5-(dimethyltriaz-1-en-1-yl)-1h-imidazole-4-carboxamide
CHEBI:94587
dacarbazine, united states pharmacopeia (usp) reference standard
bdbm233149
SR-05000001598-1
dacarbazine, european pharmacopoeia (ep) reference standard
SBI-0051328.P003
dacarbazine, pharmaceutical secondary standard; certified reference material
dacarbazine, british pharmacopoeia (bp) reference standard
dacarbazine (dtic-dome)
BRD-K35520305-001-04-5
nsc-799994
nsc799994
5-[(1e)-dimethyltriaz-1-en-1-yl]-1h-imidazole-4-carboxamide
EN300-7357020
5-(3,3-dimethyltriaz-1-enyl)-1h-imidazole-4-carboxamide
l01ax04
1 h-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-
imidazole carboxamide dimethyltriazeno
asercit
dakarbazin
fauldetic
dacarbazina almirall
dimethyl-triazeno-imidazole-carboximide
dacarbazine (mart.)
dacarbazine-dtic
dimethyl (triazeno) imidazolecarboxamide
dacarbazine (usp monograph)
dacarbazine (usp-rs)
detimedac
imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno1-
dacarbazin
dacarbazine (iarc)
dacarbazine (ep monograph)
dtic-aome
wr-139007
dimethyl triazeno imidazol carboxamide
dimethyl-triazeno-imidazole carboxamide
5-(3-3-dimethyl-1-triazenyl)-1h-imidazole-4-carboxamide
Z2289761610
KBIO1_000326
DIVK1C_000326
NCIMECH_000261
NCI60_004053
CHEBI:4305 ,
SPECTRUM_000884
BPBIO1_000428
SMP2_000251
PRESTWICK_904
BSPBIO_000388
PRESTWICK3_000574
PRESTWICK2_000574
IDI1_000326
KBIO2_006500
KBIO2_003932
KBIO3_001311
KBIO2_001364
KBIOGR_000896
KBIOSS_001364
PRESTWICK1_000574
SPBIO_001075
SPECTRUM3_000366
SPECTRUM4_000308
NINDS_000326
SPBIO_002607
SPECTRUM2_001148
PRESTWICK0_000574
SPECTRUM5_000823
BSPBIO_002091
MLS001332544
smr000857131
MLS001332543
D3634
FT-0665443
HMS1569D10
HMS2096D10
CHEMBL1574179
(e)-5-(3,3-dimethyltriaz-1-en-1-yl)-1h-imidazole-4-carboxamide
HMS2231L23
FT-0603657
FT-0624397
NCGC00091861-06
1185241-28-4
HMS3369K21
CCG-220574
gtpl9075
AKOS025402325
AC-8116
HMS3654J03
FDKXTQMXEQVLRF-UHFFFAOYSA-N
HMS3713D10
SW219867-1
(e)-5-(3,3-dimethyltriaz-1-enyl)-1h-imidazole-4-carboxamide
Q416975
Q63088173
Q27166417
5-(dimethylaminohydrazinylidene)-4-imidazolecarboxamide
2,2,3,3,4,6,6-heptachlorobiphenyl
BCP08972
wr139007
T70919
AKOS037515488

Excerpt	Reference	Relevance
" The close correspondence of the two QSAR leaves essentially no means for the synthesis of more potent, less toxic triazenes."	( Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice. Greenberg, N; Hansch, C; Hatheway, GJ; Quinn, FR, 1978)	0.26
"Decomposition of the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC, Dacarbazine) produces several potentially toxic compounds, the concentration of which depend on incubation parameters such as pH, temperature and illumination."	( Mechanisms of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (Dacarbazine) cytotoxicity toward Chinese hamster ovary cells in vitro are dictated by incubation conditions. Chao, LY; DeChang, W; Saunders, PP, 1986)	0.27
" Since it was unclear whether light exposure enhanced DTIC antitumor activity or local toxic effects in vivo, a series of experiments was performed in mice given DTIC solutions exposed to light for 2 hours at room temperature."	( Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes. Alberts, DS; Dorr, RT; Einspahr, J; Mason-Liddil, N; Soble, M, 1987)	0.27
" It appears that DTIC hyperthermic isolation perfusion is a safe procedure, however, the total dosage should be below 40 mg/kg to avoid hematologic toxicity."	( Toxicity and complications of vascular isolation and hyperthermic perfusion with imidazole carboxamide (DTIC) in melanoma. Didolkar, MS; Fitzpatrick, JL; Jackson, AJ; Johnston, GS, 1986)	0.27
" DM-COOK's greater chemical stability might be an advantage, as the decomposition of DTIC is thought to lead to products responsible for some toxic effects in humans."	( Comparison of the antitumor activity of DTIC and 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on murine transplantable tumors and their hematological toxicity. Colombo, T; D'Incalci, M, 1984)	0.27
" M&B 39565 and MCTIC were 5- to 6-fold more toxic to VA-13 cells than to IMR-90 cells for drug concentrations which produced a 2-log cell kill, as measured by colony-forming assays."	( DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one. Erickson, LC; Gibson, NW; Hickman, JA, 1984)	0.27
"5 mg/g), the drug was toxic to both aerobic and hypoxic tumor cells with some evidence of increased toxicity towards hypoxic cells."	( Selective toxicity of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide toward hypoxic mammalian cells. Mohindra, JK; Rauth, AM, 1981)	0.26
" Although the neurotoxic effects produced by different cytostatics present a different appearance and are partly of only sporadic or slight clinical importance, there is hardly a cytostatic which does not exercise a side effect on the nervous system."	( [Neurotoxic side effects of cytostatic therapy (author's transl)]. Maurach, R; Strian, F, 1981)	0.26
" Dacarbazine (5-(3,3-dimethyl-triazeno) imidazole-4-carboxamide), 3 and 6 mM, was toxic to SECs but not to hepatocytes."	( Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. Deleve, LD, 1994)	0.29
"The effects of treatment of mice with O6-benzylguanine (O6-BeG) on the levels of O6-alkylguanine-DNA alkyltransferase (ATase) in the hematopoietic compartment and on the in vivo sensitivity of hematopoietic progenitor cells to the toxic and clastogenic effects of the antitumor agents 1,3-bis(2-chloroethyl)-nitrosourea (BCNU) and temozolomide were studied."	( O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Ashby, J; Chinnasamy, N; Dexter, TM; Fairbairn, LJ; Hickson, I; Margison, GP; Rafferty, JA; Tinwell, H, 1997)	0.3
" Similar degrees of protection were seen for the methylating agent streptozotocin, but no protection was detected for the chloroethylating agents carmustine or mitozolomide in the samples for which there was protection against the toxic effects of Tz."	( Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells. Chang, J; Clemons, M; Dexter, TM; Heyworth, C; Howell, A; Lord, B; Margison, G; Testa, N; Watson, A, 2000)	0.31
" Potentiation of cytotoxicity was obtained at concentrations of NU1025 and NU1085 that were not toxic per se; however, NU1085 alone was 3-fold more cytotoxic (LC50 values ranged from 83 to 94 microM) than NU1025 alone (LC50 > 900 microM)."	( Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW, 2000)	0.31
"The DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT) has been shown to protect cells from the toxic and mutagenic effect of alkylating agents by removing lesions from the O6 position of guanine."	( Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cai, Y; Dolan, ME; Ludeman, SM; Pegg, AE; Wu, MH; Xu-Welliver, M, 2000)	0.31
" Temozolomide was safe and well tolerated."	( Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Grisoli, F; Honore, S; Martin, PM; Muracciole, X, 2001)	0.31
"Temozolomide is safe and effective in the treatment of recurrent AO and AOA."	( Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Grisoli, F; Honore, S; Martin, PM; Muracciole, X, 2001)	0.31
" This study also analyzed the ratio of the toxic effect of TMZ on MNC and on tumor cells (i."	( DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system. Alvino, E; Bonmassar, L; D'Atri, S; Falcinelli, S; Fuggetta, MP; Guadagni, F; Lacal, PM; Pagani, E; Passarelli, F; Pepponi, R; Prete, SP; Turriziani, M, 2003)	0.32
"We have studied the toxic effect of the alkylating antitumor drug N'-cyclohexyl-N-(2-chloroethyl)-N-nitrosourea (lomustine, CCNU) on Escherichia coli (E."	( Spin labeled antioxidants protect bacteria against the toxicity of alkylating antitumor drug CCNU. Gadjeva, V; Lazarova, G; Zheleva, A, 2003)	0.32
"Postoperative radiochemotherapy with 30-33 daily doses of temozolomide (75 mg/m(2)) is safe in patients with malignant glioma."	( Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Eich, HT; Kocher, M; Kunze, S; Müller, RP; Semrau, R, 2005)	0.33
" In conclusion, there were no adverse effects of the ABVD regimen on the course of HCV infection in this patient who was successfully treated for HD."	( No adverse effect of ABVD chemotherapy in a patient with chronic hepatitis C and Hodgkin's disease. Donley, K; Grgurević, I; Kujundzić, M; Martinović, M; Pavletic, S; Pejsa, V; Stancić, V, 2004)	0.32
" The mean toxic CD of doxorubicin was 170+/-33 mg/m2 (range 100-200; median 175) and the mean time of the onset EF decline was 13."	( Echocardiographic evaluation of early and chronic cardiotoxicity in adult patients treated for Hodgkin's disease with ABVD regimen. Elbl, L; Kral, Z; Navratil, M; Smardova, L; Vasova, I; Vorlicek, J, 2006)	0.33
" Similar side effect intensity of BZA2 and dacarbazine was observed, whereas BZA1 was more toxic."	( Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model. Bauder-Wüst, U; Eisenhut, M; Eskerski, H; Haberkorn, U; Wolf, M, 2006)	0.33
"This complex and highly toxic chemoimmunotherapeutic regimen should not be considered as standard therapy in patients with metastatic malignant melanoma."	( Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit? Hofmann, MA; Sterry, W; Trefzer, U, 2007)	0.34
" Four patients receiving HDC/IL-2/IFN and nine receiving DTIC experienced at least one grade 4 adverse event."	( Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Anderson, R; Burdette-Radoux, S; Gehlsen, K; Hauschild, A; Hellstrand, K; Middleton, M; Naredi, P; Thomson, D, 2007)	0.34
" This study could provide an insight into the safe usage of DTIC."	( Mechanism of UVA-dependent DNA damage induced by an antitumor drug dacarbazine in relation to its photogenotoxicity. Hiraku, Y; Iwamoto, T; Kawanishi, S; Okuda, M, 2008)	0.35
" CB related adverse events occurring in more than one patient were fatigue, gait disturbance, nystagmus, and confusion."	( Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Asher, AL; Chang, SM; Croteau, D; Grahn, AY; Husain, SR; Kunwar, S; Lang, FF; Parker, K; Puri, RK; Sampson, JH; Shaffrey, M; Sherman, JW; Vogelbaum, MA, 2007)	0.34
" Thus, the implantation of BCNU wafers prior to TMZ and radiotherapy appears safe in newly diagnosed GBM patients."	( A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. Mitchell, SB; Pan, E; Tsai, JS, 2008)	0.35
" The adverse effects related with TMZ administration are divided in three categories: myelosuppression, non haematologic toxicity, and infections."	( The safety of the temozolomide in patients with malignant glioma. Dario, A; Tomei, G, 2006)	0.33
" Although TMZ is generally safe and acute toxicity is well documented, there are limited data on long-term toxicities."	( Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? Bell, D; Khasraw, M; Wheeler, H, 2009)	0.35
" There were no toxic deaths."	( Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Couvelard, A; Faivre, S; Hammel, P; Hentic, O; Larroque, B; Lévy, P; Maire, F; Raymond, E; Ruszniewski, P; Yapur, L; Zappa, M, 2009)	0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" Three patients experienced a grade 4 adverse reaction; two pulmonary emboli and one cerebral ischemia."	( Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Bassett, R; Bedikian, A; Hwu, P; Hwu, WJ; Kim, KB; Knight, RD; Papadopoulos, NE; Patnana, M, 2010)	0.36
"The primary objective of this augmental, prospective, uncontrolled phase II multicentre trial was to assess adverse events (AE) associated with malignant glioma resection using 5-aminolevulinic (5-ALA)."	( Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. Kern, BC; Krex, D; Mehdorn, HM; Nestler, U; Pichlmeier, U; Stockhammer, F; Stummer, W; Vince, GH, 2011)	0.37
"The majority of patients with Hodgkin's disease can be cured by combination of polychemotherapy and radiotherapy (RT) that can produce late toxic pulmonary and cardiac effects which often remain at a subclinical level."	( Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. Bonfante, V; Busia, A; Laffranchi, A; Villani, F; Viviani, S, 2010)	0.36
"These data confirm that the combination of mediastinal RT with the more commonly used polychemotherapy regimens produce late toxic effects."	( Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. Bonfante, V; Busia, A; Laffranchi, A; Villani, F; Viviani, S, 2010)	0.36
" When this regimen was administered to mice containing humanized bone marrow, flow cytometric analyses indicated that the human bone marrow cells were significantly more sensitive to treatment than the murine bone marrow cells and that the regimen was highly toxic to human-derived hematopoietic cells of all lineages (progenitor, lymphoid, and myeloid)."	( Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. Bailey, B; Baluyut, AR; Cai, S; Chan, RJ; Ernstberger, A; Goebel, WS; Jones, DR; Juliar, BE; Mayo, LD; Pollok, KE; Sinn, AL; Wang, H, 2011)	0.37
"Temozolomide (TMZ) is a widely used oral alkylating agent that has been associated with the development of severe hematologic adverse events (HAEs)."	( Hematologic adverse events associated with temozolomide. Abdur, S; Bressler, LR; Letarte, N; Villano, JL; Yu, JM, 2012)	0.38
" Although there is possibly an indication that metronomic regimens of TMZ result in better PFS and response rate when compared to the conventional standard 5 day regimen, insufficient available data and study heterogeneity preclude any safe conclusions."	( Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. Athanasiou, T; Lashkari, HP; Moreno, L; Saso, S; Zacharoulis, S, 2011)	0.37
"The results suggest that Cyberknife re-treatments are relatively safe using selected dose/fraction schemes."	( Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas. Arpa, D; Cardali, S; Conti, A; De Renzis, C; Granata, F; Pontoriero, A; Romanelli, P; Siragusa, C; Tomasello, C; Tomasello, F, 2012)	0.38
" The survival rate, progression-free survival, overall survival time and adverse reactions were observed."	( [Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma]. Tu, Q; Wang, L; Zhou, R; Zhou, W, 2011)	0.37
"The adverse reactions were mild and tolerable."	( [Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma]. Tu, Q; Wang, L; Zhou, R; Zhou, W, 2011)	0.37
" Magnetic resonance imaging and laboratory tests were performed to evaluate the efficacy and adverse reactions."	( [Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas]. Cai, CL; Fang, HH; Kang, JB; Li, FM; Nie, Q, 2011)	0.37
" Hematotoxicity is listed as a frequent adverse drug reaction in the US prescribing information and hepatotoxicity has been reported infrequently in the postmarketing period."	( Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Bronder, E; Garbe, E; Herbst, H; Kauffmann, W; Klimpel, A; Orzechowski, HD; Sarganas, G; Thomae, M, 2012)	0.38
"Conformal Radiation yields low grades of MRI assessed neurotoxicity and cognitive disturbance in patients of HGG with no adverse impact on local control and survival."	( Survival outcome and neurotoxicity in patients of high-grade gliomas treated with conformal radiation and temozolamide. Aggarwal, HN; Anand, AK; Babu, AG; Chaudhory, AR; Chaudhury, PS; Jena, A; Negi, PS; Rao, A; Sachdeva, PK; Sinha, SN, )	0.13
"Combining Gliadel wafers and radiochemotherapy with TMZ may carry the risk of increased adverse events (AE)."	( Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Anile, C; Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Maira, G; Mangiola, A; Pompucci, A, 2012)	0.38
" The incidence of hematological adverse effects (AE) was recorded for all patients."	( Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis. Bock, HC; Brück, W; Giese, A; Gutenberg, A; Reifenberger, G, 2013)	0.39
"Current immunomodulatory agents for stage III and IV melanoma exert different mechanisms of action that manifest in distinct adverse events."	( Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. Armstrong, AW; Ma, C, 2014)	0.4
"This systematic review aims to synthesize safety data from clinical trials on ipilimumab, vemurafenib, interferon (IFN) alfa-2b, dacarbazine and interleukin (IL)-2 to elucidate the severe adverse events associated with each melanoma therapy."	( Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. Armstrong, AW; Ma, C, 2014)	0.4
" However severe hematologic adverse events (HAEs), including myelodysplastic syndrome and aplastic anemia, have also been reported."	( Temozolomide-related hematologic toxicity. De Sanctis, V; Enrici, RM; Minniti, G; Scaringi, C, 2013)	0.39
"Central diabetes insipidus is a rare but reversible side effect of treatment with TMZ."	( Central diabetes insipidus: a previously unreported side effect of temozolomide. Faje, AT; Klibanski, A; Makimura, H; Miller, KK; Nachtigall, L; Wexler, D, 2013)	0.39
" Although TMZ is considered to be a safe drug, it has been demonstrated to cause severe myelotoxicity; in particular, some case reports and small series studies have reported severe myelotoxicity developing during TMZ and concomitant RT."	( Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study. Amadori, A; Berti, F; Bertorelle, R; Della Puppa, A; Farina, P; Lombardi, G; Marcato, R; Rumiato, E; Sacchetto, V; Saggioro, D; Zagonel, V; Zustovich, F, 2015)	0.42
" The evaluating indicators were overall response rate (ORR), 1-year survival rate, and several of the most frequent adverse events."	( Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis. Jia, HY; Jiang, G; Lei, TC; Li, RH; Liu, YQ; Sun, C, 2014)	0.4
" The aim of this study was to investigate the benefits and adverse effects of this combined therapy in elderly patients with glioblastoma."	( Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. Mukasa, A; Narita, Y; Saito, K; Saito, N; Shibui, S; Shinoura, N; Tabei, Y, 2014)	0.4
"To determine the frequency of ocular adverse effects associated with vemurafenib (PLX4032) treatment for metastatic cutaneous melanoma."	( Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Amaravadi, RK; Caro, I; Choe, CH; Kempen, JH; McArthur, GA, 2014)	0.4
"Among the 568 patients treated with vemurafenib, ocular adverse effects developed in 22% (95% confidence interval [CI], 18."	( Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Amaravadi, RK; Caro, I; Choe, CH; Kempen, JH; McArthur, GA, 2014)	0.4
"Ocular adverse events and symptoms may be seen in more than one-fifth of patients being treated with vemurafenib."	( Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Amaravadi, RK; Caro, I; Choe, CH; Kempen, JH; McArthur, GA, 2014)	0.4
"8% of the 618 toxicities were Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2, while 15."	( Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014)	0.4
" In this project, we evaluated the effects of silibinin, a natural plant component of milk thistle seeds, to potentiate toxic effects of chemotherapy drugs such as temozolomide, etoposide and irinotecan on LN229, U87 and A172 (P53 and phosphatase and tensin homolog (PTEN) -tumor suppressor-mutated) glioma cell lines."	( The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines. Elhag, R; Mazzio, EA; Soliman, KF, 2015)	0.42
" The safety profiles were consistent with the well-characterized toxicities of both agents, and the most common grade 3 to 4 adverse effects were myelosuppression and transient elevation of transaminases in the trabectedin arm."	( Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Dean, A; Demetri, GD; Elias, A; Ganjoo, K; Hensley, ML; Jones, RL; Khokhar, NZ; Knoblauch, RE; Maki, RG; Milhem, M; Parekh, TV; Park, YC; Patel, SR; Schuetze, SM; Spira, A; Staddon, A; Tawbi, H; Van Tine, BA; von Mehren, M, 2016)	0.43
" BBBD temozolomide was toxic in the efficacy study, but there was no evidence of symptomatic neurotoxicity in rats given IA temozolomide."	( Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. Muldoon, LL; Netto, JP; Neuwelt, EA; Pagel, MA, 2016)	0.43
" Data on adverse events (AEs) were collected throughout."	( Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Chinot, OL; Cloughesy, T; Dhar, S; Garcia, J; Henriksson, R; Mason, W; Nishikawa, R; Pozzi, E; Saran, F; Wick, W, 2016)	0.43
"3; combined relative risk (RR) and 95% confidence intervals (95% CIs) were calculated for survival rates, response rates, and adverse events."	( Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma. Hou, XY; Huang, Q; Jiang, G; Tang, JQ; Xin, Y; Yang, M; Zhang, LZ; Zhang, P, 2016)	0.43
" Patients reported adverse effects in Common Toxicity Criteria for Adverse Events diaries; recorded vomiting, nausea, and rescue medication use in diaries (which were used to assess cRINV-CR); and reported QoL 4 days/week using the Modified Functional Living Index-Emesis (M-FLIE) and Osoba nausea and vomiting/retching modules."	( Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). Affronti, ML; Allen, K; Desjardins, A; Friedman, HS; Healy, PN; Herndon, JE; Kirkpatrick, J; McSherry, F; Peters, KB; Vredenburgh, JJ; Woodring, S, 2016)	0.43
"Single-dose weekly PAL is a safe and tolerable antiemetic for cRINV prevention in MG patients receiving standard RT and concomitant TMZ."	( Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). Affronti, ML; Allen, K; Desjardins, A; Friedman, HS; Healy, PN; Herndon, JE; Kirkpatrick, J; McSherry, F; Peters, KB; Vredenburgh, JJ; Woodring, S, 2016)	0.43
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."	( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016)	0.43
" Commenced 15 years ago, PRRT is now becoming established as first- and second-line therapy for gastroentero pancreatic neuroendocrine tumors (GEPNETs), and early treatment minimizes myelotoxicity, which is the most significant potential adverse event following PRRT."	( Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. Kesavan, M; Turner, JH, 2016)	0.43
" Nausea was the most common side effect (31 %), only one case (1."	( Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors. Gress, TM; Krug, S; Majumder, M; Mueller, D; Rinke, A, 2016)	0.43
" The most common treatment emergent adverse events were ocular: blurred vision, dry eye, keratitis, photophobia, and eye pain."	( Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Ansell, P; Fichtel, L; Fischer, J; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Mandich, H; Merrell, R; Munasinghe, W; Reardon, DA; Roberts-Rapp, L; Scott, AM; Sulman, EP; van den Bent, M; Xiong, H, 2017)	0.46
" We aimed to determine whether or not pulse high-dose lapatinib was a safe and tolerable regimen in addition to standard therapy."	( Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017)	0.46
"Extended cycles of temozolomide are safe and feasible for Chinese patients with disease responsive to temozolomide."	( Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma. Chan, DT; Hsieh, SY; Kam, MK; Loong, HH; Ng, SC; Poon, DM; Poon, WS; Tsang, WK, 2017)	0.46
" This review summarizes the mechanism of action, efficacy, and adverse events based on pre-clinical studies and clinical trials for TTF in GBM."	( Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives. Zhu, JJ; Zhu, P, 2017)	0.46
" For recurrent GBM, the efficacy of TTF monotherapy was shown to be equivalent in PFS and OS without systemic adverse events when compared to the control group that received best physicians-chosen chemotherapies (EF-11 trial)."	( Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives. Zhu, JJ; Zhu, P, 2017)	0.46
"Radiochemotherapy involving cisplatinum-based polychemotherapy is more toxic than radiotherapy in combination with temozolomide."	( Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients. Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M, 2018)	0.48
" Compelling clinical data also support the safety of carmustine wafer implantation (grade A recommendation) in these patients and suggest that observed adverse events can be avoided in experienced neurosurgeon hands."	( Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017)	0.46
" The observation index of both groups included the short- and long-term clinical efficacies, improvement of symptoms and signs, quality of life (QOL), and adverse responses."	( Efficacy and safety of temozolomide plus whole-brain radiotherapy in the treatment of intracranial metastases. Liu, HP; Wang, JW; Zheng, KB, 2017)	0.46
" Although temozolomide is generally a well tolerated drug, with rare severe toxic effects, sometimes certain toxicities can overcome the life risk of the underlying malignancy."	( Severe hematologic temozolomide-related toxicity and lifethreatening infections. Nikitovic, M; Stepanovic, A, )	0.13
"Treatments for advanced melanoma are associated with different adverse events (AEs), which may be costly to manage."	( Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. Chmielowski, B; Copley-Merriman, C; Liu, FX; Mauskopf, J; Stevinson, K; Wang, J; Zimovetz, EA, 2018)	0.48
"CAPTEM is effective and relatively safe for treating patients with advanced NENs."	( Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis. Fu, W; Li, W; Lu, L; Lu, Y; Lv, W; Wang, J; Zhao, Z, 2018)	0.48
" We retrieved evidence on treatment-related grade III/IV adverse events, progression-free survival (PFS) and overall survival (OS)."	( A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM, 2019)	0.51
"Patient data for multiple cardiac-related treatment-emergent adverse events (cTEAEs) were evaluated in pooled analyses of ten phase 2 trials, one phase 3 trial in STS (n = 982), and two phase 3 trials in ROC (n = 1231)."	( Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Coleman, RL; Demetri, GD; Herzog, TJ; Hu, P; Jones, RL; Knoblauch, R; McGowan, T; Monk, BJ; Patel, SR; Schuetze, SM; Shalaby, W; Triantos, S; Van Tine, BA; von Mehren, M, 2021)	0.62
" Its longitudinal variations may discriminate between highly and minimally toxic protocols regarding ovarian function."	( Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling. Barbatti, M; Behal, H; Bruno, B; Decanter, C; Delepine, J; Labreuche, J; Manier, S; Morschhauser, F; Pigny, P; Robin, C, 2021)	0.62
" In addition, OS, PFS and adverse event (AE) data on ndGBM and recurrent GBM (rGBM) were assessed."	( Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis. Li, H; Ma, W; Qu, T; Wang, Y; Wu, J; Xia, Y; Xing, H; Zhao, B, 2022)	0.72
" The most common adverse events were leukocytopenia (66."	( Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. Bu, L; Cai, J; Chen, Q; Huang, K; Meng, X; Weng, Y; Xu, Q; Zhan, R; Zhang, L; Zheng, X, 2023)	0.91

Excerpt	Reference	Relevance
" Our results provide a solid pharmacokinetic basis for considering subconjunctivally administered dacarbazine in the treatment of human ocular melanoma."	( Ocular pharmacokinetics of dacarbazine following subconjunctival versus intravenous administration in the rabbit. Kalsi, GS; Rootman, J; Silver, HK, 1991)	0.28
" The reproducibility of the intra-arterial techniques was established by the repeated pharmacokinetic analysis."	( Tourniquet infusion chemotherapy of the lower extremities--clinical and pharmacokinetic results. Eksborg, S; Ingvar, C; Jönsson, PE; Stigsson, L, 1989)	0.28
" The plasma disappearance of DTIC was biphasic, with a terminal half-life of 41."	( Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. Aigner, K; Breithaupt, H; Dammann, A, 1982)	0.26
" The half-life of the drug in the tumors was approximately 60 min."	( Pharmacokinetics of the 13C labeled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer. Artemov, D; Bhujwalla, ZM; Glickson, JD; Griffiths, JR; Judson, IR; Leach, MO; Maxwell, RJ, 1995)	0.29
"A pharmacokinetic study was undertaken in six patients with melanoma of an extremity who were undergoing hyperthermic isolation perfusion with DTIC in order to understand better its clinical pharmacokinetics."	( Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma. Buda, BS; Didolkar, MS; Fitzpatrick, JL; Jackson, AJ; Johnston, GS; Lesko, LJ; Zech, LA, 1996)	0.29
"We conclude that spectral analysis provides important pharmacokinetic information about radiolabeled anti-cancer drugs with relatively few model assumptions."	( Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Brock, CS; Cunningham, VJ; Harte, RJ; Jones, T; Matthews, JC; Meikle, SR; Price, P; Wells, P, 1998)	0.3
" Plasma samples were obtained on days 1 and 2 to evaluate the pharmacokinetic parameters of TMZ alone and in combination with CDDP."	( A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Agarwala, SS; Baker, SD; Barrington, R; Britten, CD; Diab, SG; Eckardt, JR; Eckhardt, SG; Fraass, U; Hammond, LA; Johnson, T; Rowinsky, EK; Statkevich, P; Villalona-Calero, M; Von Hoff, DD, 1999)	0.3
"Fifteen patients with advanced cancer were enrolled of which 12 were evaluable, all of whom had pharmacokinetic blood sampling."	( Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Beale, P; Brada, M; Cutler, DL; Judson, I; Marco, A; Moore, S; Reidenberg, P; Statkevich, P, 1999)	0.3
" There was no difference in the pharmacokinetic parameters of temozolomide or MTIC with or without the concomitant administration of ranitidine."	( Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Beale, P; Brada, M; Cutler, DL; Judson, I; Marco, A; Moore, S; Reidenberg, P; Statkevich, P, 1999)	0.3
" The 5-day schedule appears less toxic, and pharmacokinetic studies show that it provides greater exposure to MTIC and HMMTIC compared to the one-day schedule."	( A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. Ames, MM; Buckner, JC; Hatfield, AK; Johnson, PS; Krook, JE; Morton, RF; Nair, S; Novotny, PJ; Rajkumar, SV; Reid, JM; Safgren, SL; Scheithauer, BW, 2000)	0.31
" Statistical analyses of pharmacokinetic and pharmacodynamic end points in the control and TNP-470 treatment groups were completed by nonparametric tests."	( Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Chu, J; Gallo, JM; Li, S; Ma, J; Pulfer, S; Reed, K, 2001)	0.31
" DTIC and AIC exhibited biphasic clearance from the blood, consistent with a 2-compartment pharmacokinetic model."	( Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. Clemons, M; El Teraifi, H; Griffiths, A; Howell, A; Kelly, J; Margison, GP; Margison, JM; Morris, CQ; Ranson, M, 2003)	0.32
" It is proposed that the net balance of antiangiogenic drug-mediated pharmacodynamic actions will determine how drug disposition in tumors may be affected."	( Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. Gallo, JM; Guo, P; Li, S; Ma, J; Reed, K, 2003)	0.32
"To construct a population pharmacokinetic model for temozolomide (TMZ), a novel imidazo-tetrazine methylating agent and its metabolites MTIC and AIC in infants and children with primary central nervous system tumors."	( Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Fouladi, M; Gajjar, A; Heideman, RL; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF; Wilkinson, M, 2003)	0.32
"We evaluated the pharmacokinetics of TMZ and MTIC in 39 children (20 boys and 19 girls) with 132 pharmacokinetic studies (109 in the training set and 23 in the validation set)."	( Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Fouladi, M; Gajjar, A; Heideman, RL; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF; Wilkinson, M, 2003)	0.32
"To characterize and compare pharmacokinetic parameters in children and adults treated with temozolomide (TMZ) administered for 5 days in three doses daily, and to evaluate the possible relationship between AUC values and hematologic toxicity."	( Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. Barone, C; Caldarelli, M; Cefalo, G; Garrè, ML; Lazzareschi, I; Madon, E; Maira, G; Massimino, M; Mastrangelo, S; Mazzarella, G; Riccardi, A; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2003)	0.32
"TMZ pharmacokinetic parameters were characterized in pediatric and adult patients with primary central nervous system tumors treated with doses ranging from 120 to 200 mg/m2 per day, divided into three doses daily for 5 days."	( Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. Barone, C; Caldarelli, M; Cefalo, G; Garrè, ML; Lazzareschi, I; Madon, E; Maira, G; Massimino, M; Mastrangelo, S; Mazzarella, G; Riccardi, A; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2003)	0.32
"No difference appears to exist between pharmacokinetic parameters in adults and children when TMZ is administered in three doses daily."	( Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. Barone, C; Caldarelli, M; Cefalo, G; Garrè, ML; Lazzareschi, I; Madon, E; Maira, G; Massimino, M; Mastrangelo, S; Mazzarella, G; Riccardi, A; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2003)	0.32
" In total, 18 blood samples were collected for pharmacokinetic analysis (maximum plasma concentration, area under the concentration-time curve and total clearance) of D and F at 14 time points during therapy."	( Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences. Fazeny-Dörner, B; Mader, RM; Marosi, C; Piribauer, M; Rizovski, B; Stögermaier, B, 2004)	0.32
" The population pharmacokinetic analysis was performed with nonlinear mixed-effect modeling software."	( Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Buclin, T; Csajka, C; Decosterd, LA; Lejeune, F; Leyvraz, S; Ostermann, S; Stupp, R, 2004)	0.32
"This is the first human pharmacokinetic study on TMZ to quantify CSF penetration."	( Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Buclin, T; Csajka, C; Decosterd, LA; Lejeune, F; Leyvraz, S; Ostermann, S; Stupp, R, 2004)	0.32
" To that end, a novel method, based on physiologically based hybrid pharmacokinetic models, is presented to predict human tumor drug concentrations."	( Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Bookman, MA; Gallo, JM; Guo, P; Li, S; Ma, J; Orlansky, A; Pulfer, S; Vicini, P; Zhou, F, 2004)	0.32
"To develop a pharmacokinetic limited sampling model (LSM) for temozolomide and its metabolite MTIC in infants and children."	( Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. Freeman, BB; Gajjar, A; Iacono, LC; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF, 2005)	0.33
" This accounted for prior distribution of temozolomide and MTIC pharmacokinetic parameters based on full pharmacokinetic sampling from 38 patients with 120 pharmacokinetic studies (dosage range 145-200 mg/m(2) per day orally)."	( Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. Freeman, BB; Gajjar, A; Iacono, LC; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF, 2005)	0.33
" Furthermore, PARP activity was not inhibited by temozolomide treatment and this newly validated pharmacodynamic assay is therefore suitable for use in a proof-of-principle phase I trial a PARP-1 inhibitor in combination with temozolomide."	( Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ, 2005)	0.33
" Although this approach is promising, there has not been any attempt to define optimal metronomic dosing regimens by integrating pharmacokinetic (PK) with pharmacodynamic (PD) measurements."	( Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. Gallo, JM; Guo, P; Nuthalapati, S; Wang, X; Zhou, Q, 2007)	0.34
" Antibiotic peak concentration in blood decreased by 55%, doxorubicin circulated several times longer, and the area under the concentration-time curve increased 5 times if compared with standard doxorubicin administration."	( Doxorubicin pharmacokinetics in lymphoma patients treated with doxorubicin-loaded eythrocytes. Ataullakhanov, FI; Galkina, NM; Kulikova, EV; Medvedev, PV; Pivnik, AV; Skorokhod, O; Vitvitsky, VM; Zybunova, EE, 2007)	0.34
" Because significant obstacles prevent making these measurements in humans, development of a predictive pharmacokinetic model would be of great value to the translation of preclinical data to the clinic."	( Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Gallo, JM; Guo, P; Kruh, GD; Vicini, P; Wang, X; Zhou, Q, 2007)	0.34
" The resultant data provided the framework to develop a hybrid physiologically based pharmacokinetic model for temozolomide in brain."	( Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Gallo, JM; Guo, P; Kruh, GD; Vicini, P; Wang, X; Zhou, Q, 2007)	0.34
"A physiologically based pharmacokinetic modeling approach offers a means to translate preclinical to clinical characteristics of drug disposition in target tissues and, thus, a means to select appropriate drug dosing regimens for achieving optimal target tissue drug concentrations."	( Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Gallo, JM; Guo, P; Kruh, GD; Vicini, P; Wang, X; Zhou, Q, 2007)	0.34
"The pharmacokinetic and safety profile of TMZ in Japanese patients was comparable to that in Caucasians."	( Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. Adachi, J; Aoki, T; Matsutani, M; Mishima, K; Mizutani, T; Nishikawa, R; Nojima, K, 2007)	0.34
" The mean clearance of temozolomide was 107 mL/min/m2, with a volume of distribution of 20 L/m2 and half-life of 109 minutes."	( Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF, 2007)	0.34
" Pharmacokinetic analyses revealed lowered exposures and enhanced clearance among patients on EIAEDs."	( Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Desjardins, A; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; McLendon, R; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sathornsumetee, S; Vredenburgh, JJ, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors."	( Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD, 2008)	0.35
" Pharmacokinetic studies and ERBB-receptor expression and signaling studies were performed."	( Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD, 2008)	0.35
"The enhanced hematologic toxicity resulting from combining O(6)BG with temozolomide does not appear to be the result of a pharmacokinetic interaction between the agents."	( Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Aikin, AA; Balis, FM; Cole, DE; Fox, E; Meany, HJ; Warren, KE, 2009)	0.35
" The current phase I study investigates the effects of sorafenib on the pharmacokinetic (PK) profile of dacarbazine and its metabolite 5-amino-imidazole-4-carboxamide (AIC)."	( Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC, 2011)	0.37
"Intraindividual comparative pharmacokinetic data were obtained for doxorubicin and paclitaxel/platinum in three and two baboons, respectively."	( Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Amant, F; Chai, D; de Bruijn, E; de Hoon, J; Delforge, M; Halaska, M; Heyns, L; Noens, L; Ottevanger, N; Renard, V; Rob, L; Van Bree, R; Van Calsteren, K; Verbesselt, R; Witteveen, E, 2010)	0.36
" This method was used successfully to perform brain and plasma pharmacokinetic studies of temozolomide in mice after intraperitoneal administration."	( Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study. Farinotti, R; Fernandez, C; Goldwirt, L; Zahr, N, 2013)	0.39
"Cabozantinib at a dose of 40 mg daily with RT plus TMZ and post-RT TMZ for patients with newly diagnosed high-grade glioma was generally well tolerated, and demonstrated no pharmacokinetic interactions with concurrent TMZ."	( Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY, 2016)	0.43
" Pharmacokinetic parameters were estimated using non-compartmental analysis."	( Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. Cruz, R; Figg, WD; League-Pascual, JC; Lester-McCully, CM; Peer, CJ; Rodgers, L; Ronner, L; Shandilya, S; Warren, KE, 2017)	0.46

Excerpt	Reference	Relevance
" In the first phase, 14 patients (Group A) with progressive neurologic dysfunction following primary treatment were treated with DTIC alone (8 patients) or in combination with CCNU or methyl CCNU (6 patients) and evaluated for change in neurologic status."	( Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441). Baxter, D; Cunningham, TJ; Horton, J; Nelson, L; Olson, KB; Rosenbaum, C; Sponzo, RW; Taylor, SG, 1975)	0.25
"Twenty-one patients with disseminated malignant melanoma were treated with cis-dichlorodiammine-platinum(II) (cis-DDP): ten with cis-DDP alone at a dose of 20 mg/m2 iv x 4 days every 4 weeks and 11 with cis-DDP at a dose of 15 mg/m2 iv x 4 days combined with DTIC at a dose of 200 mg/m2 iv x 5 days every 4 weeks."	( Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Eilber, FR; Goodnight, JE; Morton, DL; Moseley, HS; Sarna, G, )	0.13
" Data from other centers have shown that augmentation of remissions for melanoma patients occurred when BCG was combined with DTIC, vincristine, and allogeneic tumor cells."	( Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma. Burgess, MA; Gottlieb, J; Gutterman, JU; Hersh, EM; Mavligit, GM; Reed, R, 1976)	0.26
" Hydroxyurea, antimetabolite, showed a time-dependent inhibition of CFE, and the combination with Ceph enhanced CFE inhibition by 29%, which is stable and independent of the treatment time."	( [Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--II. Antimetabolite, alkylating agent, nitrosourea]. Kubota, K; Kubota, R; Yamada, S, 1992)	0.28
" This provides a framework for future combinations of chemotherapy with rIL-2 alone or in combination with other biologic response modifiers in an outpatient setting."	( A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Bradley, EC; Chabot, GG; Flaherty, LE; Gualdoni, SM; Heilbrun, LK; Martino, S; Redman, BG; Valdivieso, M, 1990)	0.28
" To establish in vivo models for chemoimmunotherapy trials, we investigated IL-2 alone and in combination with dacarbazine (DTIC) and adriamycin."	( Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems. Aukerman, SL; Biernat, L; Corbett, TH; LoRusso, PM; Polin, L; Redman, BG; Valdivieso, M, 1990)	0.28
" It is noteworthy that in all subsets, ABVD (Adriamycin + bleomycin + vinblastine + dacarbazine), either combined with irradiation or alternated with MOPP (mechlorethamine + vincristine + procarbazine + prednisone), yielded superior results compared with MOPP with or without irradiation."	( Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy. Bonadonna, G; Santoro, A; Valagussa, P, 1985)	0.27
"A randomized phase II study of AMSA (amsacrine) alone and AMSA combined with DTIC (dacarbazine) was carried out in 31 and 39 patients with metastatic melanoma respectively."	( Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma. Benjamin, RS; Bodey, GP; Burgess, AM; Legha, SS; Polyzos, A, 1988)	0.27
" Recombinant interferon alfa-2a in combination with chemotherapy is now being used in trials and the early results are encouraging."	( Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC. Hersey, P; McLeod, GR; Thomson, DB, 1987)	0.27
"To define the activity of an individually escalated dacarbazine (DTIC) dose combined with interferon-alpha-2a (IFN), granulocyte-colony stimulating-factor (G-CSF) and ondansetron, 20 patients (pts) with metastatic melanoma were treated with DTIC, ondansetron 8 mg iv, G-CSF 300 micrograms sc and IFN 9 MU sc."	( Dose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma. Buter, J; de Vries, EG; Mulder, NH; Schraffordt Koops, H; Sleijfer, DT; van der Graaf, WT; Willemse, PH, )	0.13
"The antitumor and antimetastatic activity of dacarbazine (DTIC) alone or in combination with cyclophosphamide (CY) was tested in C57BL/6 mice bearing Lewis lung carcinoma (3LL)."	( Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL). Bonmassar, E; Leonetti, C; Lozupone, F; Tentori, L, 1995)	0.29
"Recent data have shown that the in vitro and in vivo cytotoxicity of bioreductive drugs could be significantly increased when combined with chemotherapy drugs such as cisplatinum, depending on the timing of administration."	( The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Guichard, M; Lartigau, E, 1996)	0.29
"Biochemotherapy, which uses recombinant interferon alpha (rIFN-alpha) and recombinant interleukin-2 (rIL-2) in combination with chemotherapy is a promising therapy for metastatic malignant melanoma."	( Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Legha, SS, 1997)	0.3
" The analysis of cell cycle indicated that the drug combination of TZM and PADPRP inhibitors provoked G1 arrest only in p53+ cells."	( Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. Benincasa, E; Bonmassar, E; Faraoni, I; Franco, D; Graziani, G; Lacal, PM; Tentori, L, 1998)	0.3
" AGT depleting agents in combination with methylating and chloroethylating agents are now in clinical testing, and may result in greater clinical efficacy in metastatic malignant melanoma."	( New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance. Gerson, S; Liu, L; Spiro, T, )	0.13
"The activity of temozolomide combined with irinotecan (CPT-11) was evaluated against eight independent xenografts (four neuroblastomas, three rhabdomyosarcomas, and one glioblastoma)."	( Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M, 2000)	0.31
" Preclinical and phase I trials have shown the additive or synergistic activity of temozolomide combined with carmustine against solid tumors, including malignant glioma, and the sequence-dependent effects of the combination."	( Temozolomide in combination with other cytotoxic agents. Prados, M, 2001)	0.31
"Alternating COPP/ABVD and rapid alternating COPP/ABV/IMEP in combination with extended-field radiotherapy are equally effective in intermediate-stage Hodgkin's lymphoma and produce excellent long-term treatment results."	( Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. Anselmo, AP; Brosteanu, O; Diehl, V; Doelken, G; Duehmke, E; Engert, A; Franklin, J; Georgii, A; Greil, R; Hasenclever, D; Herrmann, R; Josting, A; Kirchner, H; Koch, P; Koch, T; Lathan, B; Loeffler, M; Munker, R; Paulus, U; Pfistner, B; Pfreundschuh, M; Rueffer, U; Schalk, KP; Sieber, M; Tesch, H; Wolf, J, 2002)	0.31
" These results indicate that a careful selection of the antitumor agent has to be made when antitelomerase therapy is combined with chemotherapy."	( Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor. Balduzzi, A; Barbarino, M; Biroccio, A; Gold, B; Graziani, G; Levati, L; Lombardi, ML; Portarena, I; Tentori, L; Vergati, M, 2003)	0.32
" Therefore, the authors initiated a Phase I study to determine the pharmacokinetics and safety profile of temozolomide (TMZ), a novel oral alkylating agent known to cross the blood-brain barrier, in combination with interferon alpha-2b (IFN-alpha2b)."	( Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Agarwala, SS; Kirkwood, JM, 2003)	0.32
"A novel somatostatin analogue, TT-232 (which inhibits the proliferation of various cell cultures and transplantable mouse tumours), was examined regarding its effect on human melanoma and lymphoma xenografts as a single treatment or in combination with DTIC (dacarbazine) and etoposide."	( Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma. Bökönyi, G; Horváth, A; Kéri, G; Szende, B, 2003)	0.32
"This EORTC multicentre study analysed the efficacy and tolerability in patients with metastatic uveal melanoma of BOLD chemotherapy in combination with recombinant interferon alpha-2b."	( Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Gore, M; Hahka-Kemppinen, M; Hansson, J; Humblet, Y; Kivelä, T; Kloke, O; Kruit, WH; Kumpulainen, E; Parvinen, LM; Pyrhönen, S; Suciu, S; Vuoristo, MS, 2003)	0.32
" This phase I study was designed to evaluate the efficacy and safety of TMZ alone (course 1) and TMZ in combination with PCB in subsequent courses in chemotherapy-naïve patients with malignant glioma."	( Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Foster, T; Newlands, ES; Zaknoen, S, 2003)	0.32
" Total response to DTIC used in combination with IPHN-alpha increased insignificantly: 25."	( [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma]. Akimov, MA; Gershanovich, ML, 2004)	0.32
"To evaluate the efficacy of temozolomide (TMZ) combined with cisplatin (CDDP) in terms of response rate, time to progression (TTP) and overall survival (OS), as well as the tolerability of the regimen in patients with brain metastases from solid tumors."	( Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D, 2005)	0.33
"Patients (n=32) with brain metastases were treated with TMZ 150 mg/m2/day (chemotherapy-pretreated) or 200 mg/m2/day (chemotherapy-naive) for 5 days, combined with CDDP 75 mg/m2 on day 1, every 28 days."	( Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D, 2005)	0.33
"TMZ combined with CDDP is an active and well-tolerated combination in patients with brain metastases from solid tumors."	( Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D, 2005)	0.33
"The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)."	( Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005)	0.33
"This randomized phase II study was designed to compare the efficacy and tolerability of dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with natural interferon-alpha (nIFN-alpha) or recombinant interferon-alpha2b (rIFN-alpha2b) in patients with advanced melanoma."	( Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Hahka-Kemppinen, M; Kellokumpu-Lehtinen, P; Korpela, M; Parvinen, LM; Pyrhönen, S; Seppä, H; Vuoristo, MS, 2005)	0.33
" Furthermore, we show that a human haemopoietic cell line (K562) transduced with a retroviral vector encoding MGMT(P140K) is highly resistant to the cytotoxic effects of PaTrin-2 in combination with the methylating agent temozolomide, and that cells expressing MGMT(P140K) can be effectively enriched in vitro following challenge with this drug combination."	( The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine. Fairbairn, LJ; Margison, GP; Milsom, MD; Southgate, TD; Woolford, LB, 2006)	0.33
" As the combination with interferon-alfa (IFN-alpha) appears superior to single-agent DTIC regarding response rates, the purpose of this study was to compare TMZ alone and TMZ plus IFN-alpha in terms of objective response (OR), overall survival, and safety in a prospective, randomized, multicenter trial."	( Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. Becker, JC; Dummer, R; Garbe, C; Kaufmann, R; Krengel, S; Kretschmer, L; Leiter, U; Linse, R; Mauch, C; Schadendorf, D; Sebastian, G; Spieth, K; Tilgen, W; Vogt, T; von den Driesch, P, 2005)	0.33
"Two hundred ninety-four patients with untreated stage IV metastatic melanoma (American Joint Committee on Cancer staging system) were randomly assigned to receive either oral TMZ alone (200 mg/m2/day; days 1 through 5 every 28 days) or in combination with subcutaneous IFN-alpha (5 MU/m2; days 1, 3, and 5 every week)."	( Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. Becker, JC; Dummer, R; Garbe, C; Kaufmann, R; Krengel, S; Kretschmer, L; Leiter, U; Linse, R; Mauch, C; Schadendorf, D; Sebastian, G; Spieth, K; Tilgen, W; Vogt, T; von den Driesch, P, 2005)	0.33
" In conclusion, temozolomide combined with cisplatin is an active and safe first-line chemotherapy regimen with acceptable and easily manageable toxicities in patients with metastatic melanoma."	( Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial. Argon, A; Camlica, H; Tas, F; Topuz, E, 2005)	0.33
" Patients with stable or progressive malignant primary glioma received erlotinib alone or combined with temozolomide in this dose-escalation study."	( Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D, 2006)	0.33
" The main aims of this phase I trial were to determine an ATase-depleting dose (ADD) of lomeguatrib, a potent pseudosubstrate inhibitor, and to define a suitable dose of temozolomide to be used in combination with lomeguatrib in patients with advanced cancer."	( Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Bridgewater, J; Dawson, M; Donnelly, D; Gumbrell, L; Halbert, G; Jowle, D; Lee, SM; Margison, GP; McElhinney, RS; McGrath, H; McMurry, TB; Middleton, MR; Ranson, M; Waller, S, 2006)	0.33
"Lomeguatrib was administered at dose levels of 10 to 40 mg/m2 days 1 to 5, as a single agent, and also in combination with temozolomide."	( Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Bridgewater, J; Dawson, M; Donnelly, D; Gumbrell, L; Halbert, G; Jowle, D; Lee, SM; Margison, GP; McElhinney, RS; McGrath, H; McMurry, TB; Middleton, MR; Ranson, M; Waller, S, 2006)	0.33
" Groups treated with regional temozolomide alone (350 mg/kg), systemic temozolomide with O6BG, or vehicle combined with O6BG showed no significant tumor responses compared with controls."	( Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Abdel-Wahab, OI; Abdel-Wahab, Z; Augustine, C; Cheng, TY; Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T; Yoshimoto, Y, 2006)	0.33
" We designed a new regimen utilizing dose-intensified, protracted course of TMZ in combination with vinorelbine, a lipophilic large-spectrum agent, in an attempt to improve the efficacy of TMZ."	( Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. Abrey, LE; Demopoulos, A; Malkin, MG; Omuro, AM; Raizer, JJ, 2006)	0.33
" A multicentre phase II study was performed to assess the activity and toxicity of temozolomide in combination with interferon alpha-2b."	( Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. Crespo, C; del Muro, XG; Filipovich, E; García, M; Germà-Lluch, JR; López, JJ; Pérez, X; Rifà, J; Tres, A; Valladares, M, 2006)	0.33
" Previously untreated patients received temozolomide administered orally at a dose of 150 mg/m/day for 5 days every 4 weeks, in combination with interferon given continuously subcutaneously twice a week at a dose of 10 MU/m."	( Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. Crespo, C; del Muro, XG; Filipovich, E; García, M; Germà-Lluch, JR; López, JJ; Pérez, X; Rifà, J; Tres, A; Valladares, M, 2006)	0.33
"Temozolomide in combination with interferon is a well-tolerated palliative regimen that has moderate activity against metastatic melanoma."	( Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. Crespo, C; del Muro, XG; Filipovich, E; García, M; Germà-Lluch, JR; López, JJ; Pérez, X; Rifà, J; Tres, A; Valladares, M, 2006)	0.33
" In contrast, the cytotoxic drug temozolomide, when used in combination with HIF-1alpha knockdown, exhibited a superadditive and likely synergistic therapeutic effect compared with the monotherapy of either treatment alone in the D54MG glioma model."	( Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Albert, DH; Fesik, SW; Li, L; Lin, X; Shen, Y; Shoemaker, AR, 2006)	0.33
"Our results show that the DNA alkylating agent temozolomide exhibits robust antitumor efficacy when used in combination with HIF-1 inhibition in D54MG-derived tumors, suggesting that the combination of temozolomide with HIF-1 inhibitors might be an effective regimen for cancer therapy."	( Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Albert, DH; Fesik, SW; Li, L; Lin, X; Shen, Y; Shoemaker, AR, 2006)	0.33
" The observed antitumor activity warrants further evaluation of this combination as an alternative to or in combination with whole-brain radiation therapy for the treatment of multiple brain metastases."	( Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006)	0.33
" Three MMR-proficient melanoma cell clones with low or no MGMT activity were treated daily for 5 days with 50 micromol/l TMZ, alone or in combination with 5 micromol/l BG."	( A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. Alvino, E; Bonmassar, E; Caporali, S; Caporaso, P; Castiglia, D; D'Atri, S; Fischer, F; Jiricny, J; Lacal, PM; Marra, G; Pepponi, R; Zambruno, G, 2006)	0.33
" Randomized studies are needed to explore the role of celecoxib in combination with chemotherapy or as maintenance treatment in these patients."	( Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006)	0.33
"The aim of this study was to investigate the effect of temozolomide (TZM) in combination with X-rays on proliferation and migration in human glioma spheroids."	( The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation. Fehlauer, F; Muench, M; Rades, D; Richter, E, 2007)	0.34
"To compare results of treatment with temozolomide or dacarbazine, in combination with an anthracycline, in dogs with relapsed or refractory lymphoma."	( Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. Cadile, CD; Dervisis, NG; Dominguez, PA; Kitchell, BE; Newman, RG; Sarbu, L; Swanson, CN, 2007)	0.34
"The regimen, temozolomide combined with fotemustine, is an active and moderately safe first-line chemotherapy regimen with acceptable and easily manageable toxicities in patients with metastatic melanoma."	( Temozolomide in combination with fotemustine in patients with metastatic melanoma. Camlica, H; Tas, F; Topuz, E, 2008)	0.35
" The effect of ZD6474, a potent inhibitor of VEGF-receptor-2, was evaluated in combination with either radiotherapy or temozolomide."	( Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M, 2008)	0.35
" ZD6474 30 mg/kg was given alone or in combination with radiotherapy 12 Gy x 1 or with temozolomide 100 mg/kg for 3 days."	( Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M, 2008)	0.35
"ZD6474 in combination with radiotherapy significantly decreased tumour area by 66% compared with controls whereas the combination with temozolomide decreased tumour area by 74%."	( Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M, 2008)	0.35
"ZD6474 in combination with two standard modalities in the treatment of malignant glioma, radiotherapy and chemotherapy, markedly decreased the growth of an intracerebral experimental glioma."	( Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M, 2008)	0.35
"A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)."	( Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007)	0.34
"To assess interim safety and tolerability of a 10-patient, Phase II pilot study using bevacizumab (BV) in combination with temozolomide (TMZ) and regional radiation therapy (RT) in the up-front treatment of patients with newly diagnosed glioblastoma."	( Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Bergsneider, M; Cloughesy, T; Filka, E; Graham, C; Lai, A; Liau, LM; McGibbon, B; Mischel, P; Nghiemphu, PL; Pope, W; Selch, M; Yong, WH, 2008)	0.35
" At this time data are not sufficient to encourage routine off-label use of BV combined with TMZ/RT in the setting of newly diagnosed glioblastoma without longer follow-up, enrollment of additional patients, and thorough efficacy assessment."	( Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Bergsneider, M; Cloughesy, T; Filka, E; Graham, C; Lai, A; Liau, LM; McGibbon, B; Mischel, P; Nghiemphu, PL; Pope, W; Selch, M; Yong, WH, 2008)	0.35
"6% and 1/6 rat survived more than 1 year in case of MRT combined with gadolinium injection."	( Enhancement of survival of 9L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy. Bräuer-Krisch, E; Bravin, A; Keyriläinen, J; Le Duc, G; Régnard, P; Troprès, I, 2008)	0.35
" The article reports safety, efficacy, pharmacokinetic, and pharmacodynamic results of the first-in-class trial of a PARP inhibitor, AG014699, combined with temozolomide in adults with advanced malignancy."	( Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Boddy, A; Calvert, H; Curtin, N; Dewji, R; Evans, J; Harris, A; Johnson, P; Jones, C; McHugh, P; Middleton, M; Newell, D; Olsen, A; Plummer, R; Robson, L; Steinfeldt, H; Wang, D; Wilson, R, 2008)	0.35
" Dasatinib in combination with temozolomide more effectively increased the therapeutic efficacy of temozolomide than when dasatinib was combined with carboplatin or irinotecan."	( Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. de Groot, J; LaFortune, T; Milano, V; Piao, Y, 2009)	0.35
"To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS)."	( Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. Dinter, DJ; Hohenberger, P; Jakob, J; Ströbel, P; Wenz, F, 2009)	0.35
" Drug combination of TMZ plus BG and PHA-848125 produced additive or synergistic effects on cell growth, depending on the cell line."	( The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Castiglia, D; Ciomei, M; Covaciu, C; D'Atri, S; Garbin, A; Levati, L; Starace, G, 2010)	0.36
" After irradiation of the symptomatic sites, intrathecal liposomal Ara-C every 2-4 weeks was combined with temozolomide 100 mg/m(2) day 1-5/7."	( Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. Buhk, JH; Hoffmann, AL; Strik, H, 2009)	0.35
"To evaluate the effects and the toxicity of the protocol of CDV combined with CiE as pre-operative chemotherapy in childhood stage IV neuroblastoma."	( [Curative effects of the protocol of CDV combined with CiE as pre-operative chemotherapy in high-risk childhood neuroblastoma]. Feng, C; Liu, Y; Tang, SQ; Wang, JW; Yang, G, 2009)	0.35
"The protocol of CDV combined with CiE as pre-operative chemotherapy might be effective in children with stage IV neuroblastoma."	( [Curative effects of the protocol of CDV combined with CiE as pre-operative chemotherapy in high-risk childhood neuroblastoma]. Feng, C; Liu, Y; Tang, SQ; Wang, JW; Yang, G, 2009)	0.35
"To evaluate maximum tolerated dose and recommended dose (RD) for phase II studies of topotecan (TPT) combined with temozolomide (TMZ) (TOTEM) in children and adolescents with relapsed or refractory solid malignancies."	( Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. Aerts, I; Chastagner, P; Chatelut, E; Corradini, N; Dias, N; Djafari, L; Frappaz, D; Gentet, JC; Geoerger, B; Landman-Parker, J; Le Deley, MC; Leblond, P; Ndiaye, A; Paci, A; Pasquet, M; Rubie, H; Schmitt, A; Vassal, G, 2010)	0.36
" Our results demonstrate the potential of the anti-IGF-1R antibody alone and in combination with alkylating agents and support the therapeutic development of the AVE1642 for aggressive neuroblastoma."	( Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma. Brasme, JF; Daudigeos-Dubus, E; Debussche, L; Geoerger, B; Opolon, P; Vassal, G; Venot, C; Vrignaud, P, 2010)	0.36
" Metronomic dosing of temozolomide (TMZ) combined with standard radiotherapy may improve survival by increasing the therapeutic index and anti-angiogenic effect of TMZ."	( A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Bartels, U; Baruchel, S; Bouffet, E; Eisenstat, D; Gammon, J; Huang, A; Hukin, J; Johnston, DL; Samson, Y; Sharp, JR; Stempak, D; Stephens, D; Tabori, U, 2010)	0.36
" This factorial design phase I/II protocol tested dose-dense temozolomide alone and combined with cytostatic agents."	( A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Chang, E; Colman, H; Conrad, C; de Groot, J; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, K; Hunter, K; Levin, V; Mahajan, A; Puduvalli, V; Woo, S; Yung, WK, 2010)	0.36
"Sorafenib, a multikinase inhibitor of Raf and several growth factor receptors, is under investigation in combination with dacarbazine, a commonly used chemotherapeutic agent for the treatment of many cancers."	( Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC, 2011)	0.37
" On the basis of promising preclinical data, the safety and tolerability of therapy with the mTOR inhibitor RAD001 in combination with radiation (RT) and temozolomide (TMZ) was evaluated in this Phase I study."	( North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011)	0.37
"All patients received weekly oral RAD001 in combination with standard chemoradiotherapy, followed by RAD001 in combination with standard adjuvant temozolomide."	( North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011)	0.37
" On the basis of these results, the recommended Phase II dosage currently being tested is RAD001 70 mg/week in combination with standard chemoradiotherapy."	( North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011)	0.37
"RAD001 in combination with RT/TMZ and adjuvant TMZ was reasonably well tolerated."	( North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011)	0.37
" Fifty-nine patients underwent primary surgery by wide or marginal excision and were subsequently randomized to receive radiotherapy alone or in combination with six courses of chemotherapy consisting of ifosfamide, DTIC, and doxorubicin administered in 14-day intervals supported by G-CSF on days 5-13."	( Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial. Abdolvahab, F; Brodowicz, T; Dominkus, M; Ebm, C; Fakhrai, N; Jantsch, M; Kauer-Dorner, D; Kostler, WJ; Pokrajac, B; Zielinski, CC, 2010)	0.36
"The phase II trial has been prepared to assess the effectiveness of BPA (250 mg/kg)-based NCT combined with X-ray irradiation and temozolomide (75 mg/m(2)) for the treatment of newly diagnosed GBM."	( The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation. Aiyama, H; Endo, K; Ishikawa, E; Kumada, H; Matsumura, A; Mizumoto, M; Nakai, K; Nariai, T; Okumura, T; Shibata, Y; Takada, T; Tsuboi, K; Yamamoto, T; Yoshida, F; Zaboronok, A, 2011)	0.37
" The major differences of our protocol from the other past studies were simultaneous use of both sodium borocapate and boronophenylalanine, and combination with fractionated X-ray irradiation."	( Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report. Hiramatsu, R; Hirota, Y; Kawabata, S; Kirihata, M; Kuroiwa, T; Maruhashi, A; Miyata, S; Miyatake, S; Ono, K; Sakurai, Y; Takekita, Y, 2011)	0.37
" Here, we describe 3 cases of GBM patients treated with autologous formalin-fixed tumor vaccine (AFTV) combined with TMZ."	( Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - . Enomoto, T; Ishikawa, E; Matsumura, A; Morishita, Y; Nakai, K; Ohno, T; Sakamoto, N; Sato, M; Satomi, K; Takano, S; Tsuboi, K; Yamamoto, T, 2011)	0.37
"The primary end point was surpassed showing promising activity of this bevacizumab/temozolomide combination with a favourable toxicity profile."	( First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Cathomas, R; Dummer, R; Gillessen, S; Goldinger, SM; Mamot, C; Michielin, O; Mjhic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schönewolf, N; Schraml, PH; Seifert, B; Simcock, M; von Moos, R, 2012)	0.38
" The aim of the present study was to evaluate the efficacy and side effects of nimotuzumab in combination with chemotherapy for patients with malignant gliomas."	( [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH, 2011)	0.37
" Individualized chemotherapy was administered based on O(6)-methylguanine-DNA methyltransferase (MGMT) expression and previous chemotherapy responses in combined with nimotuzumab."	( [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH, 2011)	0.37
"Nimotuzumab in combination with chemotherapy has moderate activity in patients with malignant gliomas and the toxicities are well tolerable, therefore, worth further investigation."	( [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH, 2011)	0.37
" In vitro Southern Blot analysis and cytopathic effect assays demonstrate high anti-glioma potency, which was significantly increased in combination with temozolomide (TMZ), daunorubicin and cisplatin."	( YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. Anton, M; Gänsbacher, B; Haczek, C; Holm, PS; Holzmüller, R; Kasajima, A; Lage, H; Mantwill, K; Rognoni, E; Schlegel, J; Schuster, T; Treue, D; Weichert, W, 2011)	0.37
" Herein, we report the first phase I experience of the novel O6-meG pseudosubstrate lomeguatrib, combined with dacarbazine."	( Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Kirkwood, JM; Moschos, S; Radkowski, R; Shipe-Spotloe, J; Sulecki, M; Tarhini, A; Tawbi, HA; Villaruz, L; Viverette, F, 2011)	0.37
"This is a phase I dose-escalation study to determine the maximum tolerated dose and recommended phase II dose (RP2D) of lomeguatrib combined with a single dose of dacarbazine on a 21-day schedule."	( Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Kirkwood, JM; Moschos, S; Radkowski, R; Shipe-Spotloe, J; Sulecki, M; Tarhini, A; Tawbi, HA; Villaruz, L; Viverette, F, 2011)	0.37
" In this study, safety and clinical activity of L19-IL2 in combination with dacarbazine were assessed in patients with metastatic melanoma."	( A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. de Braud, F; Eigentler, TK; Garbe, C; Giovannoni, L; González-Iglesias, R; Kaspar, M; Lovato, V; Menssen, HD; Neri, D; Pflugfelder, A; Romanini, A; Schwager, K; Spitaleri, G; Tasciotti, A; Trachsel, E; Weide, B, 2011)	0.37
"The first 10 studied patients received escalating doses of L19-IL2 on days 1, 3, and 5 in combination with 1 g/m(2) of dacarbazine on day 1 of a 3-weekly therapy cycle."	( A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. de Braud, F; Eigentler, TK; Garbe, C; Giovannoni, L; González-Iglesias, R; Kaspar, M; Lovato, V; Menssen, HD; Neri, D; Pflugfelder, A; Romanini, A; Schwager, K; Spitaleri, G; Tasciotti, A; Trachsel, E; Weide, B, 2011)	0.37
"The recommended dose of L19-IL2 in combination with dacarbazine was defined as 22."	( A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. de Braud, F; Eigentler, TK; Garbe, C; Giovannoni, L; González-Iglesias, R; Kaspar, M; Lovato, V; Menssen, HD; Neri, D; Pflugfelder, A; Romanini, A; Schwager, K; Spitaleri, G; Tasciotti, A; Trachsel, E; Weide, B, 2011)	0.37
"The repeated administration of L19-IL2 in combination with dacarbazine is safe and shows encouraging signs of clinical activity in patients with metastatic melanoma."	( A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. de Braud, F; Eigentler, TK; Garbe, C; Giovannoni, L; González-Iglesias, R; Kaspar, M; Lovato, V; Menssen, HD; Neri, D; Pflugfelder, A; Romanini, A; Schwager, K; Spitaleri, G; Tasciotti, A; Trachsel, E; Weide, B, 2011)	0.37
"To study the efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide (TMZ) for gliomas."	( [Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma]. Tu, Q; Wang, L; Zhou, R; Zhou, W, 2011)	0.37
" The patients received temozolomide alone,3-dimensional conformal radiotherapy alone,3-dimensional conformal radiotherapy combined with temozolomide in the chemotherapy group,the radiotherapy group and the comprehensive therapy group respectively."	( [Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma]. Tu, Q; Wang, L; Zhou, R; Zhou, W, 2011)	0.37
"Three-dimensional conformal radiotherapy combined with temozolomide is more effective for gliomas than the simple 3-dimensional conformal radiotherapy and the temozolomide chemotherapy alone."	( [Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma]. Tu, Q; Wang, L; Zhou, R; Zhou, W, 2011)	0.37
" Levels of SHP-1 substrates (pSTAT1, pSTAT3, pLck and pSlp76) were increased (up to 3x) in peripheral blood cells following SSG with no potentiation by combination with IFN-α2b."	( Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Borden, EC; Budd, TG; Elson, P; Hollovary, E; Jacobs, B; Mitsuhashi, M; Spiro, T; Triozzi, P; Yi, T, 2011)	0.37
"To study the safety and efficacy of three-dimensional conformal radiotherapy in combination with temozolomide in treatment of patients with diffuse brainstem glioma."	( [Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas]. Cai, CL; Fang, HH; Kang, JB; Li, FM; Nie, Q, 2011)	0.37
" It is likely that clinical testing of these agents will be in combination with standard therapies to harness the apoptotic potential of both the agents."	( The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW, 2012)	0.38
"The aim of this study was to identify agents, which would be likely to offer clinical benefit when combined with selumetinib."	( The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW, 2012)	0.38
" In several models we observed that continuous exposure to selumetinib in combination with docetaxel results in tumour regression."	( The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW, 2012)	0.38
"The data presented suggests that MEK inhibition in combination with several standard chemotherapeutics or an Aurora B kinase inhibitor is a promising clinical strategy."	( The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW, 2012)	0.38
" As HSP27 and AKT interact to regulate the activity of each other, we determined whether inhibition of HSP27 was better than targeting SPARC as a therapeutic approach to inhibit both SPARC-induced glioma cell invasion and survival."	( Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. Brodie, C; Brown, SL; Golembieski, WA; King, DA; Rempel, SA; Schultz, CR, 2012)	0.38
"We conclude that inhibition of HSP27 alone, or in combination with pAKT inhibitor IV, may be an effective therapeutic approach to inhibit SPARC-induced glioma cell invasion and survival in SPARC-positive/PTEN-wildtype and SPARC-positive/PTEN-null tumors, respectively."	( Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. Brodie, C; Brown, SL; Golembieski, WA; King, DA; Rempel, SA; Schultz, CR, 2012)	0.38
"A retrospective study assessing treatment-related toxicities in tumor-bearing cats treated with temozolomide (TMZ) alone or in combination with doxorubicin was conducted."	( Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment. Dervisis, NG; Gagnon, J; Kitchell, BE, 2012)	0.38
" The primary objectives of this randomized phase 2 trial were to determine the safety and efficacy of cilengitide when combined with radiation and temozolomide for patients with newly diagnosed glioblastoma multiforme and to select a dose for comparative clinical testing."	( A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Batchelor, T; Brem, S; Fisher, JD; Grossman, SA; Hegi, ME; Lesser, G; Mikkelsen, T; Nabors, LB; Olsen, J; Peereboom, D; Rosenfeld, MR; Ye, X, 2012)	0.38
"Cilengitide was well tolerated when combined with standard chemoradiation and may improve survival for patients newly diagnosed with glioblastoma multiforme regardless of MGMT methylation status."	( A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Batchelor, T; Brem, S; Fisher, JD; Grossman, SA; Hegi, ME; Lesser, G; Mikkelsen, T; Nabors, LB; Olsen, J; Peereboom, D; Rosenfeld, MR; Ye, X, 2012)	0.38
" At the time of last relapse, temozolomide was administered alone and combined with external beam radiation therapy."	( Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. Alongi, F; Clerici, E; Navarria, P; Rognone, E; Santoro, A; Scorsetti, M; Simonelli, M, )	0.13
"To evaluate the toxicity and maximum tolerated dose (MTD) of arsenic trioxide (ATO) in combination with temozolomide (TMZ) and radiation therapy (RT) in malignant gliomas."	( Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas. Chandler, JP; Grimm, SA; Jovanovic, B; Levy, RM; Marymont, M; McCarthy, K; Muro, K; Newman, SB; Raizer, JJ, 2012)	0.38
"A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG)."	( Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012)	0.38
" Part 1 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m(2)/day for 5 days every 28 days."	( Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012)	0.38
"In part 1, the MTD of vorinostat administered on days 1 to 7 and 15 to 21 of every 28-day cycle, in combination with TMZ, was 500 mg daily."	( Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012)	0.38
"Vorinostat in combination with temozolomide is well tolerated in patients with HGG."	( Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012)	0.38
" One of the most interesting combinations that have started to become part of the therapeutic arsenal in the daily clinic is dose-dense temozolomide in combination with bevacizumab."	( A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma. Bergqvist, M; Bergström, S; Blomquist, E; Ekman, S; Henriksson, R; Johansson, F, 2012)	0.38
" (177)Lu-octreotate, in combination with capecitabine and temozolomide, is well tolerated in patients with advanced low-grade NETs, and shows substantial tumor control rates."	( Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Claringbold, PG; Price, RA; Turner, JH, 2012)	0.38
" This drug combination significantly impaired the sphere-forming ability of GSCs in vitro and tumor formation in vivo, leading to increase in the overall survival of mice bearing orthotopic inoculation of GSCs."	( Effective elimination of cancer stem cells by a novel drug combination strategy. Chen, G; Colman, H; Feng, L; Huang, P; Keating, MJ; Li, X; Wang, F; Wang, J; Wang, L; Xu, RH; Yuan, S; Zhang, H, 2013)	0.39
" We hypothesized that epigenetic modulators will reverse chemotherapy resistance, and in this article, we report studies that sought to determine the recommended phase 2 dose (RP2D), safety, and efficacy of decitabine (DAC) combined with TMZ."	( Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA, 2013)	0.39
"This study suggests that ABT-888 has the clinical potential to enhance the current standard treatment for GBM, in combination with conventional chemo-radiotherapy."	( Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Barazzuol, L; Burnet, NG; Jena, R; Jeynes, JC; Kirkby, KJ; Kirkby, NF; Meira, LB, 2013)	0.39
"Daily oral everolimus (10 mg) combined with both concurrent radiation and temozolomide followed by adjuvant temozolomide is well tolerated, with an acceptable toxicity profile."	( RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Chinnaiyan, P; Corn, BW; Dipetrillo, TA; Mehta, MP; Rojiani, AM; Wen, PY; Wendland, M; Won, M, 2013)	0.39
"To evaluate the efficacy of pulsed low-dose radiation therapy (PLRT) combined with temozolomide (TMZ) as a novel treatment approach for radioresistant glioblastoma multiforme (GBM) in a murine model."	( Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme. Chunta, JL; Grills, IS; Huang, J; Krueger, SA; Lee, DY; Marples, B; Martinez, AA; Park, SS; Wilson, GD, 2013)	0.39
"Patients treated within a Phase I/II Trial with a carbon ion boost were compared retrospectively with randomly chosen patients treated with photons or photons in combination with TMZ in a retrospective analysis."	( Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis. Bruckner, T; Combs, SE; Debus, J; Kamada, T; Kieser, M; Mizoe, JE; Tsujii, H, 2013)	0.39
"To assess objective response rate (ORR) after two cycles of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed neuroblastoma."	( Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. Aerts, I; Amoroso, L; Boubaker, A; Casanova, M; Chastagner, P; Courbon, F; Devos, A; Di Giannatale, A; Dias-Gastellier, N; Ducassoul, S; Geoerger, B; Landman-Parker, J; Le Deley, MC; Malekzadeh, K; Mc Hugh, K; Munzer, C; Riccardi, R; Rubie, H; Verschuur, A; Zwaan, CM, 2014)	0.4
" In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment."	( Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013)	0.39
" We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma."	( Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Ansell, SM; Connors, JM; Fanale, M; Huebner, D; Hunder, NN; O'Meara, MM; Park, SI; Younes, A, 2013)	0.39
"We did a phase 1, open-label, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD) or a modified-standard (AVD) treatment."	( Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Ansell, SM; Connors, JM; Fanale, M; Huebner, D; Hunder, NN; O'Meara, MM; Park, SI; Younes, A, 2013)	0.39
" The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was not exceeded at 1·2 mg/kg."	( Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Ansell, SM; Connors, JM; Fanale, M; Huebner, D; Hunder, NN; O'Meara, MM; Park, SI; Younes, A, 2013)	0.39
"Brentuximab vedotin should not be given with bleomycin in general or specifically as first-line therapy for patients with treatment naive, advanced stage Hodgkin's lymphoma."	( Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Ansell, SM; Connors, JM; Fanale, M; Huebner, D; Hunder, NN; O'Meara, MM; Park, SI; Younes, A, 2013)	0.39
"To determine the maximum tolerated dose of irinotecan administered every 2 weeks, in combination with a fixed and continuous administration of temozolomide, in patients with glioblastoma at first relapse."	( A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G, 2014)	0.4
" More generally, these results suggest that traditional therapy in combination with local, as opposed to systemic, delivery of angiogenesis inhibitors may be able to increase median survival for patients with glioblastoma."	( Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma. Bow, H; Brem, H; Hwang, LS; Murray, L; Salditch, Q; Schildhaus, N; Tyler, B; Weingart, J; Xing, J; Ye, X; Zhang, Y, 2014)	0.4
"To evaluate the safety and efficacy of nimotuzumab, a humanized monoclonal antibody specific for the epidermal growth factor receptor (EGFR), in combination with temozolomide (TMZ) and radiation therapy (RT) in the treatment of newly diagnosed glioblastoma (GBM) in Chinese patients."	( Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. Chen, S; Dai, JZ; Pan, L; Sheng, XF; Wang, Y, 2016)	0.43
" During RT, concurrent TMZ was given daily at 75 mg/m(2) for 40-42 days, combined with six weekly infusions of nimotuzumab at a 200 mg dose."	( Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. Chen, S; Dai, JZ; Pan, L; Sheng, XF; Wang, Y, 2016)	0.43
" This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma."	( Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC, 2014)	0.4
"Patients were treated with RT (60 Gy in 2 Gy fractions) combined with TMZ 75 mg m(-2) daily, and Sb administered at three dose levels (200 mg daily, 200 mg BID, and 400 mg BID) starting on day 8 of RT."	( Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC, 2014)	0.4
"Although Sb can be combined with RT and TMZ, significant side effects and moderate outcome results do not support further clinical development in malignant gliomas."	( Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC, 2014)	0.4
"Twenty-six patients received CEP-9722 150-1,000 mg/day combined with temozolomide."	( Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Aissat-Daudigny, L; Brown, PD; Cambois, A; Campone, M; Moachon, G; Plummer, R; Stephens, P, 2014)	0.4
" F8-IL2 was shown to selectively localize at the tumor site in vivo, following intravenous administration, and to mediate tumor growth retardation, which was potentiated by the combination with paclitaxel or dacarbazine."	( Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Castioni, N; Elia, G; Neri, D; Pretto, F, 2014)	0.4
"WBRT followed by IMBRT combined with concomitant TMZ is well tolerated, yielding an encouraging objective response rate; however, overall survival improves slightly comparing with RTOG 9508 randomized trial."	( Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer. Jiang, Z; Leng, C; Liang, S; Liu, H; Lu, F; Lu, S; Qi, X; Shi, J; Wang, Q; Wang, S, 2014)	0.4
"To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy."	( Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014)	0.4
"Patients who received highly emetogenic chemotherapy were randomly assigned to a treatment group (60 patients) treated with EANI combined with hydrochloride palonosetron, and control group (also 60 patients) given only hydrochloride palonosetron."	( Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014)	0.4
"EANI combined with hydrochloride palonosetron for prevention of nausea and vomiting induced by chemotherapy could be more effective than hydrochloride palonosetron alone, and can be recommended for use in prevention and treatment of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy."	( Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014)	0.4
"2 mg/kg three times weekly for 2 weeks (starting on day 1), in combination with oral panobinostat 10, 20, or 30 mg every 96 h (starting on day 8), and oral temozolomide 150 mg/m(2)/day on days 9 through 13."	( Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C, 2014)	0.4
"This triple agent of dual epigenetic therapy in combination with traditional chemotherapy was generally well tolerated by the cohort and appeared safe to be continued in a Phase II trial."	( Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C, 2014)	0.4
" Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter)."	( Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Adamska, K; Aldape, KD; Brandes, AA; Erridge, SC; Gorlia, T; Grujicic, D; Gupta, T; Hau, P; Hegi, ME; Herrlinger, U; Hicking, C; Hong, YK; Kim, CY; Kortmann, RD; Lhermitte, B; Markivskyy, A; McBain, C; Nabors, LB; Nam, DH; Perry, J; Picard, M; Pietsch, T; Rao, N; Reardon, DA; Schnell, O; Shen, CC; Steinbach, JP; Stupp, R; Taphoorn, MJ; Tarnawski, R; Thurzo, L; Tonn, JC; van den Bent, MJ; Weller, M; Weyerbrock, A; Wick, W; Wiegel, T, 2014)	0.4
" In the present work, TMZ was combined with a specific SKI, and the cytotoxic effect of each drug alone or in combination was tested on GBM cell lines."	( A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy. Choi, J; Kopp-Schneider, A; Noack, J; Régnier-Vigouroux, A; Richter, K, 2014)	0.4
" We reasoned this could be more effective if combined with a vaccine that preferentially targeted TMZ-resistant cells."	( Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. Ancelet, LR; Bauer, E; Dzhelali, M; Findlay, MP; Gasser, O; Hamilton, DA; Hermans, IF; Hunn, MK; Mester, B; Sharples, KJ; Wood, CE, 2015)	0.42
"After a biopsy (6 patients) or a resection (13 patients) of a newly diagnosed GBM, 19 patients received radiotherapy (30 fractions of 2 Gy) in combination with daily TMZ 75 mg/m(2) and BV 10 mg/kg on days 1, 14, and 28, followed by 6 monthly cycles of TMZ 150-200 mg/m(2) on days 1-5."	( Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme. Reijneveld, JC; Richel, DJ; Stalpers, LJ; van Furth, WR; van Linde, ME; Verheul, HM; Verhoeff, JJ, 2015)	0.42
"Wee1 regulates key DNA damage checkpoints, and in this study, the efficacy of the Wee1 inhibitor MK-1775 was evaluated in glioblastoma multiforme (GBM) xenograft models alone and in combination with radiation and/or temozolomide."	( The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Agar, NY; Bakken, KK; Calligaris, D; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Evans, DL; Gupta, SK; Iyekegbe, DO; Lou, Z; Ma, B; Mueller, D; Pokorny, JL; Pucci, V; Sarkaria, JN; Schroeder, MA; Shumway, SD, 2015)	0.42
"In vitro MK-1775 efficacy alone and in combination with temozolomide, and the impact on DNA damage, was analyzed by Western blotting and γH2AX foci formation."	( The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Agar, NY; Bakken, KK; Calligaris, D; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Evans, DL; Gupta, SK; Iyekegbe, DO; Lou, Z; Ma, B; Mueller, D; Pokorny, JL; Pucci, V; Sarkaria, JN; Schroeder, MA; Shumway, SD, 2015)	0.42
" However, there was no sensitizing effect of MK-1775 when combined with temozolomide in vitro."	( The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Agar, NY; Bakken, KK; Calligaris, D; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Evans, DL; Gupta, SK; Iyekegbe, DO; Lou, Z; Ma, B; Mueller, D; Pokorny, JL; Pucci, V; Sarkaria, JN; Schroeder, MA; Shumway, SD, 2015)	0.42
" Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation."	( The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. Cosgrove, L; Day, B; Fay, M; Head, R; Hosein, AN; Lim, YC; Martin, JH; Rose, S; Sminia, P; Stringer, B, 2015)	0.42
" This phase II, randomized, open-label, multicenter trial investigated the efficacy and safety of 2 dose regimens of the selective integrin inhibitor cilengitide combined with standard chemoradiotherapy in patients with newly diagnosed glioblastoma and an unmethylated MGMT promoter."	( Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V, 2015)	0.42
" Cilengitide was administered intravenously in combination with daily temozolomide (TMZ) and concomitant radiotherapy (RT; wk 1-6), followed by TMZ maintenance therapy (TMZ/RT→TMZ)."	( Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V, 2015)	0.42
"Standard and intensive cilengitide dose regimens were well tolerated in combination with TMZ/RT→TMZ."	( Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V, 2015)	0.42
" Pre-clinically, selumetinib in combination with alkylating agents enhanced antitumour activity compared with chemotherapy alone."	( Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). Carvajal, RD; Mann, H; Nathan, PD; Schwartz, GK; Smith, I, 2015)	0.42
"SUMIT is a randomised, international, double-blind, placebo-controlled, phase III study assessing the efficacy and safety of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma who have not received prior systemic therapy."	( Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). Carvajal, RD; Mann, H; Nathan, PD; Schwartz, GK; Smith, I, 2015)	0.42
" This study evaluating selumetinib in combination with dacarbazine was designed with input from the US FDA, and is the first potential registration trial to be conducted in patients with metastatic uveal melanoma."	( Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). Carvajal, RD; Mann, H; Nathan, PD; Schwartz, GK; Smith, I, 2015)	0.42
" Abemaciclib antitumor activity was assessed in subcutaneous and orthotopic glioma models alone and in combination with standard of care temozolomide (TMZ)."	( Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. Ajamie, RT; De Dios, A; Gelbert, LM; Kulanthaivel, P; Raub, TJ; Sanchez-Martinez, C; Sawada, GA; Shannon, HE; Staton, BA; Wishart, GN, 2015)	0.42
" In this study, we found that PI3K inhibitor combined with miR-125b inhibitor caused a marked increase of TMZ-induced GSC proliferation and invasiveness inhibition."	( PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway. Fei, X; Shi, L; Wang, Z; You, Y, 2015)	0.42
"The primary aim of this Phase I study was to determine the maximum tolerated dose (MTD) of TPI 287 and the safety and tolerability of TPI 287 alone and in combination with temozolomide (TMZ) in pediatric patients with refractory or recurrent neuroblastoma or medulloblastoma."	( A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. Ashikaga, T; Bergendahl, G; DeSarno, M; Eslin, D; Ferguson, W; Hanna, GK; Higgins, T; Kaplan, J; Kraveka, J; Mitchell, D; Roberts, W; Sholler, GL; Werff, AV, 2016)	0.43
"Eighteen patients were enrolled to a phase I dose escalation trial of weekly intravenous infusion of TPI 287 for two 28-day cycles with toxicity monitoring to determine the MTD, followed by two cycles of TPI 287 in combination with TMZ."	( A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. Ashikaga, T; Bergendahl, G; DeSarno, M; Eslin, D; Ferguson, W; Hanna, GK; Higgins, T; Kaplan, J; Kraveka, J; Mitchell, D; Roberts, W; Sholler, GL; Werff, AV, 2016)	0.43
"We determined the MTD of TPI 287 alone and in combination with temozolomide to be 125 mg/m(2)."	( A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. Ashikaga, T; Bergendahl, G; DeSarno, M; Eslin, D; Ferguson, W; Hanna, GK; Higgins, T; Kaplan, J; Kraveka, J; Mitchell, D; Roberts, W; Sholler, GL; Werff, AV, 2016)	0.43
" Pharmacokinetic testing did not show evidence of drug-drug interaction between irinotecan and alisertib."	( Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L, 2016)	0.43
" This phase I study aims to evaluate its safety, maximum tolerated dose (MTD), pharmacodynamic effect, and preliminary efficacy when combined with adjuvant temozolomide in GBM patients after standard chemoradiotherapy."	( A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI, 2016)	0.43
"The aim of this study was to compare the efficacy and safety of interferon (IFN) combined with dacarbazine (DTIC) (experimental group) versus DTIC alone (control group) in cutaneous malignant melanoma."	( Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma. Hou, XY; Huang, Q; Jiang, G; Tang, JQ; Xin, Y; Yang, M; Zhang, LZ; Zhang, P, 2016)	0.43
" We show that GSI in combination with RT and TMZ attenuates proliferation, decreases 3D spheroid growth and results into a marked reduction in clonogenic survival in primary and established glioma cell lines."	( NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Barbeau, LM; Chalmers, AJ; Eekers, DB; Granton, PV; Groot, AJ; Habets, R; Iglesias, VS; King, H; Prickaerts, J; Short, SC; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S, 2016)	0.43
" We investigated the pharmacologic characteristics of OTX015 as a single agent and combined with targeted therapy or conventional chemotherapies in glioblastoma cell lines."	( OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. Astorgues-Xerri, L; Bekradda, M; Berenguer-Daizé, C; Cayol, M; Cvitkovic, E; Lokiec, F; MacKenzie, S; Noel, K; Odore, E; Ouafik, L; Rezai, K; Riveiro, ME, 2016)	0.43
" Subsequently, each agent was used in combination with CNDAC at fixed concentration ratios."	( Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC. Hargis, S; Jiang, Y; Liu, X; Nowak, B; Plunkett, W, 2016)	0.43
" Its combination with other chemotherapeutic agents was reported to produce synergistic/additive effects on various cancers."	( In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine. Averineni, RK; Guan, X; Sadhu, SS; Seefeldt, T; Wang, S; Yang, Y, 2016)	0.43
"We observed no survival benefit in young adults (age < 50) with anaplastic glioma when treated with TMZ combined with RT."	( Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. Cai, J; Jiang, T; Li, S; Li, W; Peng, X; Qiu, X; Wang, Y; Wu, C; Yang, P; Yao, K; You, G; Zhang, C; Zhang, W, 2016)	0.43
"To observe the effect of RITA, a small molecule that targets p53, combined with temozolomide (TMZ) on proliferation, colony formation and apoptosis of human glioblastoma U87 cells and explore the underlying mechanism."	( [RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells]. Cao, ZX; Feng, XL; He, XY; Song, XP; Wu, QH; Xiao, WW; Zeng, HC; Zhang, B, 2016)	0.43
" RITA combined with TMZ caused a more significant inhibition of U87 cells (29."	( [RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells]. Cao, ZX; Feng, XL; He, XY; Song, XP; Wu, QH; Xiao, WW; Zeng, HC; Zhang, B, 2016)	0.43
" The present study used a patient-derived orthotopic xenograft (PDOX) nude-mouse model of melanoma with a BRAF-V600E mutation to determine the efficacy of temozolomide (TEM) combined with tumor-targeting Salmonella typhimurium A1-R."	( Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Singh, A; Unno, M; Zhang, Y; Zhao, M, 2016)	0.43
" We evaluated the safety and tolerance of additional use of D,L-methadone in patients with glioma in combination with chemotherapy."	( Safety and Tolerance of D,L-Methadone in Combination with Chemotherapy in Patients with Glioma. Friesen, C; Misch, M; Onken, J; Vajkoczy, P, 2017)	0.46
"D,L-methadone can be safely combined with standard glioma chemotherapy without increasing the risk of toxicity or vegetative symptoms such as tachycardia, sweating and restlessness."	( Safety and Tolerance of D,L-Methadone in Combination with Chemotherapy in Patients with Glioma. Friesen, C; Misch, M; Onken, J; Vajkoczy, P, 2017)	0.46
"Antagonists of inhibitors of apoptosis proteins (IAPs), alone or in combination with genotoxic therapeutics, have been shown to efficiently induce cell death in various solid tumors."	( Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death. Alexopoulos, LG; Charles, EM; Hellwig, CT; Rehm, M; Rožanc, J; Vetma, V, 2017)	0.46
" To the best of our knowledge, this is the first report of severe hypokalemia and proximal tubular renal dysfunction as a result of a possible drug-drug interaction between vinblastine, tenofovir and ritonavir-boosted atazanavir."	( Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Arcondo, F; Cordova, E; Morganti, L; Odzak, A; Rodriguez, C; Silva, M; Zylberman, M, 2017)	0.46
"New therapeutic agents in combination with the standard Stupp protocol (a protocol about the temozolomide combined with radiotherapy treatment with glioblastoma was research by Stupp R in 2005) were assessed to evaluate whether they were superior to the Stupp protocol alone, to determine the optimum treatment regimen for patients with newly diagnosed glioblastoma."	( The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis. Chen, T; Fu, A; Li, J; Li, M; Song, X; Zhu, J, 2017)	0.46
"The use of novel therapeutic agents in combination with the Stupp protocol were all shown to be superior than the Stupp protocol alone for the treatment of newly diagnosed glioblastoma, ranked as follows: cilengitide 2000mg/5/week, bevacizumab in combination with irinotecan, nimotuzumab, bevacizumab, cilengitide 2000mg/2/week, cytokine-induced killer cell immunotherapy, and the Stupp protocol."	( The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis. Chen, T; Fu, A; Li, J; Li, M; Song, X; Zhu, J, 2017)	0.46
"All intervention drugs evaluated in our study were superior to the Stupp protocol alone when used in combination with it."	( The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis. Chen, T; Fu, A; Li, J; Li, M; Song, X; Zhu, J, 2017)	0.46
"We evaluated stereotactic volume modulated arc radiotherapy (VMAT) for canine gliomas, alone (radiotherapy [RT]) and in combination with temozolomide (RT + TMZ), compared with palliation."	( Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas. Bianchi, C; Carrara, N; Dolera, M; Finesso, S; Malfassi, L; Marcarini, S; Mazza, G; Pavesi, S; Sala, M; Urso, G, 2018)	0.48
" The aim of this retrospective study was to evaluate the efficacy and toxicity of TMZ in dogs with relapsed multicentric lymphoma that failed multi-agent chemotherapy protocols, and compare the outcome to a group of dogs receiving the same drug in combination with DOX."	( Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma. Baines, SJ; Blackwood, L; Elliott, JW; Treggiari, E, 2018)	0.48
"An intestine-liver-glioblastoma biomimetic system was developed to evaluate the drug combination therapy for glioblastoma."	( Evaluation of drug combination for glioblastoma based on an intestine-liver metabolic model on microchip. He, Z; Jie, M; Li, HF; Lin, JM; Liu, H; Mao, S, 2017)	0.46
" In vivo, systemic treatment with pacritinib demonstrated blood-brain barrier penetration and led to improved overall median survival in combination with TMZ, in mice orthotopically xenografted with an aggressive recurrent GBM BTIC culture."	( The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. Aman, A; Cseh, O; Jensen, KV; Luchman, HA; Weiss, S, 2017)	0.46
"This preclinical study demonstrates the efficacy of pacritinib and supports the feasibility of testing pacritinib for the treatment of GBM, in combination with the standard of care TMZ."	( The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. Aman, A; Cseh, O; Jensen, KV; Luchman, HA; Weiss, S, 2017)	0.46
"We performed C57BL/6 mouse orthotopic glioma model by stereotactic intracranial implantation of glioma cell line GL261, mice were randomly divided into four groups: (1) control group; (2) TMZ group; (3) anti-PD-1 antibody group; (4) TMZ combined with anti-PD-1 antibody group."	( Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model. Dai, B; Li, J; Qi, N; Zhang, G, 2018)	0.48
"Anti-PD1 antibody combined with TMZ therapy for orthotopic mouse glioma model could significantly improve the survival time of tumor-bear mice."	( Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model. Dai, B; Li, J; Qi, N; Zhang, G, 2018)	0.48
"To investigate the clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent glioma."	( [Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma]. Jiang, C; Li, X; Liu, S; Tang, S; Zhao, H, 2018)	0.48
"We retrospectively analyzed the safety and efficacy of hypofractionated radiotherapy (45 Gy/15 fr) combined with temozolomide (TMZ) followed by bevacizumab (BEV) salvage treatment in 18 glioblastoma patients aged > 75 years."	( Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years. Kayama, T; Matsuda, KI; Nemoto, K; Sakurada, K; Sonoda, Y, 2018)	0.48
"Hypofractionated radiotherapy combined with TMZ and BEV salvage treatment was found to be safe and effective in glioblastoma patients aged > 75 years."	( Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years. Kayama, T; Matsuda, KI; Nemoto, K; Sakurada, K; Sonoda, Y, 2018)	0.48
" In addition, TMZ could increase the levels of miR-505 and combination with pri-miR-505 and TMZ promoted the suppressive role mediated by miR-505 in GBM cells."	( Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway. Fu, C; Liu, X; Yang, X; Zhang, C, 2018)	0.48
" Temozolomide (TMZ) is one of them, widely used even in combination with ionizing radiation."	( Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review. Almeida, T; Azqueta, A; Ferreira, J; Ramos, AA; Rocha, E, 2018)	0.48
" However, their effects and mechanisms of action, alone or in combination with anticancer drugs, namely TMZ, in glioblastoma cell, still few explored and require more attention due to the unquestionable high potential of these marine compounds."	( Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review. Almeida, T; Azqueta, A; Ferreira, J; Ramos, AA; Rocha, E, 2018)	0.48
" Six patients received temozolomide and 8 received dacarbazine + 5-FU, combined with Endostar."	( Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors. Bai, CM; Cheng, YJ; Gao, X; Meng, CT; Yan, XY; Ying, HY; Zhou, JF; Zhou, N, 2018)	0.48
" Administration of isRNA in combination with dacarbazine did not cause any additional damage to liver parenchyma, while stimulating regenerative processes in hepatic tissue of tumor-bearing animals."	( [Tumor-Suppressing, Immunostimulating, and Hepatotoxic Effects of Immunostimulatory RNA in Combination with Dacarbazine in a Murine Melanoma Model]. Chernolovskaya, EL; Kabilova, TO; Savin, IA; Sen'kova, AV; Zenkova, MA, )	0.13
" This work presents a biocompatible and tumor acidic environmental responsive CCM-camouflaged mesoporous silica nanoparticle (CMSN) that is loaded with dacarbazine (DTIC) and combined with aPD1 to achieve better antitumor efficacy."	( Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy. Li, L; Qian, Z; Qiu, L; Zhang, H; Zhao, P; Zhou, S, 2021)	0.62
"This two-stage phase I trial determined the MTD of zotiraciclib combined with either dose-dense (Arm1) or metronomic (Arm2) temozolomide using a Bayesian Optimal Interval design; then a randomized cohort expansion compared the progression-free survival rate at 4 months (PFS4) of the two arms for an efficient determination of a temozolomide schedule to combine with zotiraciclib at MTD."	( Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Aboud, O; Ahmad, S; Antony, R; Armstrong, TS; Boris, L; Bryla, C; Burton, EM; Butler, MK; Calvo, KR; Cordova, C; Figg, WD; Fink, D; Gallin, JI; Garren, N; Gilbert, MR; Gonzales, J; Grajkowska, E; Kuhns, DB; Leeper, H; Lindsley, M; Lollo, N; Long Priel, DA; Mendoza, TR; Mentges, K; Pang, Y; Peer, CJ; Penas-Prado, M; Siegel, C; Sissung, TM; Su, YT; Theeler, BJ; Vera, E; Wu, J; Yu, G; Yuan, Y, 2021)	0.62
"Zotiraciclib combined with temozolomide is safe in patients with recurrent high-grade astrocytomas."	( Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Aboud, O; Ahmad, S; Antony, R; Armstrong, TS; Boris, L; Bryla, C; Burton, EM; Butler, MK; Calvo, KR; Cordova, C; Figg, WD; Fink, D; Gallin, JI; Garren, N; Gilbert, MR; Gonzales, J; Grajkowska, E; Kuhns, DB; Leeper, H; Lindsley, M; Lollo, N; Long Priel, DA; Mendoza, TR; Mentges, K; Pang, Y; Peer, CJ; Penas-Prado, M; Siegel, C; Sissung, TM; Su, YT; Theeler, BJ; Vera, E; Wu, J; Yu, G; Yuan, Y, 2021)	0.62
" Cardiac safety for trabectedin monotherapy (T) for STS or in combination with pegylated liposomal doxorubicin (T+PLD) for ROC was evaluated in this retrospective postmarketing regulatory commitment."	( Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Coleman, RL; Demetri, GD; Herzog, TJ; Hu, P; Jones, RL; Knoblauch, R; McGowan, T; Monk, BJ; Patel, SR; Schuetze, SM; Shalaby, W; Triantos, S; Van Tine, BA; von Mehren, M, 2021)	0.62
" In this work, we evaluate LVR01, an attenuated Salmonella enterica serovar typhimurium, as neoadjuvant intralesional therapy in combination with dacarbazine in a preclinical melanoma model."	( Preclinical Evaluation of LVR01 Attenuated Salmonella as Neoadjuvant Intralesional Therapy in Combination with Chemotherapy for Melanoma Treatment. Agorio, CI; Chabalgoity, JA; Chilibroste, S; Mónaco, A; Moreno, M; Plata, MC; Vola, M, 2022)	0.72

Excerpt	Reference	Relevance
" The bioavailability of the drug over 24 hours was 107 micrograms/h."	( Ocular pharmacokinetics of dacarbazine following subconjunctival versus intravenous administration in the rabbit. Kalsi, GS; Rootman, J; Silver, HK, 1991)	0.28
" This study evaluated the effect of an increase in gastric pH, through the use of ranitidine, on the oral bioavailability and plasma pharmacokinetics of temozolomide and MTIC."	( Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Beale, P; Brada, M; Cutler, DL; Judson, I; Marco, A; Moore, S; Reidenberg, P; Statkevich, P, 1999)	0.3
"Temozolomide, an oral cytotoxic agent with approximately 100% bioavailability after one administration, has demonstrated schedule-dependent clinical activity against highly resistant cancers."	( Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P, 1999)	0.3
"Temozolomide (TMZ) is a new, orally administered, second-generation imidazotetrazine prodrug with essentially 100% oral bioavailability that has demonstrated meaningful efficacy and an acceptable safety profile in the treatment of patients with recurrent glioblastoma multiforme."	( Future directions in the treatment of malignant gliomas with temozolomide. Prados, MD, 2000)	0.31
" Predictable bioavailability and minimal toxicity make temozolomide a candidate for a wide range of clinical testing to evaluate the potential of combination treatments in different tumor types."	( Temozolomide and treatment of malignant glioma. Calvert, H; Friedman, HS; Kerby, T, 2000)	0.31
" TMZ is an alkylating agent chemically similar to dacarbazine (DTIC) with good oral bioavailability and CNS penetration."	( Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G, 2002)	0.31
" We treated 25 stage IV patients with temozolomide - a cytostatic drug with 100% oral bioavailability and considerable penetration of CNS tissue."	( [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]. Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F, 2002)	0.31
" Temozolomide, an orally bioavailable alkylating agent that crosses the blood-brain barrier, has activity against brain metastases from both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) when used as a single agent, but response rates are low."	( Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Ebert, BL; Niemierko, E; Salgia, R; Shaffer, K, 2003)	0.32
" In this work we investigated the effect of association of temozolomide (TMZ), an orally bioavailable alkylating agent, with three chemotherapeutic drugs, liposomal doxorubicin (DOXO), cis-platinum (CDDP)."	( Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines. Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; Salmaggi, A, 2004)	0.32
" Pharmacokinetics studies revealed that GPI 15427 possesses a substantial oral bioavailability (plasma Cmax after a single dose of 40 mg/kg: 1041+/-516 ng/ml)."	( Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Alemu, C; Calvin, D; Graziani, G; Hoover, R; Lapidus, R; Leonetti, C; Morgan, L; Scarsella, M; Tang, Z; Tentori, L; Vergati, M; Woznizk, K; Xu, W; Zhang, J, 2005)	0.33
" TMZ is able to cross the blood brain barrier and is stable at gastric acid pH so it has almost 100% oral bioavailability and is rapidly absorbed after it is taken orally."	( Role of temozolomide in pediatric brain tumors. Barone, G; Maurizi, P; Riccardi, R; Tamburrini, G, 2006)	0.33
" 10b is aqueous soluble, orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast xenograph model in combination with cisplatin."	( Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bontcheva-Diaz, V; Bouska, JJ; Donawho, CK; Frost, DJ; Fry, EH; Gandhi, VB; Giranda, VL; Gong, J; Grandel, R; Johnson, EF; Klinghofer, V; Liu, X; Lubisch, W; Luo, Y; Marsh, KC; Olson, AM; Park, CH; Penning, TD; Rosenberg, SH; Shi, Y; Thomas, S; Wernet, W; Zhu, GD, 2008)	0.35
"ABT-888 is a potent, orally bioavailable PARP-1/2 inhibitor shown to potentiate DNA damaging agents."	( The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Bontcheva-Diaz, VD; Bouska, JJ; Bukofzer, G; Colon-Lopez, M; Donawho, CK; Frost, DJ; Giranda, VL; Guan, R; Jarvis, K; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Olson, A; Palma, JP; Penning, TD; Rodriguez, LE; Rosenberg, SH; Saltarelli, MJ; Shi, Y; Stavropoulos, JA; Zhu, GD, )	0.13
" Although the bioavailability of temozolomide is approximately 100%, pathology or anatomical changes of the gastrointestinal tract may adversely affect absorption, and consequently therapeutic response."	( Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. Beumer, JH; Egorin, MJ; Park, DM; Shah, DD, 2009)	0.35
" In addition, 3a is aqueous soluble, orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carboplatin or cyclophosphamide."	( Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. Bontcheva-Diaz, V; Bouska, JJ; Donawho, CK; Frost, DJ; Gandhi, VB; Giranda, VL; Gong, J; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Marsh, KC; Olson, AM; Osterling, DJ; Penning, TD; Shi, Y; Zhu, GD, 2009)	0.35
" Thus, our results show that polymeric nanocapsules are able to increase the intratumoral bioavailability of indomethacin and reduce the growth of implanted gliomas."	( Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR, 2009)	0.35
" Temozolomide's characteristics which make it a candidate for a wide range of clinical testing to evaluate the potential of combination treatments in different tumor types are its predictable bioavailability and minimal toxicity."	( Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Beli, I; Chaldeopoulos, D; Fotineas, A; Koukourakis, GV; Kouloulias, V; Kouvaris, J; Maravelis, G; Pantelakos, P; Papadimitriou, C; Zacharias, G, 2009)	0.35
" In addition, 22b is orally bioavailable across multiple species, crosses the blood-brain barrier, and appears to distribute into tumor tissue."	( Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor. Bontcheva-Diaz, V; Bouska, JJ; Buchanan, FG; Bukofzer, GT; Donawho, CK; Frost, DJ; Fry, EH; Gandhi, VB; Giranda, VL; Gong, J; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Marsh, KC; Olson, AM; Osterling, DJ; Park, CH; Penning, TD; Rodriguez, LE; Shi, Y; Thomas, S; Zhu, GD, 2010)	0.36
" Recently, the clinical use of temozolomide (TMZ) has become the more commonly used analog of DTIC-related oral agents because of its greater bioavailability and ability to cross the blood brain barrier."	( Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. Burd, R; Limesand, KH; Mendoza, EE; Mitchell, GC; Radhakrishnan, VM; Sittadjody, S; Thangasamy, T, 2010)	0.36
" Further in vivo experiments on laboratory animals and analysis of absorption rate and side effects are required."	( Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme. Cernea, D; Cocis, A; Fischer-Fodor, E; Florian, IS; Ioani, H; Irimie, A; Kacso, G; Petrescu, M; Soritau, O; Timis, T; Tomuleasa, C; Virag, P, )	0.13
" We evaluated the preclinical potential of a novel, orally bioavailable PI3K/mTOR dual inhibitor (XL765) in in vitro and in vivo studies."	( Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Aftab, DT; Berger, MS; Haas-Kogan, DA; James, CD; Mueller, S; Ozawa, T; Polley, MY; Prados, MD; Prasad, G; Sottero, T; Weiss, WA; Yang, X, 2011)	0.37
" Future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo."	( Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Forsyth, P; Gorlia, T; Lacombe, D; Macdonald, DR; Mason, W; Mirimanoff, RO; Rossetti, AO; Stupp, R; van den Bent, MJ; Vecht, CJ; Weller, M, 2011)	0.37
" This preclinical study sought to test the efficacy of the food additive Triacetin (glyceryl triacetate, GTA) as a novel therapy to increase acetate bioavailability in glioma cells."	( Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. Davies, MT; Driscoll, HE; Jaworski, DM; Lawler, SE; Long, PM; Penar, PL; Pendlebury, WW; Spees, JL; Teasdale, BA; Tsen, AR; Viapiano, MS, 2014)	0.4
"CNDAC (2'-C-cyano-2'-deoxy-1-β-d-arabino-pentofuranosyl-cytosine, DFP10917) and its orally bioavailable prodrug, sapacitabine, are undergoing clinical trials for hematologic malignancies and solid tumors."	( Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC. Hargis, S; Jiang, Y; Liu, X; Nowak, B; Plunkett, W, 2016)	0.43
" Its high bioavailability (40%~100%) and high tissue distribution in both monkeys and rats were its most important pharmacokinetic features."	( Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. Chen, CH; Chen, XY; Chen, Y; Ding, J; Gao, ZW; He, JX; He, Q; Huan, XJ; Li, XH; Liao, XM; Lu, XL; Miao, ZH; Shen, YY; Song, SS; Su, Y; Sun, YM; Tan, C; Tong, LJ; Wang, M; Wang, YQ; Wang, YT; Xiong, B; Yang, CH; Yang, XY, 2017)	0.46
" However, its pharmacological activity is reduced due MTIC low bioavailability in the brain."	( Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. Andrade, S; Coelho, MÁN; Loureiro, JA; Pereira, MC; Ramalho, MJ, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"The study aimed to enhance the solubility, dissolution, and oral bioavailability of standardized Piper longum fruits ethanolic extract (PLFEE) via fourth-generation ternary solid dispersion (SD) for melanoma therapy."	( Quality by design-based development and optimization of fourth-generation ternary solid dispersion of standardized Piper longum extract for melanoma therapy. Agrawal, AK; Dubey, PK; Kumar, DN; Mohapatra, D; Pandey, V; Sahu, AN; Shreya, S, 2023)	0.91
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" This drug combination does not appear to offer any therapeutic advantage within the dosage range tested in disseminated malignant melanoma."	( Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma. Baker, LH; Izbicki, RM; Ratanatharathorn, V; Samson, MK, 1976)	0.26
" 5-Azacytidine was administered subcutaneously at a dosage of 100 mg/m2/day for 10 days."	( Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma. Bellet, RE; Berd, D; Catalano, RB; Mastrangelo, MJ, 1978)	0.26
" DTIC monotherapy was administered to 14 patients; one patient received additionally vitamin A in high dosage and a further patient VP 16 (a podophyllotoxin preparation)."	( [Dacarbacinum (DTIC) and bronchogenic carcinoma (author's transl)]. Titscher, R, 1978)	0.26
" This combination appears to be safe, provided the field of radiation is not so large that is may add significantly to the myelosuppressive effect of chemotherapy and the dosage of concomitantly administered radiopotentiating agent(s) is reduced."	( Feasibility of integration of modalities in melanomas and sarcomas. Berger, JL; Friedman, M; Holyoke, ED; Karakousis, CP; Lopez, R; Takita, H, 1979)	0.26
" It is concluded that after current dosage of the drug, bleeding disorders caused by impairment of platelet functions are improbable."	( Influence of imidazole carboxamide on platelet functions and coagulation in vitro. Klener, P; Kubisz, P, )	0.13
" At the normal therapeutic dosages, methotrexate is eliminated by the kidneys as the unchanged drug; appropriate dosage modifications are mandatory if renal function is compromised."	( Clinical pharmacology of systemic chemotherapeutic agents in skin neoplasms. Hall, SW; Loo, TL, 1978)	0.26
" The optimum dosage and frequency of DTIC therapy have not yet been established."	( [DTIC in the therapy of solid tumours (author's transl)]. Kokron, O; Pridun, N; Zischinsky, W, 1978)	0.26
" Dose-response curves determined after single exposures to 60Co gamma radiation indicate that human malignant melanomas remain radioresistant after transplantation in mutant nude mice."	( Effect of cobalt-60 gamma rays and DTIC (5-(3,3 dimethyl-1-triazeno)-imidazole-r-carboxamide) on human malignant melanomas grown in athymic nude mice. Brustad, T; Johannessen, JV; Mossige, J; Rofstad, EK, 1977)	0.26
" This study indicates that low doses of piperazinedione can produce variable and severe myelosuppression when used in combination with other myelosuppressive agents, and that only small increments in dosage may produce marked increases in the degree of myelosuppression."	( Severe myelosuppression from piperazinedione, (NSC No. 135758), cyclophosphamide plus dimethyl-triazeno-imidazole carboxamide (DTIC). Klahr, C; Presant, CA, 1977)	0.26
" Wehn 1-(-chloroethyl)-3-cyclohexyl-1-nitrosourea was given in divided dosage at an interval of 8 days, marked and persistent tumor regression was observed."	( Chemotherapy of a human malignant melanoma transplanted in the nude mouse. Jacobsen, GK; Povlsen, CO, 1975)	0.25
" Dosage was fotemustine 100 mg/m2 and dacarbazine 200 mg/m2 intravenously twice monthly on days 1 and 8, repeated for a maximum of six courses."	( Fotemustine plus dacarbazine in advanced stage III malignant melanoma. Binder, M; Dorffner, R; Glebowski, E; Pehamberger, H; Winkler, A; Wolff, K, 1992)	0.28
" Regimen B, employing a lower dosage of metoclopramide and steroids and using a more simple schedule of administration should be the preferred treatment."	( Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients. Basurto, C; Boschetti, E; Bracarda, S; Del Favero, A; Lupattelli, M; Picciafuoco, M; Roila, F; Sassi, M; Tonato, M, 1992)	0.28
" Dose-response studies indicated that exceedingly high doses of DTIC were necessary to produce antimetastatic effects even when drug treatment was combined with the calcium channel blocker verapamil."	( Efficacy of dacarbazine (DTIC) in preventing metastases arising from intraocular melanomas in mice. Gamel, JW; Niederkorn, JY; Sanborn, GE, 1992)	0.28
" WHO grade 3-4 toxicity was seen in 27 patients leading to delay and reduced dosage of therapy; in 4 patients treatment was discontinued, 8 patients had no side effects."	( A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine. Gröhn, P; Hakala, T; Heikkinen, M; Jakobsson, M; Korpela, M; Kumpulainen, E; Numminen, S; Nuortio, L; Salmi, R; Vuoristo, MS, 1992)	0.28
" In a multivariate analysis where both disease-related and treatment-related factors were taken into account drug dosage remained a significant prognostic factor."	( Treatment of Hodgkin's disease with MOPP chemotherapy: effect of dose and schedule modification on treatment outcome. Bezwoda, MA; Bezwoda, WR; Dansey, R, 1990)	0.28
" Intralymphatic therapy with methanol extraction residue of BCG (MER-BCG) has been tested, and trials are now in progress with IL-2 to assess the optimal dosage by this route."	( Role of interferons in the therapy of melanoma. Ernstoff, MS; Kirkwood, JM, 1990)	0.28
" A review of cisplatin-based therapy in metastatic melanoma suggests that there is no dose-response relationship."	( A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. Bajorin, DF; Chapman, PB; Cody-Johnson, BV; Heelan, RT; Lovett, DR; Oettgen, HF; Portlock, CS; Steffens, TA; Templeton, MA; Wong, GY, 1991)	0.28
" Examination of dose intensity received when combining treatment arms revealed a weak doxorubicin dose-response relationship."	( Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. Baker, LH; Balcerzak, S; Benjamin, RS; Bonnet, JD; Chapman, R; Fletcher, WS; Metch, B; Ryan, J; Weiss, GR; Zalupski, M, 1991)	0.28
" In a panel of 12 human cancer cell lines [melanoma (4), ovary (2), head and neck (3), lung (1), bladder (1), breast (1)], the dose-response curves of S 10036 (0-100 microM) were similar to those obtained with equimolar concentrations of BCNU and CCNU; they indicated a moderately more marked effect for two and an equal effect for six melanoma cell lines with S 10036 as compared with BCNU."	( In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea. Bizzari, JP; Deloffre, P; Etienne, MC; Fischel, JL; Formento, P; Frenay, M; Gioanni, J; Milano, G, 1990)	0.28
" There was statistically significant greater myelosuppression, stomatitis, and diarrhea in the very high dosage DTIC and melphalan (Regimen A) compared with the other two regimens."	( High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Carr, T; Chadwick, G; Craig, P; Jones, R; Lind, M; Morgenstern, G; Thatcher, D, 1989)	0.28
" Unlike other methylation-resistant cell types, the neuroblastomas showed an initial decline in the MTIC dose-response profile for cell survival followed by a plateau at higher doses."	( Sensitivity of human neuroblastoma to activated dacarbazine: relationships between cell survival, methyltransferase activity and activation of adenovirus-5. Lihou, MG; Parsons, PG; Smith, PJ, 1988)	0.27
" Further work is necessary to determine the best combined dosage and method of administration for optimum immunobiological effect."	( Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC. Hersey, P; McLeod, GR; Thomson, DB, 1987)	0.27
" Attenuation schedules and data relating to the total administered dosage should be provided."	( Chemotherapy for soft tissue sarcoma. Brennan, MF; DeCosse, JJ; Greenall, MJ; Magill, GB, 1986)	0.27
" Doxorubicin should be administered preferably as 3-weekly bolus injections at doses higher than 60 mg/m2 because of its dose-response relationship."	( The treatment of soft tissue sarcomas with focus on chemotherapy: a review. Pinedo, HM; Verweij, J, 1986)	0.27
"This study addressed two major questions regarding therapeutic use of Adriamycin ([Adr] Adria Laboratories, Columbus, OH) in adult soft tissue sarcomas: the influence of dosing schedule and the value of adding imidazole carboxamide (DTIC) to Adr."	( Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. Amato, DA; Borden, EC; Carbone, PP; Creech, RH; Enterline, HT; Lerner, HJ; Rosenbaum, C; Shiraki, MJ, 1987)	0.27
" All of the compounds of this class had significant activity against the B16 melanoma, with the most active compound, 2-[(methoxycarbonyl)sulfenyl]-1-methyl-1-[(4- methylphenyl)sulfonyl]hydrazine, producing percent T/C values for B16 melanoma tumor bearing mice of between 182 and 232 at dosage levels of from 12."	( Synthesis and evaluation of 1-(arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1-methylhydrazines++ + as antineoplastic agents. Cosby, LA; Hrubiec, RT; Sartorelli, AC; Shyam, K, 1986)	0.27
" We report a patient with malignant melanoma metastatic to the liver in whom an apparent dose-response relationship to dacarbazine was demonstrated."	( Dose-response relationship to dacarbazine demonstrated in a patient with malignant melanoma. Harrison, BR; Hoelzer, KL; Luedke, DW; Mahanta, B, 1986)	0.27
" Both cell lines showed a dose-response relationship to DTIC after 1- or 6-hour exposures in the presence or absence of light."	( Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes. Alberts, DS; Dorr, RT; Einspahr, J; Mason-Liddil, N; Soble, M, 1987)	0.27
" It appears that DTIC hyperthermic isolation perfusion is a safe procedure, however, the total dosage should be below 40 mg/kg to avoid hematologic toxicity."	( Toxicity and complications of vascular isolation and hyperthermic perfusion with imidazole carboxamide (DTIC) in melanoma. Didolkar, MS; Fitzpatrick, JL; Jackson, AJ; Johnston, GS, 1986)	0.27
"To address the problem of drug dosage as a limiting factor for successful chemotherapy, seven patients with Stage IV neuroblastoma were treated with very high dose cyclophosphamide with imidazole carboximide (DTIC) and vincristine sulfate in conjunction with intensive supportive care."	( Very high dose cyclophosphamide with imidazole carboximide and vincristine sulfate in the treatment of stage IV neuroblastoma. Glaubiger, D; Levine, AS; Magrath, IT; Pizzo, PA; Poplack, DG; Srinivasan, U, 1985)	0.27
" cytostatic antibiotic), the dosage (20% LD50 vs."	( Immunosuppression by cytostatic drugs? Duncker, D; Müller-Ruchholtz, W; Ulrichs, K; Yu, MY, 1984)	0.27
" At a dosage equitoxic with that of dimethyltriazenes, cyclophosphamide causes the absence of tumor cells in the peritoneal cavity and in the brains and livers of mice bearing P388 and L1210 leukemias."	( Infiltration of liver and brain by tumor cells in leukemic mice: prevention by dimethyltriazenes and cyclophosphamide. Giraldi, T; Grill, V; Mallardi, F; Perissin, L; Sava, G; Zorzet, S, 1984)	0.27
" The response achieved with our dose modification was no better than that achieved in several series with conventionally dosed CYVADIC."	( Treatment of advanced soft tissue sarcomas with a modified CYVADIC protocol. Biran, S; Pfeffer, MR; Sulkes, A, 1984)	0.27
" Cytostatics are dosed per liter of perfused extremity."	( [Technic of isolated perfusion of the extremities. Experience with 171 cases]. Aigner, K; Schwemmle, K, 1983)	0.27
" The results of pilot clinical trials are reported, including toxicity, timing and dosage studies in 20 patients and subsequent studies of patients with metastatic melanoma treated at three separate centers, using a single lot of purified, allogeneic melanoma TAA."	( Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunochemotherapy of malignant melanoma. Arlen, M; Cohen, M; Hollinshead, A; Kundin, WD; Scherrer, J; Tanner, K; Yonemoto, R, 1982)	0.26
" The results imply that dosage scheduling in the treatment of murine melanomas must be individualized."	( Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas. Hill, GJ; Hill, HZ, 1982)	0.26
" For future administration of Dacarbazine in malignant melanoma (a) patients with pre-existent liver disease should be excluded from DTIC-treatment, (b) the prodromi and cardinal symptoms should be carefully registered and (c) high dosage corticosteroid therapy with fibrinolytic measures should be immediately administered."	( [Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)]. Altenähr, E; Doering, C; Orfanos, CE; Pickartz, H, 1982)	0.26
" Comparison of various dosage schedules within the same patient did not reveal relevant differences of the areas under the concentration-time curves."	( Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. Aigner, K; Breithaupt, H; Dammann, A, 1982)	0.26
" Side effects were severe however, and it was necessary to discontinue treatment in 5 patients, and modify dosage in 9 other patients."	( [Palliative chemotherapy of adult soft tissue sarcomas with an association of cyclophosphamide-vincristine-adriamycine-dacarbazine (CYVADIC) (author's transl)]. Brunet, R; Bui, B; Chauvergne, J; Durand, M, 1981)	0.26
" A linear dose-response curve was observed for methyl methanesulfonate over a 100-fold dose range."	( Methylation of cysteine in hemoglobin following exposure to methylating agents. Bailey, E; Connors, TA; Farmer, PB; Gorf, SM; Rickard, J, 1981)	0.26
" Dosage escalation was associated with a higher complete remission rate and lower fatality rate."	( Protected environment - prophylactic antibiotic program for malignant sarcomas: randomized trial during remission induction chemotherapy. Benjamin, RS; Bodey, GP; Burgess, A; Murphy, WK; Rodriguez, V, 1981)	0.26
" Patients received intravenous DTIC from day 1 at a dosage of 400-500 mg/m2, repeated every 21 days (in the case of good tolerance--25 patients--the dose was increased to 600-800 mg/m2) combined with subcutaneous IFN-alpha 2a (9 x 10(6) U three times/week, increased in the case of good tolerance to 15 x 10(6) U three times/week)."	( Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations. Betticher, DC; Clemons, M; Lee, SM; Morris, C; Thatcher, N, 1995)	0.29
"The activity of HDI in these pretreated ASTS patients and the apparent circumvention of SDI resistance suggest a real dose-response relationship for ifosfamide and deserve further evaluation."	( High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C, 1995)	0.29
" Toxicity was tolerable, and more than 80% of ideal dosing was achieved during the first two cycles of treatment."	( Megestrol melanoma study. Garrison, M; Nathanson, L, )	0.13
" Pretreatment of mice with O6-benzylguanine increased temozolomide-induced mortality, requiring reduction of the dosage from 1200 to 750 mg/m2 on the single-day regimen."	( Activity of temozolomide in the treatment of central nervous system tumor xenografts. Bigner, DD; Catino, JJ; Dolan, ME; Friedman, HS; Keir, S; Marcelli, S; Pegg, AE; Schold, SC, 1995)	0.29
" Since ifosfamide induced unexpectedly higher toxicity, response was corrected based on the shape of the dose-response curve for ifosfamide."	( Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts. Budach, V; Budach, W; Reipke, P; Scheulen, ME; Schmauder, B; Stuschke, M, 1994)	0.29
"Dacarbazine (DTIC) is a chemotherapy drug which has antitumor activity at standard doses, exhibits a steep dose-response effect in vitro, and is associated with relatively few non-hematologic toxicities."	( A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. Adkins, DR; Boldt, DH; Freytes, C; Irvin, R; Kuhn, J; LeMaistre, CF; Roodman, GD; Salzman, D; Von Hoff, DD, )	0.13
" We have recently shown wide interindividual variation in the depletion and subsequent regeneration of ATase in peripheral blood mononuclear cells (PMCs) following DTIC and this has now been extended to ascertain whether or not depletion is related to dosage of DTIC used and repeated treatment cycles of chemotherapy."	( Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Dougal, M; Lee, SM; Margison, GP; Thatcher, N, 1993)	0.29
" A statistically significant relationship was seen between the development of severe haematological toxicity (WHO > or = 3) with increasing dosage of DTIC and significant subclinical pulmonary damage was seen in 11 patients where the lung function was monitored during the course of treatment."	( Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Lee, SM; Margison, GP; Thatcher, N; Woodcock, AA, 1993)	0.29
" Comparisons with BCNU were made on both single and multiple dosing schedules, since temozolomide cytotoxicity is highly schedule dependent."	( Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. May, BL; Newlands, ES; Porteus, JK; Wedge, SR, 1996)	0.29
" applications of IFN-alpha in 2 MU daily doses from days 1 to 4, completing the treatment with a DTIC application on day 5, given at the same dosage as in Group 1 (Group 2)."	( DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma. Rudolf, Z; Strojan, P, 1996)	0.29
") was examined using single and daily x5 dosing regimens in athymic mice bearing subcutaneous A375P xenografts."	( Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Newlands, ES; Porteous, JK; Wedge, SR, 1997)	0.3
" rIFN alpha 2a was administered at the dosage of 3 MIU subcutaneously 3 times a week until progression."	( Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma. Caponigro, F; Casaretti, R; Comella, G; Comella, P; Daponte, A; Fiore, F; Frasci, G; Gravina, A; Ionna, F; Mozzillo, N; Parziale, AP; Presutti, F, 1997)	0.3
" Further follow-up is required to assess the effect of dosage and the effect on survival and late toxicities."	( BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Bischoff, H; Diehl, V; Duehmke, E; Engert, A; Franklin, J; Georgii, A; Glunz, A; Haedicke, C; Hasenclever, D; Hermann, R; Holmer, L; Krause, S; Lathan, B; Loeffler, M; Paulus, U; Pfreundschuh, M; Rueffer, JU; Sextro, M; Sieber, M; Stappert-Jahn, U; Tesch, H; von Kalle, K; Winnerlein-Trump, E; Wolf, J; Wulf, G, 1998)	0.3
"Thirty-three patients with newly diagnosed glioblastoma multiforme (GBM) and five patients with newly diagnosed anaplastic astrocytoma (AA) were treated with Temodal at a starting dose of 200 mg/m2 daily for 5 consecutive days with repeat dosing every 28 days after the first daily dose."	( DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. Ashley, DM; Bigner, DD; Bigner, SH; Cokgor, I; Colvin, OM; Dugan, M; Friedman, AH; Friedman, HS; Haglund, MM; Henry, AJ; Kerby, T; Krischer, J; Lovell, S; Marchev, F; McLendon, RE; Modrich, PL; Provenzale, JM; Rasheed, K; Rich, J; Seman, AJ; Stewart, E, 1998)	0.3
" Following 1 cycle of MAID at the standard dose, four patients were to be treated at each of five dosage levels: +25%, +45%, +65%, +85%, +100%."	( Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS). Bui, BN; Chevallier, B; Chevreau, C; Coindre, JM; Cour-Chabernaud, V; Gil, B; Krakowski, I; Maugard, C; Mihura, J, 1999)	0.3
" We attempted to improve its efficacy and decrease its toxicity by using decrescendo dosing of interleukin-2 (IL-2), posttreatment granulocyte colony-stimulating factor (G-CSF), and low-dose tamoxifen."	( Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. Boasberg, PD; Cannon, M; Edwards, S; Essner, R; Fawzy, NW; Foshag, LJ; Fournier, P; Gammon, G; Guo, M; Johnson, TD; Kristedja, TS; Martin, MA; Morton, DL; O'Day, SJ; Stern, S; Weisberg, M, 1999)	0.3
" Decrescendo IL-2 dosing and administration of G-CSF seemed to reduce toxicity, length of hospital stay, and readmission rates."	( Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. Boasberg, PD; Cannon, M; Edwards, S; Essner, R; Fawzy, NW; Foshag, LJ; Fournier, P; Gammon, G; Guo, M; Johnson, TD; Kristedja, TS; Martin, MA; Morton, DL; O'Day, SJ; Stern, S; Weisberg, M, 1999)	0.3
"Patients were randomized to receive either oral temozolomide at a starting dosage of 200 mg/m(2)/d for 5 days every 28 days or intravenous (IV) DTIC at a starting dosage of 250 mg/m(2)/d for 5 days every 21 days."	( Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Aamdal, S; Aaronson, N; Cebon, J; Coates, A; Dreno, B; Fierlbeck, G; Fraass, U; Gore, M; Grob, JJ; Henz, M; Kapp, A; Middleton, MR; Muller, M; Schadendorf, D; Seiter, S; Statkevich, P; Thatcher, N; Tilgen, W; Weiss, J, 2000)	0.31
" This review discusses the mechanism of action of TMZ and strategies for overcoming pathways of resistance to this promising agent, including the use of TMZ in combination with other chemotherapeutic agents or radiation therapy, and exploration of alternate dosing schedules."	( Future directions in the treatment of malignant gliomas with temozolomide. Prados, MD, 2000)	0.31
"The combination of GM-CSF with biochemotherapy is feasible and there appears to be a dose-response relationship with GM-CSF in terms of host immunological response, and possibly clinical efficacy."	( GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma. A'Hern, RP; Ayliffe, MJ; Eisen, T; Gore, ME; Hill, ME; Johnston, SR; Moore, J; Riches, PG; Thomas, JM; Vaughan, MM, 2000)	0.31
" One day after the last dose of vehicle or TNP-470, a steady-state dosing regimen of TMZ was administered with subsequent collection and high-performance liquid chromatography analysis of plasma and either tumor homogenate or tumor microdialysis steady-state TMZ concentrations, and in some cases [5-(3-methyltriazen-1-yl)imidazole-4-carboximide] MTIC, its active metabolite."	( Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Chu, J; Gallo, JM; Li, S; Ma, J; Pulfer, S; Reed, K, 2001)	0.31
" In this study, we evaluated the relation between TMZ dosing and AGT depletion in patients with deep visceral tumors and in peripheral blood mononuclear cells (PBMCs) to determine whether the dose of TMZ was sufficient to inactivate AGT and lead to therapeutic efficacy."	( Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Gerson, SL; Haaga, J; Liu, L; Majka, S; Spiro, TP; Willson, JK, 2001)	0.31
" For patients with recurrent malignant glioma, temozolomide provides a therapeutic option with a predictable safety profile, clinical efficacy, and convenient dosing that can provide important quality-of-life benefits."	( Temozolomide for recurrent high-grade glioma. Macdonald, DR, 2001)	0.31
" Also under investigation are modifications to the temozolomide dosing schedule, other routes of administration, and treatment regimens that include temozolomide in combination with other chemotherapeutic and biologic agents."	( Future directions for temozolomide therapy. Yung, WK, 2001)	0.31
" The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days."	( Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S, 2001)	0.31
" In patients with advanced stage soft tissue sarcomas (ASTS), a dose-response relationship has been established for doxorubicin and ifosfamide."	( [High-dose chemotherapy in soft tissue sarcomas of adults]. Biron, P; Blay, JY; Ray-Coquard, I, 2001)	0.31
" The standard dosage is 150-200 mg/m2 per day for 5 days in a 28-day cycle."	( A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Abrey, LE; Bazylewicz, KA; Khan, RB; Malkin, MG; Raizer, JJ, 2002)	0.31
" Despite prompt initiation of antimycotic therapy the outcome was fatal; dosage of conventional and liposomal amphotericin B was limited due to treatment-related toxicities."	( A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation. Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K, 2001)	0.31
"To evaluate the antitumor effects and toxicities of whole brain irradiation (WBI) with temozolomide (TMZ) administered by prolonged oral dosing in patients with melanoma metastatic to the brain."	( Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G, 2002)	0.31
" This review will focus on the different pharmacological strategies aimed at overcoming tumor resistance to TMZ such as new formulations of the drug or dosing schedules, and combined treatments with other chemotherapeutic agents, modulators of DNA repair systems, or gene therapy."	( Pharmacological strategies to increase the antitumor activity of methylating agents. Graziani, G; Tentori, L, 2002)	0.31
" Assuming linearity of the dose-response effect, the point estimate was used to calculate a doubling dose for the induction of heritable translocations of 12 mg/kg."	( Induction of chromosomal aberrations by dacarbazine in somatic and germinal cells of mice. Adler, ID; Jentsch, I; Kliesch, U; Speicher, MR, 2002)	0.31
" However, the dose-response relationship was acute."	( Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Billups, C; Cheshire, PJ; Fouladi, M; Friedman, HS; Houghton, PJ; Leggas, M; Peterson, JK; Stewart, CF; Woo, MH, 2002)	0.31
" The drug is well tolerated with dose limiting myelosuppression and thrombocytopenia occurring in less than 10% of patients at current dosage schedules."	( The use of temozolomide in recurrent malignant gliomas. Gaya, A; Greenstein, A; Rees, J; Stebbing, J, 2002)	0.31
" Body surface area-based dosing was statistically significantly associated with a reduction in interpatient variability in drug clearance for only five of the 33 agents: docosahexaenoic acid (DHA)-paclitaxel, 5-fluorouracil/eniluracil, paclitaxel, temozolomide, and troxacitabine."	( Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. Baker, SD; Donehower, RC; Grochow, LB; Rowinsky, EK; Schellens, JH; Sparreboom, A; Verweij, J, 2002)	0.31
"We assessed whether split dosing with the methylating agent DTIC is an effective strategy for inactivating the DNA repair protein O6-alkylguanine DNA-ATase in order to decrease tumour resistance to BCNU."	( Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. Clemons, M; El Teraifi, H; Griffiths, A; Howell, A; Kelly, J; Margison, GP; Margison, JM; Morris, CQ; Ranson, M, 2003)	0.32
" Two patients in the first triplet had G3-G4 local toxicity, so that the scheduled F dosage was halved."	( Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities. De Salvo, GL; Foletto, M; Lejeune, FJ; Lise, M; Lopes, M; Mocellin, S; Pilati, PL; Pontes, L; Ribeiro, M; Rossi, CR, 2003)	0.32
" For example, Abdelbasit and Plackett proposed an optimal design assuming that the dose-response relationship follows some specified linear models."	( Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Fang, HB; Houghton, PJ; Tan, M; Tian, GL, 2003)	0.32
" The model is fit to serial ANC measurements obtained after TMZ dosing and it is able to explain, among other things, the lag in ANC reduction following a dose of TMZ, the ANC nadir, and the 'rebound effect' observed where the ANC recovers to levels greater than that observed pre-TMZ dose."	( A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Fouladi, M; Gajjar, AJ; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF, 2003)	0.32
" In the last 2 years, studies have focused on exploring strategies to optimize the efficacy of temozolomide, including evaluating different temozolomide dosing schedules and combining temozolomide with other antineoplastic agents, radiation therapy, or drug resistance-modifying agents."	( Temozolomide: realizing the promise and potential. Dolan, ME; Nagasubramanian, R, 2003)	0.32
" Temozolomide has activity and a favorable safety profile in all dosing schedules tested."	( Temozolomide: realizing the promise and potential. Dolan, ME; Nagasubramanian, R, 2003)	0.32
" Extended TMZ dosing regimens may be superior by delivering the drug continuously at a higher dose over time."	( Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD, 2004)	0.32
" Alternate temozolomide dosing schedules such as continuous daily administration may enhance antitumor activity through sustained depletion of the DNA repair protein O6-alkylguanine DNA alkyltransferase."	( Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. Baker, SD; Batra, VK; Cutler, DL; Donehower, RC; Rudek, MA; Statkevich, P, 2004)	0.32
" In phase II of the study, four weeks after completion of RT, a monochemotherapy using TMZ was administered at the dosage of 200 mg/m2/day per 5 days every 28 days for 6 cycles."	( Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Campanella, C; Costa, A; Fedele, F; Frati, A; Frati, L; Gagliardi, FM; Innocenzi, G; Lanzetta, G; Minniti, G; Nappa, M; Rozzi, A; Salvati, M; Vecchione, A, )	0.13
" This observation suggests a strategy of individualized dosing adapted to hematotoxicity."	( Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Brosteanu, O; Diehl, V; Hasenclever, D; Loeffler, M, 2004)	0.32
" Median thalidomide dosage was 200 mg/day."	( Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. Baumann, F; Baumert, BG; Bernays, RL; Bjeljac, M; Brandner, S; Kollias, SS; Rousson, V; Yonekawa, Y, )	0.13
" IC(50) values were calculated from dose-response relationships using cell counts and a formazan dye assay (WST-1)."	( Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. Hamilton, G; Kaczirek, K; Mittlböck, M; Niederle, B; Passler, C; Pfragner, R; Prager, G; Raderer, M; Scheuba, C; Schindl, M; Siegl, V; Weinhäusel, A, 2004)	0.32
"The response rate, efficacy, side-effects, reasons for discontinuation of therapy and survival rate of 47 patients treated with temozolomide in combination with two different dosing regimens of IFN-alpha 2b were documented."	( Temozolomide and interferon alpha 2b in metastatic melanoma stage IV. Fialla, R; Forstinger, Ch; Fritsch, P; Hofmann-Wellenhof, R; Kehrer, H; Kerl, H; Kindermann-Glebowski, E; Klein, G; Koller, J; Konrad, K; Kos, C; Lang, A; Mischer, P; Pachinger, W; Pehamberger, H; Raml, J; Ratzinger, G; Richtig, E; Seeber, A; Smolle, J; Steiner, A; Ulmer, H; Wolff, K; Zelger, B, 2004)	0.32
"We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents."	( Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004)	0.32
" We develop a maximum likelihood method based on the expectation/conditional maximization (ECM) algorithm to estimate the dose-response relationship while accounting for the informative censoring and the constraints of model parameters."	( Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. Fang, HB; Houghton, PJ; Tan, M; Tian, GL, 2005)	0.33
" Attempts to maximise efficacy have led to manipulation of both dosage and drug scheduling and the evidence for the various strategies is reviewed."	( Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Middleton, MR; Payne, MJ; Pratap, SE, 2005)	0.33
"Temozolomide has been studied in soft-tissue sarcomas with varying dosing schedules."	( Temozolomide in uterine leiomyosarcomas. Aghajanian, C; Anderson, S, 2005)	0.33
" Cisplatin-temozolomide combinations are well tolerated without additional toxicity to single-agent treatments; the recommended phase II dosage is 80 mg m(-2) cisplatin and 150 mg m(-2) x 5 temozolomide in heavily treated, and 200 mg m(-2) x 5 temozolomide in less-heavily pretreated children."	( Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. Chastagner, P; Couanet, D; Djafari, L; Doz, F; Frappaz, D; Gentet, JC; Geoerger, B; Geoffray, A; Margison, GP; O'Quigley, J; Pein, F; Raquin, MA; Rubie, H; Vassal, G; Wartelle, M; Watson, AJ, 2005)	0.33
"The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma."	( Phase II trial of temozolomide in children with recurrent high-grade glioma. Abate, ME; Attinà, G; Caldarelli, M; Cefalo, G; Clerico, A; Colosimo, C; Di Rocco, C; Garré, ML; Lazzareschi, I; Madon, E; Massimino, M; Maurizi, P; Mazzarella, G; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2006)	0.33
"We identified a transcriptomic signature that predicts a common in vitro and in vivo resistance phenotype to these agents, a proportion of which is imprinted recurrently by gene dosage changes in the resistant glioblastoma genome."	( Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. Bredel, C; Bredel, M; Duran, GE; Harsh, GR; Juric, D; Recht, LD; Scheck, AC; Sikic, BI; Vogel, H; Yu, RX, 2006)	0.33
" We reviewed the charts of patients diagnosed with Hodgkin's lymphoma between 1 January 1990 and 31 December 2002 who were treated with ABVD chemotherapy, and seen at the University of Iowa with complete diagnosis, staging, and treatment dosing records."	( Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. Chand, VK; Link, BK; Ritchie, JM; Shannon, M; Wooldridge, JE, 2006)	0.33
" Extended dosing has met with early favourable results."	( Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Middleton, MR; Sabharwal, A, 2006)	0.33
" There was no particular dose-response of dacarbazine on any parameters tested."	( Dacarbazine induces genotoxic and cytotoxic germ cell damage with concomitant decrease in testosterone and increase in lactate dehydrogenase concentration in the testis. Bairy, KL; D'Souza, UJ; Gopalakrishna, K; Kumar, SG; Narayana, K; Samuel, VP, 2006)	0.33
" Temozolomide and capecitabine were administered concomitantly to 4 sequential cohorts at different dosing levels on Days 1-5 and Days 8-12, with cycles repeated every 21 days until disease progression."	( Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006)	0.33
" Three patients (12%) were changed to standard temozolomide dosing due to side effects, including intractable nausea (n = 2) and multiple cytopenias (n = 1)."	( Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. Gasco, J; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH, 2007)	0.34
"Dose-limiting adverse effects of thrombocytopenia and leukopenia prevent augmentation of current temozolomide (TMZ) dosing protocols; therefore, we hypothesized that the direct intracranial delivery of TMZ would lead to improved efficacy in an animal model of malignant glioma in an animal model."	( Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Brem, H; Brem, S; Caplan, J; Legnani, F; Li, K; Pradilla, G; Tyler, B, 2007)	0.34
"Metronomic dosed (MD) chemotherapy as opposed to conventional dosed (CD) chemotherapy is considered an alternate strategy to target angiogenesis and limit host toxicity."	( Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. Gallo, JM; Guo, P; Nuthalapati, S; Wang, X; Zhou, Q, 2007)	0.34
" Subsequently the tumor recurred and the patient had a dramatic and durable response to standard 5 day dosing of adjuvant temozolomide."	( Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. Doherty, LM; Drappatz, J; Kesari, S; Monje, ML; Ramakrishna, NR; Wen, PY; Young, G, 2007)	0.34
"The efficacy of LM and TMZ in the current dosing schedule is similar to that of TMZ alone."	( Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ, 2007)	0.34
" The preclinical pharmacokinetic model was scaled to predict temozolomide concentrations in human CSF, normal brain, and brain tumor, and through a series of Monte Carlo simulations, the accumulation of temozolomide in brain tumors under conditions of altered blood-brain barrier permeability, fractional blood volume, and clinical dosing schedules was evaluated."	( Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Gallo, JM; Guo, P; Kruh, GD; Vicini, P; Wang, X; Zhou, Q, 2007)	0.34
" Through a series of model simulations, it was shown that the brain tumor accumulation of temozolomide varied substantially based on changes in blood-brain barrier permeability and fractional tumor blood volume but minimally based on clinical dosing regimens."	( Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Gallo, JM; Guo, P; Kruh, GD; Vicini, P; Wang, X; Zhou, Q, 2007)	0.34
"A physiologically based pharmacokinetic modeling approach offers a means to translate preclinical to clinical characteristics of drug disposition in target tissues and, thus, a means to select appropriate drug dosing regimens for achieving optimal target tissue drug concentrations."	( Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Gallo, JM; Guo, P; Kruh, GD; Vicini, P; Wang, X; Zhou, Q, 2007)	0.34
"The effects of 'metronomic' or extended chemotherapy dosing schedules (ECS) are mediated through poorly understood anti-angiogenic mechanisms."	( Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth. Greenman, J; Hetherington, JW; Lam, T; Little, S; Maraveyas, A, 2007)	0.34
" Single-dose temozolomide at five dosage levels (267, 355, 472, 628, and 835 mg/m(2)) was given at least 6 h after completion of O(6)-benzylguanine bolus."	( Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Boyett, JM; Broniscer, A; Danks, MK; Friedman, HS; Gajjar, A; Goldman, S; Gururangan, S; Kun, LE; MacDonald, TJ; Packer, RJ; Poussaint, TY; Stewart, CF; Wallace, D, 2007)	0.34
" Because preclinical studies suggested that a twice-daily dosing schedule might be more effective, the safety and efficacy of twice-daily dosing of temozolomide were studied in patients with recurrent gliomas at their first, second, or third recurrence."	( Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Alavi, J; Balmaceda, C; Chen, J; Cheung, YK; Fine, RL; Fisher, PG; Pannullo, S; Peereboom, D; Sisti, M, 2008)	0.35
"Twice-daily dosing may enhance the efficacy of temozolomide in the treatment of recurrent gliomas without increasing toxicity."	( Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Alavi, J; Balmaceda, C; Chen, J; Cheung, YK; Fine, RL; Fisher, PG; Pannullo, S; Peereboom, D; Sisti, M, 2008)	0.35
" It may also allow a reduction in dosage and a decrease in systemic toxicity."	( Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Bi, X; Dou, M; Huang, G; Zhang, N, 2008)	0.35
" Lower dosing of TMZ also is associated with a more beneficial toxicity profile."	( Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Bischof, M; Combs, SE; Debus, J; Edler, L; Rausch, R; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T; Zabel-du Bois, A, 2008)	0.35
" The patients were divided into two groups according to the chemotherapy (3-7 treatment cycles): with DTIC-given orally daily for 5 days, every 3 weeks as a single 2200 mg/kg dose and with the combination-DTIC (the same dose) + CCNU-administered orally at a dosage of 120 mg/m(2) once every 40 days in accordance with protocols, approved by the Bulgarian Ministry of Health."	( Influence of therapy on the antioxidant status in patients with melanoma. Dimov, A; Gadjeva, V; Georgieva, N, 2008)	0.35
" Accordingly, a clinical trial using oral temozolomide (TMZ) and subcutaneous PEG-interferon alpha-2b (PEG) in patients with metastatic melanoma was designed to determine the maximal tolerated dosage of both drugs and the antitumoral response."	( Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study. Bedane, C; Cupissol, D; Delaunay, M; Dereure, O; Dreno, B; Guillot, B; Khamari, A; Picot, MC, 2008)	0.35
" Further studies using ATO and AA with TMZ with this dosing schedule in advanced melanoma are not warranted."	( Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Bael, TE; Gollob, JA; Peterson, BL, 2008)	0.35
" Imatinib doses up to 1,000 mg/day for 8 consecutive days are well tolerated when combined with standard TMZ dosing for MG patients."	( Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Desjardins, A; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; McLendon, R; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sathornsumetee, S; Vredenburgh, JJ, 2008)	0.35
" Noninvasive imaging of apoptosis facilitates optimization of therapeutic protocols regarding dosing and schedule and enables identification of efficacious combination therapies."	( Noninvasive imaging of apoptosis and its application in cancer therapeutics. Coppola, JM; Rehemtulla, A; Ross, BD, 2008)	0.35
" If further studies are to be performed, emerging data suggest that higher daily doses of lomeguatrib and a dosing period beyond that of TMZ should be evaluated."	( A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Khan, OA; Levitt, NC; Margison, GP; Michael, M; Middleton, MR; Midgley, R; Mortimer, P; Olver, I; Ranson, M; Watson, AJ, 2008)	0.35
" Several preliminary studies have been initiated to address the issue of resistance and suppression of MGMT activity, and have used alternative temozolomide dosing schedules and O(6)-guanine mimetic agents as substrates for MGMT."	( Mechanisms of disease: temozolomide and glioblastoma--look to the future. Chamberlain, MC; Mrugala, MM, 2008)	0.35
" A variety of dosing schedules that increase the duration of exposure and the cumulative dose of temozolomide are currently being investigated for the treatment of glioma, with the goal of improving antitumor activity and overcoming resistance."	( New (alternative) temozolomide regimens for the treatment of glioma. Platten, M; Weller, M; Wick, W, 2009)	0.35
" The toxicity of the dose-intense pre-RT regimen used in this study may warrant evaluation of other, less intense dosing strategies."	( Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA, 2009)	0.35
" Consistent with a functional significance of MGMT induction, treatment of GBM43 with a protracted low-dose TMZ regimen was significantly less effective than a shorter high-dose regimen, while survival for GBM14 was improved with the protracted dosing regimen."	( Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Carlson, BL; Decker, PA; Grogan, PT; James, CD; Kitange, GJ; Lamont, JD; Sarkaria, JN; Schroeder, MA; Wu, W, 2009)	0.35
" Extended ABT-888 dosing schedules showed no advantage compared to simultaneous TMZ administration."	( The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Bontcheva-Diaz, VD; Bouska, JJ; Bukofzer, G; Colon-Lopez, M; Donawho, CK; Frost, DJ; Giranda, VL; Guan, R; Jarvis, K; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Olson, A; Palma, JP; Penning, TD; Rodriguez, LE; Rosenberg, SH; Saltarelli, MJ; Shi, Y; Stavropoulos, JA; Zhu, GD, )	0.13
" The system analysis technique, embodied in the convolution integral, generated an impulse response function that, when convolved with temozolomide plasma concentration input functions, yielded predicted normal brain and brain tumor temozolomide concentration profiles for different temozolomide dosing regimens (75-200 mg/m(2)/d)."	( A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Aboagye, EO; Brock, CS; Gallo, JM; Price, PM; Rosso, L; Saleem, A; Turkheimer, FE, 2009)	0.35
" The inhibition of the target in non-tumour peripheral blood cells (taken as a potential surrogate marker) was measured periodically, and valproate dosing adjusted with the attempt to reach a measurable inhibition."	( A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Ballarini, M; Contegno, F; Croci, D; Goldhirsch, A; Minucci, S; Munzone, E; Nolè, F; Pelicci, PG; Rocca, A; Salmaggi, A; Testori, A; Tosti, G, 2009)	0.35
"O(6)-BG when added to a 1-day dosing regimen of temozolomide was able to restore temozolomide sensitivity in patients with temozolomide-resistant anaplastic glioma, but there seemed to be no significant restoration of temozolomide sensitivity in patients with temozolomide-resistant GBM."	( Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009)	0.35
" It has become common practice to re-expose patients to TMZ who had been previously treated with TMZ, or to switch patients to alternative dosing regimens of TMZ when there are signs of relapse or progress on standard TMZ therapeutic regimens."	( Rechallenge with temozolomide in patients with recurrent gliomas. Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W, 2009)	0.35
"This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)."	( Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009)	0.35
"Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies."	( A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ, 2009)	0.35
" Early recovery of MGMT activity in tumours suggested that more protracted dosing with LM is required."	( O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Beith, J; Davis, ID; Haydon, A; Hayward, O; Hersey, P; Kefford, R; Lorigan, P; Margison, GP; McArthur, G; McGown, G; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Thomson, D; Thorncroft, M; Watson, AJ, 2009)	0.35
" Regarding the dosing schedule and administration scheme, as well as the co-administration with other anticancer drugs, a C score was attributed for the off label situations."	( [Prescription guidebook for temozolomide usage in brain tumors]. Borget, I; Brignone, M; Cartalat-Carel, S; Chinot, O; Hassani, Y; Taillandier, L; Taillibert, S; Tilleul, P, 2009)	0.35
"Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both."	( Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. Abrey, LE; Clarke, JL; DeAngelis, LM; Gavrilovic, I; Hormigo, A; Iwamoto, FM; Karimi, S; Lassman, AB; Nolan, CP; Panageas, K; Sul, J, 2009)	0.35
" Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ."	( [Treatment of glioma with temozolomide]. Nishikawa, R, 2009)	0.35
" Neither the extent of the initial resection nor dexamethasone dosing was associated with pseudoprogression."	( Population-based study of pseudoprogression after chemoradiotherapy in GBM. Cairncross, JG; de Robles, PA; Dharmawardene, M; Easaw, JC; Forsyth, PA; Hamilton, MG; Magliocco, AM; McIntyre, JB; Parney, IF; Roldán, GB; Scott, JN; Yan, ES, 2009)	0.35
" Afterward, adjuvant TMZ chemotherapy was discontinued in one patient and the dosage of TMZ was reduced in the other."	( Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Backes, H; Brunn, A; Burghaus, L; Galldiks, N; Heiss, WD; Jacobs, AH; Kracht, LW; Ullrich, RT, 2010)	0.36
" The present findings suggest that glucocorticoid-regulated oscillation in the hepatic MGMT expression is the underlying cause of dosing time-dependent changes in DTIC-induced hepatotoxicity."	( Glucocorticoid-dependent expression of O(6)-methylguanine-DNA methyltransferase gene modulates dacarbazine-induced hepatotoxicity in mice. Egawa, T; Horiguchi, M; Kaji, H; Kim, J; Koyanagi, S; Makino, K; Matsunaga, N; Ohdo, S, 2010)	0.36
" 44 of the patients underwent chemo-radiotherapy with Temodal dosed 75 mg/m2, and the rest 135 ones received RT alone."	( Postoperative chemo-radiotherapy with temodal in patients with glioblastoma multiforme--survival rates and prognostic factors. Radev, LR; Semerdjieva, ML; Vlaikova, MI; Yaneva, MP, )	0.13
" In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity."	( Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011)	0.37
" The originally approved temozolomide dosing regimen is 150 to 200 mg/m(2) per day (Days 1 to 5 every 28-day cycle [5 of 28 days])."	( Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Hwu, WJ; Neyns, B; Reardon, DA; Tosoni, A, 2010)	0.36
" Metronomic dosing of temozolomide (TMZ) combined with standard radiotherapy may improve survival by increasing the therapeutic index and anti-angiogenic effect of TMZ."	( A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Bartels, U; Baruchel, S; Bouffet, E; Eisenstat, D; Gammon, J; Huang, A; Hukin, J; Johnston, DL; Samson, Y; Sharp, JR; Stempak, D; Stephens, D; Tabori, U, 2010)	0.36
"Chemoradiotherapy with metronomic dosing of TMZ showed similar toxicity to previous TMZ regimens, and does not appear to improve survival in paediatric DIBSG."	( A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Bartels, U; Baruchel, S; Bouffet, E; Eisenstat, D; Gammon, J; Huang, A; Hukin, J; Johnston, DL; Samson, Y; Sharp, JR; Stempak, D; Stephens, D; Tabori, U, 2010)	0.36
" Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated."	( Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011)	0.37
" These combinations appear to be the most promising for in vivo pre-clinical studies, with a view to testing in melanoma patients as a continuous dosing strategy, due to the in vitro additive inhibitory effect on growth seen in both endothelial and cancer cells."	( Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P, 2010)	0.36
" On the basis of these results, the recommended Phase II dosage currently being tested is RAD001 70 mg/week in combination with standard chemoradiotherapy."	( North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011)	0.37
"After diagnostic surgery or biopsy, treatment with tipifarnib started 5 to 9 days before initiating radiotherapy, twice daily, in 4-week cycles using discontinuous dosing (21 out of 28 days), until toxicity or progression."	( A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Abrey, L; Chang, SM; Cloughesy, TF; DeAngelis, LM; Demopoulos, A; Drappatz, J; Fine, HA; Fink, K; Kesari, S; Lamborn, KR; Lassman, AB; Lieberman, FS; Malkin, MG; Mehta, MP; Nghiemphu, PL; Prados, MD; Robins, HI; Torres-Trejo, A; Wen, PY, 2011)	0.37
" All patients received TMZ at a dosage of 90 mg/m(2)/day for 42 days to a dose of 59."	( Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Bouffet, E; Cohen, KJ; Heideman, RL; Holmes, EJ; Lavey, RS; Pollack, IF; Zhou, T, 2011)	0.37
" We identified melanoma cell lines with different sensitivities to single versus prolonged clinical dosing regimens of temozolomide treatment and assessed a variety of potential resistance mechanisms using this model."	( Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution. Boeckmann, L; Emmert, S; Kuschal, C; Nickel, AC; Schaefer, A; Schön, MP; Thomale, J; Thoms, KM, 2011)	0.37
" Cediranib was dosed at 3 mg/kg daily five times a week orally for 2 weeks."	( Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic. Andersen, B; Dicker, AP; Lawrence, RY; Liu, Y; Wachsberger, PR; Xia, X, 2011)	0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" In our case, TMZ administration, despite changing the TMZ dosing regimen to prompt a drug response, was incapable of depleting MGMT stores."	( Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Cusimano, M; Fadul, CE; Gonzalez, R; Horvath, E; Kovacs, K; Moshkin, O; Ortiz, LD; Rotondo, F; Scheithauer, BW; Syro, LV; Uribe, H, )	0.13
"We conducted a phase I clinical trial of the combination of SCH 66336 with temozolomide administered on the standard 5-day dosing schedule."	( A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. Coan, AD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Peters, KB; Reardon, DA; Threatt, S; Vredenburgh, JJ, 2011)	0.37
" Additional trials are needed to better define the optimal dosing in such patients."	( A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P, 2012)	0.38
" The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment."	( Rechallenge with temozolomide in recurrent glioma. Botturi, A; Fariselli, L; Ferrari, D; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Simonetti, G, 2011)	0.37
" These may include TMZ concentrations in the brain parenchyma, TMZ dosing schemes, hypoxic microenvironments, niche factors, and the re-acquisition of stem cell properties by non-stem cells."	( Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Beier, CP; Beier, D; Schulz, JB, 2011)	0.37
" Temozolomide, dosed according to MGMT methylation status, demonstrated modest clinical activity in elderly patients with AML, especially in those presenting with fewer comorbidities and low disease burden."	( Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. Arber, DA; Coutre, SE; Gotlib, J; Kohrt, HE; Medeiros, BC; Zehnder, JL; Zhang, B, 2012)	0.38
"Seventy-one eligible patients 70 years of age or older with newly diagnosed GBM and a Karnofsky performance status ≥60 were treated with a short course of RT (40 Gy in 15 fractions over 3 weeks) plus TMZ at the dosage of 75 mg/m(2) per day followed by 12 cycles of adjuvant TMZ (150-200 mg/m(2) for 5 days during each 28-day cycle)."	( Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Arcella, A; Caporello, P; De Sanctis, V; Enrici, RM; Giangaspero, F; Lanzetta, G; Minniti, G; Salvati, M; Scaringi, C, 2012)	0.38
"A dosage of 10 mg everolimus daily with TMZ 150 mg/m(2)/day for five consecutive days every 28 days in patients is the recommended dose for this regimen."	( A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. Easaw, J; Eisenhauer, E; Kavan, P; Lwin, Z; Macdonald, D; Macneil, M; Mason, WP; McIntosh, L; Thiessen, B; Urva, S, 2012)	0.38
" Scheduling of docetaxel before selumetinib was more beneficial than when selumetinib was dosed before docetaxel and demonstrated a pro-apoptotic phenotype."	( The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW, 2012)	0.38
" It could therefore be used as an important platform for better prediction of drug dosing and schedule towards personalized medicine."	( Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system. Barker, J; Foltz, G; Honkakoski, P; Küblbeck, J; Li, W; Lin, B; Ma, L; Zhang, J; Zhou, C, 2012)	0.38
" Moreover, this class of compounds possesses a generally favorable in vitro ADME profile, along with good exposure levels in plasma and brain following intraperitoneal dosing (30 mg/kg body weight) in mice."	( Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors. Dorjsuren, D; Jadhav, A; Maloney, DJ; Rai, G; Simeonov, A; Vyjayanti, VN; Wilson, DM, 2012)	0.38
" These results suggest that GBMs with EGFR amplification are a heterogenous group of tumors and that behavior might differ according to the degree of amplification, although not in a straightforward dose-response manner."	( Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Bortoluzzi, S; Cieply, K; Fardo, DW; Hamilton, RL; Hobbs, J; Horbinski, C; Nikiforova, MN, 2012)	0.38
" However, the results were quite similar despite the different dosage used and the combination with dacarbazine in the first line treatment."	( Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. Ascierto, PA; Simeone, E, )	0.13
"The effectiveness of temozolomide (TMZ) dosing schemes and the "rechallenge" of recurrent glioblastoma (GBM) with TMZ are controversial."	( Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. Beier, CP; Beier, D; Brawanski, K; Hau, P; Schriefer, B; Schulz, JB; Weis, J, 2012)	0.38
" Prospective pharmacokinetic studies to devise a rational dosing strategy for vinblastine in patients receiving ritonavir/lopinavir are warranted."	( Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Boro, J; Cheung, MC; Ezzat, HM; Harris, M; Hicks, LK; Leitch, HA; Lima, VD; Montaner, JS, 2012)	0.38
" These data reassuringly suggest that BEV does not significantly change the ECF tumor concentrations of TMZ in either tumor-bearing or normal brain when dosed 36 h prior to TMZ."	( The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. Blakeley, JO; Brastianos, H; Brem, H; Grossman, R; Rudek, MA; Tyler, B; Zadnik, P, 2012)	0.38
" Dose-response and cellular growth assays indicate that erlotinib reduces cell proliferation in all tested cell lines without inducing cytotoxic effects."	( EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth. Fernández de Mattos, S; Ramis, G; Rodríguez, J; Thomàs-Moyà, E; Villalonga, P, 2012)	0.38
" No DLTs were encountered, but vorinostat dosing could not be escalated further due to thrombocytopenia."	( Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012)	0.38
" Treatment was well tolerated in all dosage groups."	( Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Claringbold, PG; Price, RA; Turner, JH, 2012)	0.38
" It was designed to maximize cytoreduction via high dosing of synergistically interacting agents, while minimizing morbidity in patients with resistant neuroblastoma (NB) and ineligible for clinical trials due to myelosuppression from previous therapy."	( 5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma. Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS, 2013)	0.39
" continuous dosing in combination with dacarbazine, 300 mg/m(2) for three consecutive days every 21 days until disease progression or intolerable toxicity."	( Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. Dei Tos, AP; Del Vescovo, R; Frezza, AM; Santini, D; Schiavon, G; Silletta, M; Tonini, G; Vincenzi, B; Zobel, BB, 2013)	0.39
" This regimen was based on our studies with carcinoid cell lines that showed synergistic cytotoxicity with sequence-specific dosing of 5-fluorouracil preceding temozolomide (TMZ)."	( Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Allendorf, J; Chabot, JA; Dinnen, RD; Fine, RL; Gulati, AP; Krantz, BA; Lee, JA; Mao, Y; Moss, RA; Mowatt, KB; Schreibman, S; Schrope, B; Sherman, WH; Stevens, PD; Tsushima, DA, 2013)	0.39
" In a human GBM xenograft model, a single daily dosage of MB does not activate AMP-activated protein kinase signaling, and no tumor regression was observed."	( Reversing the Warburg effect as a treatment for glioblastoma. Bigner, DD; Choudhury, GR; Ghorpade, A; Keir, ST; Li, W; Liu, R; Poteet, E; Ryou, MG; Simpkins, JW; Tang, L; Wen, Y; Winters, A; Yan, H; Yang, SH; Yuan, F, 2013)	0.39
" Sufficient information on steroid dosing was available in 72 patients included in the final analysis."	( Steroid management in newly diagnosed glioblastoma. Deangelis, LM; Deutsch, MB; Lassman, AB; Panageas, KS, 2013)	0.39
"Temozolomide (TMZ) is important chemotherapy for glioblastoma multiforme (GBM), but the optimal dosing schedule is unclear."	( Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Anderson, SK; Ballman, KV; Carlson, BL; Cen, L; Decker, PA; Giannini, C; Grogan, PT; Kitange, GJ; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schroeder, MA; Wu, W, 2013)	0.39
"The efficacies of different clinically relevant dosing regimens were compared in a panel of 7 primary GBM xenografts in an intracranial therapy evaluation model."	( Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Anderson, SK; Ballman, KV; Carlson, BL; Cen, L; Decker, PA; Giannini, C; Grogan, PT; Kitange, GJ; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schroeder, MA; Wu, W, 2013)	0.39
" There was no clear relationship between vorinostat dosage and drug exposure over the dose range studied."	( A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Ahern, C; Ames, MM; Blaney, SM; Fouladi, M; Gilbertson, RJ; Horton, T; Hummel, TR; Ingle, AM; McGovern, RM; Reid, JM; Wagner, L; Weigel, B, 2013)	0.39
"2mpk (equivalent to 10mpk of 1), 2 gave essentially the same exposure of 1 compared to dosing 10mpk of 1 itself."	( Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38α inhibitor. Barrish, JC; Dodd, JH; Everlof, G; Galella, MA; Gesenberg, C; Leftheris, K; Lin, J; Liu, C; Malley, M; Marathe, PH; McKinnon, M; Schieven, GL; Zhang, H, 2013)	0.39
" Comparisons included no chemotherapy, non-temozolomide chemotherapy or different dosing schedules of temozolomide."	( Temozolomide for high grade glioma. Garside, R; Grant, R; Hart, MG; Rogers, G; Stein, K, 2013)	0.39
" We report five patients who received long-term treatment with TMZ chemotherapy at normal dosing levels."	( Long-term treatment with temozolomide in malignant glioma. Defrates, SR; Lightner, DD; Mannas, JP; Pittman, T; Villano, JL, 2014)	0.4
"Myelotoxicity during initial cycles of chemotherapy for Hodgkin lymphoma is associated with better outcome, supporting the concept of individualised dosing based on pharmacodynamic end points to optimise results."	( A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. Dive, C; Gibb, A; Greystoke, A; Hampson, G; Illidge, T; Johnson, P; Linton, K; Lister, A; Neeson, S; Pettitt, A; Radford, J; Ranson, M; Smith, E, 2013)	0.39
" Circulating cell death biomarkers may assist in the development of future individualised dosing strategies."	( A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. Dive, C; Gibb, A; Greystoke, A; Hampson, G; Illidge, T; Johnson, P; Linton, K; Lister, A; Neeson, S; Pettitt, A; Radford, J; Ranson, M; Smith, E, 2013)	0.39
"Mutagenic and clastogenic effects of some DNA damaging agents such as methyl methanesulfonate (MMS) and ethyl methanesulfonate (EMS) have been demonstrated to exhibit a nonlinear or even "thresholded" dose-response in vitro and in vivo."	( Quantitative assessment of the dose-response of alkylating agents in DNA repair proficient and deficient ames tester strains. Guérard, M; Tang, L; Zeller, A, 2014)	0.4
" Overall, we have verified that TMZ in addition to being an alkylating and cytotoxic chemotherapy, also possess immune modulatory effect in MM patients treated with standard dosage of TMZ."	( Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer. Iversen, TZ, 2013)	0.39
" Patients aged over 70 years with favorable KPS, or patients aged 60-70 years with borderline KPS, should be considered for monotherapy utilizing standard TMZ dosing for patients with MGMT-methylated tumors, and hypofractionated RT (34 Gy in ten fractions or 40 Gy in 15 fractions) for patients with MGMT-unmethylated tumors."	( Treatment options and outcomes for glioblastoma in the elderly patient. Arvold, ND; Reardon, DA, 2014)	0.4
"Temozolomide, when dosed at 50, 25, 10, or 5 mg/kg, 5 days per week, beginning 3 days after inoculation, completely prevented the formation of experimental brain metastases from MGMT-negative 231-BR-EGFP cells."	( Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Biernat, W; Duchnowska, R; Gril, B; Hewitt, SM; Hua, E; Jassem, J; Liewehr, DJ; Palmieri, D; Qian, Y; Sosińska-Mielcarek, K; Stark, AM; Steeg, PS; Steinberg, SM; Woditschka, S, 2014)	0.4
" The ECM algorithm for incomplete data is applied to estimating the dose-response relationship in the proposed model."	( Modeling sustained treatment effects in tumor xenograft experiments. Deng, D; Fang, HB; Tan, M; Zhang, T, 2014)	0.4
" In vivo drug efficacy, pharmacokinetics, and pharmacodynamics were analyzed using clinically relevant dosing regimens."	( Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Bakken, KK; Boakye-Agyeman, F; Carlson, BL; Gupta, SK; Kizilbash, SH; Mladek, AC; Reid, J; Sarkaria, JN; Schroeder, MA, 2014)	0.4
"In vitro cytotoxicity assays do not adequately model the therapeutic index of PARP inhibitors, as concentrations of veliparib and TMZ required to sensitize TMZ-resistant cancer cells in vivo cannot be achieved using a tolerable dosing regimen."	( Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Bakken, KK; Boakye-Agyeman, F; Carlson, BL; Gupta, SK; Kizilbash, SH; Mladek, AC; Reid, J; Sarkaria, JN; Schroeder, MA, 2014)	0.4
"The EORTC-NCIC regimen for glioblastoma requires different dosing of temozolomide (TMZ) during radiation and maintenance therapy."	( Analyzing temozolomide medication errors: potentially fatal. Bressler, LR; Gabay, MP; Letarte, N; Long, KE; Stachnik, JM; Villano, JL, 2014)	0.4
" In phase II, participants were randomized (stratified by age and KPS) to receive A, T or AT; A was dosed at 40 mg/day and T at 75 mg/m(2) for 21 of 28 days."	( Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S, 2015)	0.42
" We therefore evaluated a 5-day dosing schedule of temozolomide and examined MGMT as a predictive biomarker for temozolomide treatment in SCLC."	( Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Bergagnini, I; Drilon, A; Ginsberg, MS; Heguy, A; Holodny, AI; Huberman, K; Kadota, K; Kris, MG; Krug, LM; Pietanza, MC; Riely, GJ; Sima, CS; Sumner, DK; Travis, WD; Zauderer, MG, 2014)	0.4
" Because tasisulam is highly albumin-bound, patients in the tumor-specific confirmation arms were dosed targeting specific albumin-corrected exposure ranges (AUCalb) identified during dose-escalation (3,500 hμg/mL [75th percentile] for docetaxel, temozolomide, and cisplatin; 4,000 hμg/mL for gemcitabine and erlotinib)."	( An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD, 2015)	0.42
" Dose-response analysis of cultured GBM cells revealed that DP68 is more potent than DP86 and TMZ and that DP68 was effective even in cell lines resistant to TMZ."	( Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. Gynther, M; Mladek, AC; Phillips, RM; Ramirez, YP; Rautio, J; Ross, AH; Sakaria, JN; Wheelhouse, RT, 2015)	0.42
" All patients received conformal WBRT (3 Gy × 10-30 Gy), with or without concomitant TMZ administered at a dosage of 75 mg/m(2)/day during the irradiation period."	( Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer. Bourgier, C; Cao, KI; Gerber, S; Gobillion, A; Kirova, YM; Le Scodan, R; Lebas, N; Levy, C; Pierga, JY; Savignoni, A, 2015)	0.42
" All patients received the first cycle of TMZ at a dosage of 150 mg/m(2) starting on the second or third postsurgical day."	( Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Albanese, V; Barbagallo, GM; Caltabiano, R; Certo, F; Lanzafame, S; Longo, A; Motta, F; Palmucci, S; Paratore, S; Parra, HS; Privitera, G; Scaglione, G, 2014)	0.4
"01), and higher posttreatment dosing of corticosteroid (P=."	( Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Arcella, A; Bozzao, A; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Scaringi, C; Terrenato, I, 2015)	0.42
" Since TMZ is the most active cytotoxic agent against GBM, and the standard dosing of TMZ has shown favorable safety profile in clinical trials, re-challenge with TMZ in increased dose density schedules for recurrent tumors that have evaded from prior standard TMZ therapy appears to be a rational approach and has been intensively exploited."	( Dose-dense temozolomide: is it still promising? Nagane, M, 2015)	0.42
" Even though dosing and timing might have been the reasons for this failure, it might also be that TREO does not reach the brain in sufficient amount."	( Transport of treosulfan and temozolomide across an in-vitro blood-brain barrier model. Hupert, M; Linz, U; Santiago-Schübel, B; Stab, J; Wagner, S; Wien, S, 2015)	0.42
" The economic evaluation compared the costs and outcomes of ipilimumab by assuming that the 3 mg/kg dosing regimen was clinically equivalent in efficacy to an ipilimumab 10 mg/kg dosing regimen plus DTIC and by using a treatment sequencing approach that incorporated second-line active therapy and third-line best supportive care (BSC)."	( Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence. Eastwood, A; Giannopoulou, C; McKenna, C; Moe-Byrne, T; Sideris, E; Wade, R, 2015)	0.42
"8- and 21-fold, respectively, when similarly dosed in P-gp-deficient mice."	( Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. Ajamie, RT; De Dios, A; Gelbert, LM; Kulanthaivel, P; Raub, TJ; Sanchez-Martinez, C; Sawada, GA; Shannon, HE; Staton, BA; Wishart, GN, 2015)	0.42
" We investigated the maximum tolerated dose (MTD) of iniparib with monthly (m) and continuous (c) temozolomide (TMZ) dosing schedules in patients with malignant gliomas (MG)."	( Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. Blakeley, JO; Chi, AS; Desideri, S; Emmons, G; Garcia Ribas, I; Grossman, SA; Mikkelsen, T; Nabors, LB; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X, 2015)	0.42
"Midazolam causes a hormetic dose-response relationship in human neuroblastoma cells."	( Pretreatment but not subsequent coincubation with midazolam reduces the cytotoxicity of temozolomide in neuroblastoma cells. Bauer, I; Braun, S; Pannen, B; Werdehausen, R, 2015)	0.42
" We confirmed in these studies that after completion of the Q7D×3 dosing of IrC™, but not IRN, the tumor-associated vascular was normalized as compared to untreated tumors."	( Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT, 2015)	0.42
" In comparing DNA damage signaling after dosing with veliparib/TMZ or TMZ alone, increased phosphorylation of damage-responsive proteins (KAP1, Chk1, Chk2, and H2AX) was observed only in MGMT promoter-hypermethylated lines."	( Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. Bakken, KK; Ballman, KV; Boakye-Agyeman, F; Carlson, BL; Cen, L; Decker, PA; Eckel-Passow, JE; Gupta, SK; Jenkins, RB; Kitange, GJ; Kizilbash, SH; Mladek, AC; Pokorny, JL; Reid, JM; Sarkar, G; Sarkaria, JN; Schroeder, MA; Sulman, EP; Verhaak, RG, 2016)	0.43
" This study provides strong scientific rationale for the development of an optimized dosing regimen for a PARP inhibitor with TMZ/IR for upfront treatment of GBM."	( Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Lemasson, B; Li, Y; Rehemtulla, A; Ross, BD; Tsein, C; Wang, H; Zhu, Y, 2016)	0.43
" Treatment of TMZ along with a sublethal dosage range of SU1498, a chemical inhibitor of the VEGF receptor signaling, induced significant cell death in both TMZ-sensitive and TMZ-resistant GBM cells without changing the status of the MGMT promoter methylation."	( Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1. Choi, C; Choi, K; Kim, E; Lee, J; Ryu, SW, 2016)	0.43
" So far, inhibition of angiogenesis by compounds such as bevacizumab, cediranib, enzastaurin or cilengitide as well as alternative dosing schedules of temozolomide did not prolong survival, neither at primary diagnosis nor at recurrent disease."	( Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives. Gramatzki, D; Roth, P; Seystahl, K; Weller, M, 2016)	0.43
" According with the poor Performance Status (PS = 2) and to reduce the toxicity of the treatment was chosen an intermittent dosing regimen of metronomic temozolomide (75 mg/m(2)/day-one-week-on/on-week-off)."	( Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. Arcella, A; Ascierto, PA; Cicala, D; De Divitiis, C; Grimaldi, AM; Iaffaioli, RV; Romano, GM; Simeone, E; Tafuto, S; Tatangelo, F; von Arx, C, 2016)	0.43
" In vivo, we implanted the cells orthotopically in nude mice and administered CBL0137 in various dosing regimens to assess brain and tumor accumulation of CBL0137, its effect on tumor cell proliferation and apoptosis, and on survival of mice with and without temozolomide (TMZ)."	( Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Barone, TA; Burkhart, CA; Gudkov, AV; Gurova, KV; Haderski, G; Plunkett, RJ; Purmal, AA; Safina, A, 2017)	0.46
" As a comparison group 33 patients with bevacizumab for at least 6 months continuously dosed at 10 mg/kg every 2 weeks were selected."	( Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. Hertenstein, A; Hielscher, T; Menn, O; Platten, M; Wick, A; Wick, W; Wiestler, B; Winkler, F, 2016)	0.43
" Dose-response curves were constructed using cell proliferation and sphere-forming assays."	( The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. Clark, PA; Deming, DA; Gaal, JT; Kuo, JS; Pasch, CA; Robins, HI; Strebe, JK, 2017)	0.46
" Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective."	( Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. Alsop, DC; Callahan, A; Giarusso, B; O'Loughlin, L; Timmons, J; Wong, ET, 2016)	0.43
" As a part of the study, two DNA alkylating agents, methylnitrosourea (MNU) and temozolomide (TMZ), were dosed by single oral gavage at 25, 50, and 100mg/kg body weight."	( Evaluation of the mutagenicity of alkylating agents, methylnitrosourea and temozolomide, using the rat Pig-a assay with total red blood cells or reticulocytes. Ando, M; Inoue, Y; Iwase, Y; Kato, T; Muto, S; Uno, Y; Yamada, K, 2016)	0.43
"6 μg/day) with negligible leakage into the peripheral blood (<100 ng) rendering ~1000 fold differential drug dosage in tumor versus peripheral blood."	( Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma. Ashokan, A; Gowd, GS; Junnuthula, VR; Koyakutty, M; Nair, SV; Panikar, D; Peethambaran, R; Ramachandran, R; Thomas, A; Thomas, J; Unni, AK, 2017)	0.46
"Temozolomide (TMZ) for malignant gliomas is traditionally dosed in 5 out of a 28-day cycle, however alternative regimens exist, including dose-dense."	( Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma. Howard, TA; Villano, JL; Zhou, Z, 2017)	0.46
" At recurrence, alternate dosing of temozolomide has shown to further deplete methyl-guanine-methyltransferase (MGMT) conferring added activity for patients who have progressed on the standard dosing regimen."	( Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T, 2017)	0.46
" Modern techniques, such as intensity-modulated radiation therapy (IMRT) and proton therapy allow for modifications in radiation dosing and delivery while improving conformality and limiting irradiation of normal tissue."	( Fractionated Radiotherapy of Intracranial Gliomas. Ghia, AJ, 2018)	0.48
"8% of actual body weight calculated body surface area dosing was determined for concurrent phase temozolomide."	( Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma. Chambers, C; Coppens, R; de Robles, P; Dersch-Mills, D; Folkman, F; Ghosh, S; Hsu, PYH; Leckie, C, 2021)	0.62
"Temozolomide doses at full actual body weight calculated body surface area dosing during the concurrent phase is required to achieve a similar median OS as seen in the pivotal trial by Stupp et al."	( Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma. Chambers, C; Coppens, R; de Robles, P; Dersch-Mills, D; Folkman, F; Ghosh, S; Hsu, PYH; Leckie, C, 2021)	0.62
"To investigate the toxicity profile and establish an optimal dosing schedule of zotiraciclib with temozolomide in patients with recurrent high-grade astrocytoma."	( Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Aboud, O; Ahmad, S; Antony, R; Armstrong, TS; Boris, L; Bryla, C; Burton, EM; Butler, MK; Calvo, KR; Cordova, C; Figg, WD; Fink, D; Gallin, JI; Garren, N; Gilbert, MR; Gonzales, J; Grajkowska, E; Kuhns, DB; Leeper, H; Lindsley, M; Lollo, N; Long Priel, DA; Mendoza, TR; Mentges, K; Pang, Y; Peer, CJ; Penas-Prado, M; Siegel, C; Sissung, TM; Su, YT; Theeler, BJ; Vera, E; Wu, J; Yu, G; Yuan, Y, 2021)	0.62
" Once validated, polymorphisms predicting drug metabolism may allow personalized dosing of zotiraciclib."	( Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Aboud, O; Ahmad, S; Antony, R; Armstrong, TS; Boris, L; Bryla, C; Burton, EM; Butler, MK; Calvo, KR; Cordova, C; Figg, WD; Fink, D; Gallin, JI; Garren, N; Gilbert, MR; Gonzales, J; Grajkowska, E; Kuhns, DB; Leeper, H; Lindsley, M; Lollo, N; Long Priel, DA; Mendoza, TR; Mentges, K; Pang, Y; Peer, CJ; Penas-Prado, M; Siegel, C; Sissung, TM; Su, YT; Theeler, BJ; Vera, E; Wu, J; Yu, G; Yuan, Y, 2021)	0.62
" Cardiac and carotid radiation doses and chemotherapy exposure were combined with established dose-response relationships and population-based mortality and incidence rates."	( Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma. Buckle, A; Clifton-Hadley, L; Cutter, DJ; Darby, SC; Diez, P; Hoskin, PJ; Illidge, T; Ntentas, G; Popova, B; Radford, J; Ramroth, J, 2021)	0.62
" There is insufficient data to make a recommendation about which alternative TMZ dosing provides the best benefits."	( Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults. Germano, IM; Olson, JJ; Ormond, DR; Wen, P; Ziu, M, 2022)	0.72
"This retrospective, observational study included adults with stage III/IV cHL initiating 1L doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine, or an escalated dosing regimen of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone within the US Oncology Network between January 2017 and October 2019."	( Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective. Beeks, A; Fanale, M; He, D; Liu, N; Robert, N; Yasenchak, C; Yu, KS, 2023)	0.91

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
alkylating agent	Highly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
prodrug	A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
carcinogenic agent	A role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
dacarbazine	A monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma.
monocarboxylic acid amide	A carboxamide derived from a monocarboxylic acid.
imidazoles	A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
triazene derivative	A nitrogen molecular entity resulting from the formal substitution of one or more of the hydrogens of triazene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	35.4813	0.1778	14.3909	39.8107	AID2147
interleukin 8	Homo sapiens (human)	Potency	74.9780	0.0473	49.4806	74.9780	AID651758
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	4.2527	3.1890	29.8841	59.4836	AID1224846
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	13.3332	0.0060	38.0041	19,952.5996	AID1159521
AR protein	Homo sapiens (human)	Potency	37.0088	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743042; AID743054
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	16.8159	0.0112	12.4002	100.0000	AID1030
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	39.8107	0.0013	18.0743	39.8107	AID926; AID938
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	9.2780	0.0002	14.3764	60.0339	AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	36.8425	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	43.6479	0.0015	30.6073	15,848.9004	AID1224848; AID1224849; AID1259403
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	44.6684	0.0002	29.3054	16,493.5996	AID588513
cytochrome P450 2D6	Homo sapiens (human)	Potency	21.8761	0.0010	8.3798	61.1304	AID1645840
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	44.2774	0.0010	19.4141	70.9645	AID743191
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	37.5780	0.0016	28.0151	77.1139	AID1259385
activating transcription factor 6	Homo sapiens (human)	Potency	22.1912	0.1434	27.6121	59.8106	AID1159516
geminin	Homo sapiens (human)	Potency	16.7889	0.0046	11.3741	33.4983	AID624296
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	9.4495	0.1259	12.2344	35.4813	AID1458
lamin isoform A-delta10	Homo sapiens (human)	Potency	11.2202	0.8913	12.0676	28.1838	AID1487
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	6.3096	1.0000	10.4756	28.1838	AID1457
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	6.3096	0.0447	17.8581	100.0000	AID485294
glp-1 receptor, partial	Homo sapiens (human)	Potency	10.0000	0.0184	6.8060	14.1254	AID624417
Fumarate hydratase	Homo sapiens (human)	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
EWS/FLI fusion protein	Homo sapiens (human)	Potency	18.6548	0.0013	10.1577	42.8575	AID1259252; AID1259253
polyprotein	Zika virus	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
IDH1	Homo sapiens (human)	Potency	8.1995	0.0052	10.8652	35.4813	AID686970
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	6.3096	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	6.3096	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	6.3096	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	0.0820	0.0046	11.3741	33.4983	AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	566.5000	0.1100	7.1903	10.0000	AID1449628; AID1473738
Matrix metalloproteinase-9	Homo sapiens (human)	IC50 (µMol)	0.5560	0.0000	0.7053	10.0000	AID625178
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PAX8	Homo sapiens (human)	AC50	5.3400	0.0488	5.4354	69.1700	AID687027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
skeletal system development	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of protein phosphorylation	Matrix metalloproteinase-9	Homo sapiens (human)
proteolysis	Matrix metalloproteinase-9	Homo sapiens (human)
apoptotic process	Matrix metalloproteinase-9	Homo sapiens (human)
embryo implantation	Matrix metalloproteinase-9	Homo sapiens (human)
cell migration	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular matrix disassembly	Matrix metalloproteinase-9	Homo sapiens (human)
macrophage differentiation	Matrix metalloproteinase-9	Homo sapiens (human)
collagen catabolic process	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to reactive oxygen species	Matrix metalloproteinase-9	Homo sapiens (human)
endodermal cell differentiation	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of apoptotic process	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of apoptotic process	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of DNA binding	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
ephrin receptor signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of keratinocyte migration	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to lipopolysaccharide	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to cadmium ion	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to UV-A	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Matrix metalloproteinase-9	Homo sapiens (human)
regulation of neuroinflammatory response	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of receptor binding	Matrix metalloproteinase-9	Homo sapiens (human)
response to amyloid-beta	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney development	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of cation channel activity	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular matrix organization	Matrix metalloproteinase-9	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
endopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
metalloendopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
serine-type endopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
protein binding	Matrix metalloproteinase-9	Homo sapiens (human)
collagen binding	Matrix metalloproteinase-9	Homo sapiens (human)
peptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
metallopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
zinc ion binding	Matrix metalloproteinase-9	Homo sapiens (human)
identical protein binding	Matrix metalloproteinase-9	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular region	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular space	Matrix metalloproteinase-9	Homo sapiens (human)
collagen-containing extracellular matrix	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular exosome	Matrix metalloproteinase-9	Homo sapiens (human)
tertiary granule lumen	Matrix metalloproteinase-9	Homo sapiens (human)
ficolin-1-rich granule lumen	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular space	Matrix metalloproteinase-9	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1224817	Assays to identify small molecules inhibitory for eIF4E expression	2015	Chemistry & biology, Jul-23, Volume: 22, Issue:7	Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1764138	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 48 hrs relative to control	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	l-Hypaphorine and d-hypaphorine: Specific antiacetylcholinesterase activity in rat brain tissue.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1132405	Toxicity in mouse B16 cells allografted mouse at 216 mg/kg, ip qd for 9 days	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1455302	Antitumor activity against mouse B16 cells implanted in nude mouse assessed as inhibition of tumor growth at 15 mg/kg, iv administered every other day for 20 days relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Glutathione S-Transferase π-Activatable O
AID1147881	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in survival at 125 mg/kg administered on day 1 followed by 5 injections with 1 day interval relative to control	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID116629	Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 200 mg/kg	1980	Journal of medicinal chemistry, Sep, Volume: 23, Issue:9	Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID1869916	Toxicity in BALB/c mouse assessed as change in body weight at 70 mg/kg, iv measured once every two days for 7 days
AID457505	Cytotoxicity against human fibroblasts after 48 hrs by SRB assay	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents.
AID1132406	Toxicity in mouse B16 cells allografted mouse at 130 mg/kg, ip qd for 9 days	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID409952	Inhibition of human brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID526640	Toxicity in mouse B16-F1 cells xenografted C57/BL mouse assessed as reduction of body weight at 60 mg/kg, ip administered 7 days after tumor inoculation qd for 14 days	2010	Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20	Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID477295	Octanol-water partition coefficient, log P of the compound	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1148443	Toxicity in CDF1 mouse assessed as concentration required for producing T/C of 140	1978	Journal of medicinal chemistry, Jun, Volume: 21, Issue:6	Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice.
AID116626	Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 12.5 mg/kg	1980	Journal of medicinal chemistry, Sep, Volume: 23, Issue:9	Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID1147898	Toxicity in mouse L1210 cells allografted BDF1 mouse assessed as reduction in body weight at 120 mg/kg administered on day 1 followed by 5 injections with 1 day interval	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID1147865	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as survival at 180 mg/kg administered on day 1 followed by 5 injections with 1 day interval	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1147866	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as survival at 125 mg/kg administered on day 1 followed by 5 injections with 1 day interval	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID1147883	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in survival at 80 mg/kg administered on day 1 followed by 5 injections with 1 day interval relative to control	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1147884	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in survival at 53 mg/kg administered on day 1 followed by 5 injections with 1 day interval relative to control	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID1869924	Antitumor activity against human A-375 cells implanted in BALB/c mouse assessed as shrinkage of tumor tissue at 70 mg/kg, ip measured once every two days for 14 days
AID409950	Inhibition of human brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID550850	Cytotoxicity against human OVCAR3 cells after 6 days by MTT assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Design, synthesis, and biological evaluation of N-acetyl-S-(p-chlorophenylcarbamoyl)cysteine and its analogs as a novel class of anticancer agents.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID409947	Inhibition of human recombinant MAOB at 1 mM by fluorimetric method	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID132734	Percent increase in life span was measured in B6d2F1 mice after implanting B16 melanoma cells(ic) at an intracerebral (ic) optimal dose of 10-40 mg/ (kg day)	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID1132404	Toxicity in mouse B16 cells allografted mouse at 360 mg/kg, ip qd for 9 days	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
AID457503	Antiproliferative activity against human A375 cells after 48 hrs by SRB assay	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID404382	Antiproliferative activity against fibroblast cells after 48 hrs by SRB assay	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma.
AID550851	Cytotoxicity against human SK-MEL-2 cells after 6 days by MTT assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Design, synthesis, and biological evaluation of N-acetyl-S-(p-chlorophenylcarbamoyl)cysteine and its analogs as a novel class of anticancer agents.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1148442	Toxicity in mouse assessed as concentration required for producing T/C of 140	1978	Journal of medicinal chemistry, Jun, Volume: 21, Issue:6	Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice.
AID1132417	Antitumor activity against mouse B16 cells allografted mouse assessed as host survival at 360 mg/kg, ip qd for 9 days relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1132394	Antitumor activity against mouse L1210 cells allografted mouse assessed as host survival at 100 mg/kg, ip qd for 9 days relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID40577	Effect of compound on the survival time of mice bearing the B16 melanoma at a daily dose of 150 mg/kg	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis and evaluation of 1-(arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1-methylhydrazines++ + as antineoplastic agents.
AID1147868	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as survival at 53 mg/kg administered on day 1 followed by 5 injections with 1 day interval	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1132381	Antitumor activity against mouse P388 cells allografted mouse assessed as host survival at 100 mg/kg, ip qd for 9 days relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625276	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1764137	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 24 hrs relative to control	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	l-Hypaphorine and d-hypaphorine: Specific antiacetylcholinesterase activity in rat brain tissue.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1123539	Mutagenicity in Salmonella typhimurium strain TA92 assessed as number of bacterial revertants after 2 days by Ames test in presence of rat liver S9 fraction	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Ames test of 1-(X-phenyl)-3,3-dialkyltriazenes. A quantitative structure-activity study.
AID116635	Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 50 mg/kg	1980	Journal of medicinal chemistry, Sep, Volume: 23, Issue:9	Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID1636357	Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1147897	Toxicity in mouse L1210 cells allografted BDF1 mouse assessed as reduction in body weight at 125 mg/kg administered on day 1 followed by 5 injections with 1 day interval	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID73186	In vitro cytotoxicity against human lymphoblastoid cell (GM892 A)	1995	Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9	Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.
AID404381	Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID665020	Cytotoxicity against human A375 cells after 48 hrs by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis of new 2-galactosylthiazolidine-4-carboxylic acid amides. Antitumor evaluation against melanoma and breast cancer cells.
AID1132418	Antitumor activity against mouse B16 cells allografted mouse assessed as host survival at 216 mg/kg, ip qd for 9 days relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
AID1132823	Distribution coefficient, log P of the compound	1978	Journal of medicinal chemistry, Jun, Volume: 21, Issue:6	Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
AID1636440	Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1181988	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	New benzothieno[3,2-d]-1,2,3-triazines with antiproliferative activity: synthesis, spectroscopic studies, and biological activity.
AID457502	Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID134111	Mean life extension in mice bearing Trypanosoma rhodesiense, after ip administration at a dose of 0.2 mmol/kg	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Methylating agents as trypanocides.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1636495	Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 258.5 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1147880	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in survival at 180 mg/kg administered on day 1 followed by 5 injections with 1 day interval relative to control	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID1147899	Toxicity in mouse L1210 cells allografted BDF1 mouse assessed as reduction in body weight at 80 mg/kg administered on day 1 followed by 5 injections with 1 day interval	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID116624	Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 100 mg/kg	1980	Journal of medicinal chemistry, Sep, Volume: 23, Issue:9	Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID132179	Maximum increase in life span was measured in B6d2F1 mice after implanting murine leukemia L1210 cells(ic, 10e4 cells) at an intracerebral optimal dose of 160 mg/ (kg day)(qd 1-9)	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID678718	Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID526641	Toxicity in mouse B16-F1 cells xenografted C57/BL mouse assessed as reduction of body weight at 30 mg/kg, ip administered 7 days after tumor inoculation qd for 14 days	2010	Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20	Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID134249	Mean life extension in mice bearing Trypanosoma rhodesiense, after ip administration at 0.5 mmol/kg dose	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Methylating agents as trypanocides.
AID1147867	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as survival at 80 mg/kg administered on day 1 followed by 5 injections with 1 day interval	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID37924	Effect of compound on the body weight of mice bearing the B16 melanoma at a daily dose of 12.5 mg/kg	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis and evaluation of 1-(arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1-methylhydrazines++ + as antineoplastic agents.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1869921	Antitumor activity against human A-375 cells implanted in BALB/c mouse assessed as reduction in tumor weight at 70 mg/kg, ip measured once every two days for 14 days
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1147882	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in survival at 120 mg/kg administered on day 1 followed by 5 injections with 1 day interval relative to control	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID526637	Antitumor activity against mouse B16-F1 cells xenografted in C57/BL mouse assessed as reduction of tumor growth at 60 mg/kg, ip administered 7 days after tumor inoculation qd for 14 days	2010	Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20	Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1147896	Toxicity in mouse L1210 cells allografted BDF1 mouse assessed as reduction in body weight at 180 mg/kg administered on day 1 followed by 5 injections with 1 day interval	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID116630	Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 25 mg/kg	1980	Journal of medicinal chemistry, Sep, Volume: 23, Issue:9	Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1132822	Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase of host lifespan	1978	Journal of medicinal chemistry, Jun, Volume: 21, Issue:6	Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1132419	Antitumor activity against mouse B16 cells allografted mouse assessed as host survival at 130 mg/kg, ip qd for 9 days relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID37923	Effect of compound on the body weight of mice bearing the B16 melanoma at a daily dose of 100 mg/kg	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis and evaluation of 1-(arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1-methylhydrazines++ + as antineoplastic agents.
AID19219	Partition coefficient (logP)	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID40574	Effect of compound on the survival time of mice bearing the B16 melanoma at a daily dose (mg/kg) of,50	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis and evaluation of 1-(arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1-methylhydrazines++ + as antineoplastic agents.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID38043	Effect of compound on the body weight of mice bearing the B16 melanoma at a daily dose of 150 mg/kg	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis and evaluation of 1-(arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1-methylhydrazines++ + as antineoplastic agents.
AID299636	Antiproliferative activity against human SK-MEL-188 cells after 48 hrs by SRB assay	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Synthesis and antiproliferative activity of thiazolidine analogs for melanoma.
AID1147900	Toxicity in mouse L1210 cells allografted BDF1 mouse assessed as reduction in body weight at 53 mg/kg administered on day 1 followed by 5 injections with 1 day interval	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Synthesis and antileukemic activities of furanyl, pyranyl, and ribosyl derivatives of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide and 3-(3,3-dimethyl-1-triazeno)pyrazole-4-carboxamide.
AID231797	Ratio of cytotoxicity against Raji cells to that of GM892 A cells.	1995	Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9	Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.
AID1869918	Antitumor activity against human A-375 cells implanted in BALB/c mouse assessed as tumor growth inhibition at 70 mg/kg, ip measured once every two days for 14 days
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID40575	Effect of compound on the survival time of mice bearing the B16 melanoma at a daily dose of 100 mg/kg	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis and evaluation of 1-(arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1-methylhydrazines++ + as antineoplastic agents.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409949	Inhibition of human liver MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID550849	Cytotoxicity against human GC3/C1 cells after 6 days by MTT assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Design, synthesis, and biological evaluation of N-acetyl-S-(p-chlorophenylcarbamoyl)cysteine and its analogs as a novel class of anticancer agents.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID404380	Antiproliferative activity against human A375 cells after 48 hrs by SRB assay	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma.
AID132184	Maximum increase in life span was measured in B6d2F1 mice after implanting murine leukemia L1210 cells(ip, 10e5 cells) at an intraperitoneal optimal dose of 108 mg/ (kg day)(qd 1-9)	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID457504	Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents.
AID526639	Toxicity in mouse B16-F1 cells xenografted C57/BL mouse assessed as reduction of body weight at 10 mg/kg, ip administered 7 days after tumor inoculation qd for 14 days	2010	Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20	Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
AID1132421	Binding affinity to synthetic melanin at 5.8 mg/100 mL after 15 mins by UV-spectroscopic analysis	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID132738	Percent increase in life span was measured in B6d2F1 mice after implanting murine leukemia Ependymoblastoma cells(ic) at an oral optimal dose of 64 mg/ (kg injection)	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID116633	Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 400 mg/kg	1980	Journal of medicinal chemistry, Sep, Volume: 23, Issue:9	Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID550848	Cytotoxicity against human UACC62 cells after 6 days by MTT assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Design, synthesis, and biological evaluation of N-acetyl-S-(p-chlorophenylcarbamoyl)cysteine and its analogs as a novel class of anticancer agents.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1132826	Octanol-saturated water partition coefficient, log D of the compound	1978	Journal of medicinal chemistry, Jun, Volume: 21, Issue:6	Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
AID299637	Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Synthesis and antiproliferative activity of thiazolidine analogs for melanoma.
AID165776	In vitro cytotoxicity against Raji cell line	1995	Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9	Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.
AID299638	Antiproliferative activity against human fibroblasts after 48 hrs by SRB assay	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Synthesis and antiproliferative activity of thiazolidine analogs for melanoma.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1802950	ICL Enzyme Assay from Article 10.3109/14756360903425221: \\5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.\\	2010	Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 25, Issue:6	5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	916 (12.70)	18.7374
1990's	757 (10.50)	18.2507
2000's	1776 (24.63)	29.6817
2010's	3391 (47.03)	24.3611
2020's	371 (5.14)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,463 (19.36%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	787 (10.42%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	1,122 (14.85%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	17 (0.22%)	0.25%
Observational	0 (0.00%)	0.25%
Other	4,167 (55.15%)	84.16%
Other	15 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (175)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo [NCT00324155]	Phase 3	681 participants (Actual)	Interventional	2006-08-31	Completed
Phase III Trial of High Dose Interferon Alfa 2-b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients With High Risk Melanoma [NCT00006237]	Phase 3	432 participants (Actual)	Interventional	2000-08-31	Completed
Efficacy and Safety of Tunlametinib Capsules Versus Combination Chemotherapy of Investigator's Choice in Advanced NRAS-mutant Melanoma Patients Who Had Previously Received Immunotherapy [NCT06008106]	Phase 3	165 participants (Anticipated)	Interventional	2023-09-22	Not yet recruiting
[NCT01569204]	Phase 2	100 participants (Anticipated)	Interventional	2012-10-31	Completed
A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage [NCT03159897]	Phase 3	500 participants (Anticipated)	Interventional	2017-08-01	Active, not recruiting
A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma [NCT04685616]	Phase 3	1,042 participants (Anticipated)	Interventional	2022-04-14	Recruiting
Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects [NCT02181738]	Phase 2	294 participants (Actual)	Interventional	2014-08-12	Completed
CD20-Immunotargeting in Metastatic Melanoma Patients- A Prospective, Open Label, Sequential Pilot Study [NCT01376713]	Phase 2	10 participants (Actual)	Interventional	2011-06-30	Completed
A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma [NCT01343277]	Phase 3	579 participants (Actual)	Interventional	2011-06-30	Completed
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma [NCT02288897]	Phase 3	20 participants (Actual)	Interventional	2015-04-30	Terminated(stopped due to Inadequate rate of enrollment)
A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma [NCT00936221]	Phase 2	385 participants (Actual)	Interventional	2009-07-31	Completed
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia [NCT04638790]	Phase 3	300 participants (Anticipated)	Interventional	2020-02-01	Recruiting
Phase II Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Dacarbazine (DTIC) Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma [NCT00110994]	Phase 2	101 participants (Actual)	Interventional	2005-04-30	Completed
A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma [NCT00130442]	Phase 2	134 participants (Actual)	Interventional	2005-06-30	Completed
Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group [NCT00091572]	Phase 3	859 participants (Actual)	Interventional	2004-10-20	Completed
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients [NCT03023124]	Phase 2	50 participants (Anticipated)	Interventional	2018-03-04	Recruiting
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma [NCT03004833]	Phase 2	110 participants (Actual)	Interventional	2017-02-21	Active, not recruiting
Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy [NCT01710176]	Phase 3	550 participants (Actual)	Interventional	2011-06-01	Active, not recruiting
A Prospective, Multicenter, Randomized, Open-label, Active Controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Dacarbazine in the Treatment of Patients With Non-resectable or Metastatic Stage [NCT01280565]	Phase 3	134 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to Sponsor decision based on portfolio prioritization)
A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma [NCT00257205]	Phase 3	655 participants (Actual)	Interventional	2006-03-31	Completed
Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas [NCT03277924]	Phase 1/Phase 2	270 participants (Anticipated)	Interventional	2017-05-31	Recruiting
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy [NCT01716806]	Phase 2	131 participants (Actual)	Interventional	2012-10-31	Completed
Adcetris (Brentuximab Vedotin), Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL) [NCT01920932]	Phase 2	77 participants (Actual)	Interventional	2013-08-12	Active, not recruiting
A Phase II, Multicenter, Open Label Study of Treatment Intensification With ACVD and Brentuximab-Vedotin in Advanced-stage Hodgkin Lymphoma Patients With a Positive Interim PET Scan After 2 ABVD Cycles [NCT03527628]	Phase 2	220 participants (Anticipated)	Interventional	2018-01-01	Recruiting
Phase II Multicenter Randomized Study to Compare Dacarbazine With Melatonin or Metformin Versus Dacarbazine in the First Line Therapy of Disseminated Melanoma [NCT02190838]	Phase 2	57 participants (Actual)	Interventional	2014-04-30	Terminated(stopped due to Preliminary terminated due to inefficacy)
A Single-center, Open-arm, Single-arm Phase II Trial of the PD-1 Antibody Tirelizumab Plus Dacarbazine as First-line Treatment for Advanced Melanoma [NCT05466474]	Phase 2	40 participants (Anticipated)	Interventional	2022-12-30	Recruiting
HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma [NCT01356680]	Phase 3	1,100 participants (Actual)	Interventional	2012-01-13	Completed
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) [NCT04893356]		75 participants (Anticipated)	Observational	2021-01-20	Active, not recruiting
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma [NCT01771107]	Phase 1/Phase 2	41 participants (Actual)	Interventional	2013-03-07	Active, not recruiting
Prospective Randomized Comparison of ABVD Versus BEACOPP Chemotherapy With or Without Radiotherapy for Advanced Stage or Unfavorable Hodgkin's Lymphoma (HL) [NCT01251107]	Phase 3	331 participants (Actual)	Interventional	2000-03-31	Completed
Phase II Clinical Trial of Camrelizumab Combined With AVD (Epirubicin, Vincristine and Dacarbazine) in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma [NCT04067037]	Phase 2	60 participants (Anticipated)	Interventional	2019-08-26	Recruiting
A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha (aIFN) Plus Thymosin a1 Versus Both DTIC Plus Thymosin a1 and DTIC Plus aIFN in P [NCT00911443]	Phase 2	488 participants (Actual)	Interventional	2002-07-31	Completed
A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma [NCT01868451]		118 participants (Actual)	Interventional	2013-05-31	Active, not recruiting
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11) [NCT05008224]	Phase 2	146 participants (Actual)	Interventional	2021-10-07	Active, not recruiting
A Phase II, Multi-center, Open-label, Uncontrolled Study to Evaluate the Efficacy and Safety of BAY 43-9006 Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma. [NCT00492297]	Phase 2	83 participants (Actual)	Interventional	2005-04-30	Completed
A Multi-centre, Two-arm, Randomized, Open, Phase II Study Investigating SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma [NCT00991250]	Phase 2	140 participants (Anticipated)	Interventional	2009-10-31	Recruiting
Phase III Study Comparing Rituximab-supplemented ABVD (R-ABVD) With ABVD Followed by Involved-field Radiotherapy (ABVD-RT) in Limited Stage (Stage I-IIA With no Areas of Bulk) Hodgkin's Lymphoma [NCT00992030]	Phase 3	112 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Low recruitment and difficulty in having study data)
Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma [NCT00533702]	Phase 2	106 participants (Actual)	Interventional	2007-11-30	Completed
Multicenter, Double-blinding, Randomized Controlled, Phase II Clinical Trial on Combined Chemotherapy of Endostar (Recombinant Human Endostatin) for Untreated Patients With Advanced Melanoma [NCT00813449]	Phase 2	140 participants (Anticipated)	Interventional	2008-08-31	Recruiting
Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma [NCT00816959]	Phase 3	1,200 participants (Anticipated)	Interventional	2011-07-31	Not yet recruiting
European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents [NCT02684708]	Phase 3	2,200 participants (Anticipated)	Interventional	2015-10-01	Active, not recruiting
A Randomized Study to Investigate the Efficacy and Safety of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma [NCT04733183]	Phase 2	98 participants (Anticipated)	Interventional	2020-08-28	Recruiting
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma [NCT05675410]	Phase 3	1,875 participants (Anticipated)	Interventional	2023-05-11	Recruiting
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin's Lymphoma [NCT00369681]	Phase 2	51 participants (Actual)	Interventional	2006-05-31	Completed
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Association With Chemotherapy in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma [NCT00849875]	Phase 2	48 participants (Actual)	Interventional	2009-05-26	Terminated(stopped due to Early end of trial notification after termination of long term follow up due to lack of scientific justification to continue collect information.)
A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging [NCT00822120]	Phase 2	371 participants (Actual)	Interventional	2009-07-31	Completed
A Randomized, Parallel, 3-arm Study to Characterize the Effect of Ipilimumab + Chemotherapy in Patients With Untreated Advanced Melanoma [NCT00796991]	Phase 1	72 participants (Actual)	Interventional	2009-02-28	Completed
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma [NCT03070392]	Phase 2	378 participants (Actual)	Interventional	2017-10-16	Active, not recruiting
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma [NCT01143402]	Phase 2	120 participants (Actual)	Interventional	2010-06-30	Completed
Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine [NCT00794235]	Phase 2	12 participants (Anticipated)	Interventional	2008-12-31	Completed
HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET [NCT00736320]	Phase 3	1,150 participants (Actual)	Interventional	2009-11-30	Active, not recruiting
A Phase II Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Previously Untreated With Dacarbazine Patients in Unresectable Stage IIIb/IIIc or Stage IV(Mla/Mlb) Malignant Melanoma [NCT04200040]	Phase 2	165 participants (Anticipated)	Interventional	2017-08-27	Recruiting
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma [NCT00864253]	Phase 3	529 participants (Actual)	Interventional	2009-04-23	Completed
Phase II Randomized, Parallel-Group Trial on PTK-ZK With or Without DTIC in Patients With Non-resectable Metastatic Malignant Melanoma [NCT00615160]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2006-12-31	Terminated(stopped due to Substance was withdrawn from further development.)
Phase I/II Clinical Trial for the Evaluation of the Interaction Between Chemotherapy and Immunotherapy in Melanoma Patients [NCT00559026]	Phase 1	10 participants (Actual)	Interventional	2004-09-30	Completed
Phase II Study of Dacarbazine With the Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Patients With Unresectable/Metastatic Melanoma [NCT01164007]	Phase 2	40 participants (Actual)	Interventional	2006-06-30	Completed
Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma [NCT00920153]	Phase 3	442 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Other new drugs)
Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance [NCT01100528]	Phase 2	38 participants (Actual)	Interventional	2009-11-11	Completed
Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma [NCT00837148]	Phase 2	37 participants (Actual)	Interventional	2009-02-28	Completed
A Phase II Open Label, Multicenter, Randomized, Parallel Study Comparing the Efficacy of R-mabHD Alone and a Combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD)in Treating Patients With Hodgkin's Disease. [NCT00797472]	Phase 2	120 participants (Anticipated)	Interventional	2011-07-31	Not yet recruiting
A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2) [NCT00654732]	Phase 2	58 participants (Actual)	Interventional	2008-03-19	Completed
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects [NCT03646123]	Phase 2	255 participants (Actual)	Interventional	2019-01-28	Active, not recruiting
Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma [NCT00779714]	Phase 3	360 participants (Anticipated)	Interventional	2008-10-31	Recruiting
A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine, and Dacarbazine (APVD) for Patients With Untreated Classical Hodgkin Lymphoma [NCT03331341]	Phase 2	50 participants (Actual)	Interventional	2019-01-09	Active, not recruiting
A Randomized, Open-label, Cross-over Pharmacokinetic Study of Dacarbazine in Combination With Genasense® in Subjects With Advanced Melanoma [NCT00542893]	Phase 1	0 participants	Interventional	2006-04-30	Completed
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma [NCT05269355]	Phase 2/Phase 3	345 participants (Actual)	Interventional	2022-05-23	Active, not recruiting
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma [NCT03907488]	Phase 3	995 participants (Actual)	Interventional	2019-08-29	Active, not recruiting
A Phase 1B Study of Unesbulin (PTC596) in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma [NCT03761095]	Phase 1	41 participants (Actual)	Interventional	2019-03-13	Active, not recruiting
Dose Definition and Activity Evaluation Study of the Tumor-Targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Combination With Dacarbazine in Patients With Metastatic Melanoma [NCT01055522]	Phase 2	102 participants (Actual)	Interventional	2008-06-30	Terminated
A Phase 1 Dose-Escalation Safety Study of Brentuximab Vedotin in Combination With Multi-Agent Chemotherapy as Frontline Therapy in Patients With Hodgkin Lymphoma [NCT01060904]	Phase 1	51 participants (Actual)	Interventional	2010-01-31	Completed
A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus [NCT00033644]	Phase 2	0 participants	Interventional	2002-03-31	Terminated
IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2) [NCT05987332]	Phase 2/Phase 3	380 participants (Anticipated)	Interventional	2023-10-31	Recruiting
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma [NCT05922904]	Phase 2	50 participants (Anticipated)	Interventional	2023-12-14	Recruiting
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma [NCT03016819]	Phase 3	325 participants (Anticipated)	Interventional	2017-08-15	Active, not recruiting
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma [NCT00580320]	Phase 1	17 participants (Actual)	Interventional	2004-09-30	Completed
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma. [NCT01133977]	Phase 1/Phase 2	97 participants (Actual)	Interventional	2010-04-30	Completed
Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma [NCT01132807]	Phase 2	164 participants (Actual)	Interventional	2010-05-31	Completed
BRIM 3: A Randomized, Open-Label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving Vemurafenib (RO5185426) or Dacarbazine [NCT01006980]	Phase 3	675 participants (Actual)	Interventional	2010-01-31	Completed
A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma [NCT01152788]	Phase 2	64 participants (Actual)	Interventional	2010-08-05	Completed
An International, Multicentre, Randomised Controlled Trial. Treatment for Classical Hodgkin Lymphoma in Children and Adolescents Standard Treatment (Chemotherapy and RT) Compared With Experimental Treatment (Chemotherapy Without RT or Restricted to RT) [NCT02797717]		2,200 participants (Anticipated)	Interventional	2015-11-30	Recruiting
[NCT00006200]	Phase 2	0 participants	Interventional		Active, not recruiting
NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma [NCT00410631]	Phase 3	642 participants (Anticipated)	Interventional	2004-10-31	Recruiting
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma [NCT01712490]	Phase 3	1,334 participants (Actual)	Interventional	2012-11-09	Active, not recruiting
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation [NCT01028222]	Phase 2	55 participants (Actual)	Interventional	2010-06-30	Completed
A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients With Advanced Solid Tumours [NCT00516802]	Phase 1	40 participants (Actual)	Interventional	2007-01-31	Completed
Phase I Safety Study of the Combination of Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy (CC-5013-MEL-003) [NCT00412581]	Phase 1	28 participants (Actual)	Interventional	2005-09-30	Completed
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma [NCT01227889]	Phase 3	251 participants (Actual)	Interventional	2010-12-23	Completed
PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS [NCT00002802]	Phase 3	500 participants (Anticipated)	Interventional	1990-07-31	Completed
A Multicenter, Randomized, Double-blind Study of Dacarbazine With or Without Genasense in Chemotherapy-naive Subjects With Advanced Melanoma and Low LDH (The AGENDA Trial) [NCT00518895]	Phase 3	300 participants (Anticipated)	Interventional	2007-07-31	Completed
An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma [NCT02979522]	Phase 1/Phase 2	59 participants (Actual)	Interventional	2017-09-06	Completed
A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human α ν Integrins (CNTO 95), Alone and in Combination With Dacarbazine, in Subjects With Stage IV Melanoma [NCT00246012]	Phase 1/Phase 2	144 participants (Actual)	Interventional	2005-05-31	Completed
A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma [NCT01476410]	Phase 2	48 participants (Actual)	Interventional	2011-11-30	Active, not recruiting
Continuation Protocol For G3139 (Bcl-2 Antisense Oligonucleotide) And Dacarbazine In Patients With Malignant Melanoma Who Responded To This Combination In Protocol GM301 [NCT00070343]		0 participants	Interventional	2003-08-31	Active, not recruiting
Hodgkin's Disease Study [NCT00416377]		353 participants (Anticipated)	Interventional		Active, not recruiting
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma [NCT03430297]	Phase 3	256 participants (Actual)	Interventional	2018-02-02	Active, not recruiting
First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents [NCT00433459]	Phase 3	2,134 participants (Actual)	Interventional	2007-01-31	Completed
A Randomized, Controlled Phase II Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor [NCT03279601]	Phase 2	148 participants (Anticipated)	Interventional	2017-09-01	Recruiting
A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma [NCT00354523]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2004-12-31	Terminated(stopped due to Study closed following Phase I portion, insufficient activity to continue to Phase II.)
Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons [NCT00498979]	Phase 1	22 participants (Actual)	Interventional	2007-05-31	Completed
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors [NCT00600496]	Phase 1	140 participants (Actual)	Interventional	2007-12-14	Active, not recruiting
A Phase II Study of Rituximab + ABVD for Patients With Hodgkin's Disease [NCT00504504]	Phase 2	85 participants (Actual)	Interventional	2001-03-31	Completed
A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin Lymphoma [NCT00678327]	Phase 3	1,202 participants (Actual)	Interventional	2008-08-29	Active, not recruiting
A Phase II Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) for Patients With Hodgkin's Disease [NCT01404936]	Phase 2	35 participants (Actual)	Interventional	1996-07-31	Completed
Trial Protocol for the Treatment of Children With High Risk Neuroblastoma (NB2004-HR) [NCT00526318]		360 participants (Anticipated)	Interventional	2007-01-31	Recruiting
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study [NCT01359956]	Phase 3	269 participants (Actual)	Interventional	2002-04-30	Completed
Adjuvant Interleukin2 (Proleukin)and 5-(3,3 Dimethyl-1-Triazeno) Imidazole-4-Carboxamide (DTIC) in Resected High-Risk Primary and Regionally Metastatic Melanoma [NCT00553618]	Phase 2	160 participants (Anticipated)	Interventional	2007-08-31	Active, not recruiting
HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD [NCT02661503]	Phase 3	1,500 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma [NCT00226473]	Phase 4	200 participants	Interventional	2001-09-30	Recruiting
A Phase I/II Study of Sunitinib and Dacarbazine in Patients With Metastatic Melanoma [NCT00496223]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to toxicities required dose reduction compromising effectiveness and PI left Moffitt)
Phase II Trial of Sequenced Chemotherapy With Dacarbazine and Carmustine With Neulasta® Support in Previously Treated Metastatic Melanoma [NCT01692691]	Phase 2	1 participants (Actual)	Interventional	2012-08-31	Terminated(stopped due to PI decision)
A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma [NCT01551459]	Phase 2	124 participants (Anticipated)	Interventional	2010-10-31	Completed
Phase II Open-Label Study of Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemo [NCT00099970]	Phase 2	40 participants	Interventional	2004-12-31	Completed
Randomized Study Of Dacarbazine Versus Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) In Patients With Advanced Malignant Melanoma [NCT00016263]	Phase 3	0 participants	Interventional	2000-07-31	Completed
A Phase II, Randomized, Open-Label Study Evaluating The Antitumor Activity Of MEDI-522, A Humanized Monoclonal Antibody Directed Against The Human Alpha V Beta 3 Integrin, ± Dacarbazine In Patients With Metastatic Melanoma [NCT00066196]	Phase 2	110 participants	Interventional	2003-08-31	Completed
ProMune™ (CPG 7909 Injection) With or Without Chemotherapy for the Treatment of Stage III b/c or IV Melanoma: A Randomized, Multi-Center, Open Label, Parallel Group, Active-Controlled, Phase II/III Study [NCT00070642]	Phase 2	184 participants (Actual)	Interventional	2003-12-31	Completed
A Prospective Random Assignment Trial Comparing Complete Metastasectomy to Chemotherapy for Selected Patients With Stage IV Melanoma [NCT00072124]	Phase 3	0 participants	Interventional	2003-09-30	Completed
Neuroblastoma Study Phase II Study of Various Therapies in Patients With Neuroblastoma [NCT00017225]	Phase 2	0 participants	Interventional	1997-05-31	Completed
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment With 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects With Recurrent Metastatic Melanoma [NCT00395070]	Phase 3	390 participants (Actual)	Interventional	2006-10-31	Completed
A Phase I/II Study Of Neoadjuvant Chemotherapy, Angiogenesis Inhibitor SU5416 (NSC # 696819; A TK Inhibitor Anti-Angionesises Compound), And Radiation Therapy In The Management Of High Risk, High-Grade, Soft Tissue Sarcomas Of The Extremities And Body Wal [NCT00023738]	Phase 1/Phase 2	0 participants	Interventional	2001-08-31	Completed
Protocol For The Treatment Of Children And Adolescents With Hodgkin's Disease [NCT00025064]	Phase 2	260 participants (Anticipated)	Interventional	2000-01-31	Active, not recruiting
Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy [NCT00038558]	Phase 3	25 participants (Actual)	Interventional	2001-11-30	Completed
Protocol for a Randomized Phase III Study of the Stanford V Regimen, Compared With ABVD for the Treatment of Advanced Hodgkin's Disease [NCT00041210]	Phase 3	850 participants (Anticipated)	Interventional	2001-10-31	Active, not recruiting
Optimising Therapy for Boys With Hodgkin's Lymphoma and Quality Assurance of Therapy for Girls With Hodgkin's Lymphoma Until Start of a New Prospective Trial for Hodgkin's Lymphoma in Childhood and Adolescence [NCT00416832]	Phase 2	648 participants (Anticipated)	Interventional	2002-11-30	Completed
Bevacizumab, Dacarbazine and Interferon Alfa-2a Combination as a First-Line Therapy in Patients With Locally Advancing or Metastatic Melanoma [NCT00308607]	Phase 2	27 participants (Actual)	Interventional	2005-08-31	Completed
A Phase 2, Single Arm Study on Dacarbazine (DTIC) Followed by Immunotherapy Re-challenge in Unresectable or Metastatic Melanoma With Primary Resistance to PD-1/PD-L1 or PD-1 + CTLA-4 Blockade [NCT04225390]	Phase 2	38 participants (Anticipated)	Interventional	2020-01-13	Recruiting
A Phase II Multi-Center Open-Label Trial of Six Doses of Pembrolizumab Monotherapy Prior to Limited Chemotherapy as Front-Line Therapy for Patients With Classical Hodgkin Lymphoma, Including Elderly Patients. [NCT06164275]	Phase 2	30 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma [NCT01692678]	Phase 3	16 participants (Actual)	Interventional	2012-08-07	Completed
Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma [NCT00802880]	Phase 2	80 participants (Actual)	Interventional	2009-03-31	Completed
A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension. [NCT01705392]	Phase 2	2 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to Lack of financing of the study drug. Not sufficient financial support.)
Temozolomide or Dacarbazine-based Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor [NCT01845675]	Phase 2	14 participants (Actual)	Interventional	2013-04-30	Completed
A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma [NCT01721772]	Phase 3	418 participants (Actual)	Interventional	2013-01-18	Completed
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma [NCT01693068]	Phase 2	194 participants (Actual)	Interventional	2012-12-05	Completed
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Previously Untreated Unresectable or Metastatic Melanoma [NCT01681212]	Phase 2	21 participants (Actual)	Interventional	2012-10-31	Completed
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previ [NCT03233347]	Phase 2	82 participants (Anticipated)	Interventional	2017-10-13	Active, not recruiting
A Prospective Multicenter Study on HIV-associated Hodgkin Lymphoma [NCT01468740]	Phase 2	130 participants (Anticipated)	Interventional	2004-03-31	Recruiting
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study [NCT02292979]	Phase 2	170 participants (Actual)	Interventional	2015-03-31	Completed
Metronomic Therapy in Patients With Metastatic Melanoma: A Phase II Study of Low Dose Vinblastine, Cyclophosphamide, and Dacarbazine [NCT01542255]	Phase 2	7 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Low accrual not allowing to support statistical endpoints)
Randomized, Phase II Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Patients With Advanced Melanoma (KEYNOTE 002) [NCT01704287]	Phase 2	540 participants (Actual)	Interventional	2012-11-20	Completed
A Randomized, Open-Label, Two-arm, Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine [NCT02545075]	Phase 3	182 participants (Actual)	Interventional	2015-10-31	Completed
A Prospective Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial of Temsirolimus in Combination With Pioglitazone, Etoricoxib and Metronomic Low-dose Trofosfamide Versus Dacarbazine (DTIC) in Patients With Advanced Melanoma [NCT01614301]	Phase 1/Phase 2	136 participants (Anticipated)	Interventional	2012-05-31	Recruiting
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease [NCT00000626]	Phase 2	27 participants	Interventional		Completed
Phase III Trial Investigating the Potential Benefit of Intensified Peri-operative Chemotherapy With in High-risk CINSARC Patients With Resectable Soft-tissue SARComas [NCT03805022]	Phase 3	351 participants (Anticipated)	Interventional	2019-02-14	Recruiting
Adjuvant Therapy for Melanoma Patients With Regional Lymph Node Metastases With Interferon Alfa-2B vs. Biochemotherapy Using Cisplatin + Vinblastine + DTIC + Interferon Plus IL-2 [NCT00002882]	Phase 3	140 participants (Actual)	Interventional	1995-11-30	Completed
Pilot Study for the Treatment of Children With Newly Diagnosed Advanced Stage Hodgkin's Disease: Upfront Dose Intensive Chemotherapy [NCT00004010]	Phase 2	99 participants (Actual)	Interventional	1999-10-31	Completed
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY AND RADIATION THERAPY IN THE MANAGEMENT OF HIGH-RISK, HIGH-GRADE, SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND BODY WALL [NCT00002791]	Phase 2	0 participants	Interventional	1997-02-28	Completed
A Randomized Phase III Trial Comparing Early High Dose Chemotherapy and an Autologous Stem Cell Transplant to Conventional Dose ABVD Chemotherapy for Patients With Advanced Stage Poor Prognosis Hodgkin's Disease as Defined by the International Prognostic [NCT00005090]	Phase 3	11 participants (Actual)	Interventional	2000-04-30	Terminated(stopped due to poor accrual)
A UKLG Randomised Trial of Initial Chemotherapy for Advanced Stage Hodgkins Disease [NCT00003421]	Phase 3	800 participants (Anticipated)	Interventional	1998-06-30	Completed
Phase II Study of Outpatient CDDP and DTIC Followed by GM-CSF, IFN-a2b, and IL-2 in Patients With Advanced Melanoma [NCT00004141]	Phase 2	46 participants (Actual)	Interventional	1998-08-31	Completed
A Phase III Study of Radiotherapy or ABVD Plus Radiotherapy Versus ABVD Alone in the Treatment of Early Stage Hodgkin's Disease [NCT00002561]	Phase 3	405 participants (Actual)	Interventional	1994-01-25	Completed
TREATMENT OF METASTATIC MELANOMA WITH DTIC, CDDP AND IFN ALPHA WITH OR WITHOUT IL-2: A RANDOMIZED PHASE III TRIAL [NCT00002669]	Phase 2	90 participants (Anticipated)	Interventional	1995-06-30	Completed
The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma [NCT01763164]	Phase 3	402 participants (Actual)	Interventional	2013-07-12	Completed
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma [NCT02505269]	Phase 2	34 participants (Actual)	Interventional	2015-08-07	Completed
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) [NCT03712202]	Phase 2	155 participants (Actual)	Interventional	2018-11-28	Active, not recruiting
Phase 2 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Gemcitabine Followed by Systemic Adjuvant Chemotherapy With Dacarbazine for Locally Recurrent Uterine Leiomyosarcoma (LMS) [NCT04727242]	Phase 2	25 participants (Anticipated)	Interventional	2021-01-28	Recruiting
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL) [NCT01390584]	Phase 2	6 participants (Actual)	Interventional	2013-05-24	Terminated(stopped due to slow accrual)
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease [NCT00003389]	Phase 3	854 participants (Actual)	Interventional	1999-06-17	Completed
Effect of Refnot on Immunity in Cancer Patients [NCT05898451]	Phase 2	55 participants (Actual)	Interventional	2009-06-04	Completed
A Randomized Phase III Trial of Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, IL-2 and Interferon A-2B Versus Cisplatin, Vinblastine, Dacarbazine Alone in Patients With Metastatic Malignant Melanoma [NCT00003027]	Phase 3	482 participants (Anticipated)	Interventional	1997-11-13	Completed
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 [NCT03755804]	Phase 2	250 participants (Anticipated)	Interventional	2018-12-12	Recruiting
TAGGED: A Phase 2 Study Using Low Dose/Metronomic Trabectedin, Gemcitabine, and Dacarbazine as 2nd/3rd/4th Line Therapy for Advanced Leiomyosarcoma [NCT04535271]	Phase 2	80 participants (Anticipated)	Interventional	2021-09-09	Recruiting
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study [NCT03517137]	Phase 2	150 participants (Actual)	Interventional	2019-08-01	Active, not recruiting
BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma [NCT00049595]	Phase 3	552 participants (Actual)	Interventional	2002-08-31	Completed
A Pilot Phase II Study of Pre-Operative Radiation Therapy and Thalidomide (IND 48832; NSC 66847) for Low Grade Primary Soft Tissue Sarcoma or Pre-Operative MAID/Thalidomide/Radiation Therapy for High/Intermediate Grade Primary Soft Tissue Sarcoma of the E [NCT00089544]	Phase 2	23 participants (Actual)	Interventional	2004-06-17	Terminated
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667) [NCT03407144]	Phase 2	340 participants (Anticipated)	Interventional	2018-04-09	Active, not recruiting
Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma [NCT00003647]	Phase 3	0 participants	Interventional	1998-07-31	Completed
A Phase I/II Study of Dasatinib and Dacarbazine in Patients With Metastatic Melanoma [NCT00597038]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2007-11-30	Completed
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal M [NCT01974752]	Phase 3	152 participants (Actual)	Interventional	2014-04-30	Completed
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) [NCT04221035]	Phase 3	800 participants (Anticipated)	Interventional	2019-11-05	Recruiting
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma [NCT01327885]	Phase 3	452 participants (Actual)	Interventional	2011-03-10	Completed
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above (cHL 001) [NCT05404945]	Phase 2	44 participants (Anticipated)	Interventional	2022-07-26	Recruiting
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma [NCT01835145]	Phase 2	47 participants (Actual)	Interventional	2013-07-31	Completed
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma [NCT03226249]	Phase 2	30 participants (Actual)	Interventional	2017-11-09	Active, not recruiting
Phase I/II of Nivolumab and A(B)VD in the Front-line Setting for High Risk Hodgkin Lymphoma [NCT03033914]	Phase 1/Phase 2	81 participants (Anticipated)	Interventional	2017-01-25	Recruiting
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy [NCT01721746]	Phase 3	405 participants (Actual)	Interventional	2012-12-21	Completed
Brentuximab Vedotin Plus AVD in Non-bulky Limited Stage Hodgkin Lymphoma [NCT01534078]	Phase 2	34 participants (Actual)	Interventional	2012-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00003389 (3) [back to overview]	Failure-free Survival at 5 Years
NCT00003389 (3) [back to overview]	5-year Overall Survival
NCT00003389 (3) [back to overview]	Incidence of Second Cancers
NCT00006237 (3) [back to overview]	5-year Overall Survival
NCT00006237 (3) [back to overview]	5-year Relapse-Free Survival
NCT00006237 (3) [back to overview]	Toxicity
NCT00089544 (1) [back to overview]	Treatment Delivery With Compliance Defined as Receiving at Least 95% of the Pre-operative Protocol Dose of RT, All 3 Cycles of MAID (if Applicable), and Receive Thalidomide on 75% of the Days During Radiation
NCT00091572 (4) [back to overview]	Duration of Objective Response
NCT00091572 (4) [back to overview]	Objective Response Rate in Subjects With Measurable Lesions
NCT00091572 (4) [back to overview]	Overall Survival
NCT00091572 (4) [back to overview]	Progression Free Survival
NCT00110994 (10) [back to overview]	Number of Participants in Tumor Response Categories
NCT00110994 (10) [back to overview]	Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to the Visit When the Best Tumor Response Was Noted
NCT00110994 (10) [back to overview]	Time to Progression (TTP)
NCT00110994 (10) [back to overview]	Progression Free Survival (PFS)
NCT00110994 (10) [back to overview]	Overall Survival (OS)
NCT00110994 (10) [back to overview]	Duration of Response (DOR)
NCT00110994 (10) [back to overview]	Change of European Quality of Life Visual Analogue Scale (EQ-VAS) Score From Baseline to the Visit at Which Best Response Was First Noted
NCT00110994 (10) [back to overview]	Change of European Quality of Life Visual Analogue Scale (EQ-VAS) Score From Baseline to the End of Treatment
NCT00110994 (10) [back to overview]	Change of European Quality of Life 5-dimensional (EQ-5D) Questionnaire Index Score From Baseline to the End of Treatment
NCT00110994 (10) [back to overview]	Change of European Quality of Life 5-dimensional (EQ-5D) Questionnaire Index Score From Baseline to the Visit at Which Best Response Was First Noted
NCT00130442 (4) [back to overview]	Duration of Response
NCT00130442 (4) [back to overview]	Non-progression Rate
NCT00130442 (4) [back to overview]	Time to Progression
NCT00130442 (4) [back to overview]	Survival
NCT00246012 (22) [back to overview]	Total Clearance (CL) of Intetumumab After Intravenous Administration - Phase 1 (Part 1)
NCT00246012 (22) [back to overview]	Time to Worsening in Eastern Cooperative Oncology Group (ECOG) Performance Status - Phase 2
NCT00246012 (22) [back to overview]	Progression-Free Survival (PFS) - Phase 2
NCT00246012 (22) [back to overview]	Percentage of Participants Who Achieved Stable Disease (SD) - Phase 2
NCT00246012 (22) [back to overview]	Percentage of Participants Who Achieved CR - Phase 2
NCT00246012 (22) [back to overview]	Percentage of Participants Who Achieved a Best Overall Tumor Response as Complete Response (CR) or Partial Response (PR) - Phase 2
NCT00246012 (22) [back to overview]	Percentage of Participants Who Achieved a Best Overall Response as CR, PR, or SD - Phase 2
NCT00246012 (22) [back to overview]	Overall Survival (OS) - Phase 2
NCT00246012 (22) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLTs) - Phase 1
NCT00246012 (22) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Intetumumab - Phase 2
NCT00246012 (22) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Intetumumab - Phase 1 (Part 2)
NCT00246012 (22) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Intetumumab - Phase 1 (Part 1)
NCT00246012 (22) [back to overview]	Half-life of Intetumumab - Phase 1 (Part 2)
NCT00246012 (22) [back to overview]	Half-life of Intetumumab - Phase 1 (Part 1)
NCT00246012 (22) [back to overview]	Area Under the Serum Concentration Versus Time Curve (AUC) of Intetumumab - Phase 1 (Part 2)
NCT00246012 (22) [back to overview]	Area Under the Serum Concentration Versus Time Curve (AUC) of Intetumumab - Phase 1 (Part 1)
NCT00246012 (22) [back to overview]	Area Under the Concentration Versus Time Curve Between Zero to Infinite Time (AUCinf) of Intetumumab - Phase 1 (Part 1)
NCT00246012 (22) [back to overview]	Change From Baseline in Functional Assessment of Cancer Therapy-Melanoma Subscale (FACT-MS) Score - Phase 2
NCT00246012 (22) [back to overview]	Volume of Distribution (Vz) of Intetumumab - Phase 1 (Part 1)
NCT00246012 (22) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) Score - Phase 2
NCT00246012 (22) [back to overview]	Volume of Distribution (Vz) of Intetumumab - Phase 1 (Part 2)
NCT00246012 (22) [back to overview]	Total Clearance (CL) of Intetumumab After Intravenous Administration - Phase 1 (Part 2)
NCT00324155 (13) [back to overview]	Number of Participants With Grade 2-3 and Grade 3-4 Immune-related Adverse Events (irAEs) With Resolution Resolved
NCT00324155 (13) [back to overview]	Time to Resolution of Grade 2-3, Grade 3-4 Immune-related Adverse Events (irAEs)
NCT00324155 (13) [back to overview]	Survival Rate at 1 Year, 18 Months, 2 Years, and 3 Years
NCT00324155 (13) [back to overview]	Progression-free Survival (PFS) Rate Truncated at Week 12
NCT00324155 (13) [back to overview]	Number of Participants With Adverse Events (AEs), Drug-related AEs, AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Hypersensitivity, Immune-related AEs/SAEs, and Inflammatory AEs/SAEs
NCT00324155 (13) [back to overview]	Median Number of Months of Progression-free Survival (PFS)
NCT00324155 (13) [back to overview]	Duration of Stable Disease (SD): Randomized Participants With Stable Disease
NCT00324155 (13) [back to overview]	Duration of Response (DOR): Randomized Participants With Response of Complete Response (CR) or Partial Response (PR)
NCT00324155 (13) [back to overview]	Best Overall Response Rate (BORR)
NCT00324155 (13) [back to overview]	Time to Response: All Randomized Participants With Response to Treatment
NCT00324155 (13) [back to overview]	Percentage of Participants With Brain Metastasis-Free Survival at Time of Data Cutoff
NCT00324155 (13) [back to overview]	Overall Survival (OS)
NCT00324155 (13) [back to overview]	Disease Control Rate (DCR)
NCT00369681 (3) [back to overview]	Effect of Rituximab on EBV(+) Tumors
NCT00369681 (3) [back to overview]	Relationship Between Marker Detection and Clinical Outcome
NCT00369681 (3) [back to overview]	Event-free Survival
NCT00492297 (11) [back to overview]	Percentage of Subjects With Progression-free Survival at Specific Time-points
NCT00492297 (11) [back to overview]	Overall Best Response
NCT00492297 (11) [back to overview]	Disease Control (DC)
NCT00492297 (11) [back to overview]	Time to Response
NCT00492297 (11) [back to overview]	Time to Progression
NCT00492297 (11) [back to overview]	Progression-free Survival
NCT00492297 (11) [back to overview]	Duration of Complete Response
NCT00492297 (11) [back to overview]	Duration of Stable Disease
NCT00492297 (11) [back to overview]	Duration of Response
NCT00492297 (11) [back to overview]	Duration of Partial Response
NCT00492297 (11) [back to overview]	Overall Survival
NCT00504504 (1) [back to overview]	5-year Failure-free Survival Rate for Participants With Hodgkin's Disease Given Rituximab With ABVD
NCT00533702 (7) [back to overview]	Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 12 Weeks
NCT00533702 (7) [back to overview]	Duration of Response
NCT00533702 (7) [back to overview]	Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate) at 12 Weeks
NCT00533702 (7) [back to overview]	Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
NCT00533702 (7) [back to overview]	Percentage of Participants With Stable Disease (SD) or Better (Disease Control Rate) at 6 Weeks
NCT00533702 (7) [back to overview]	Progression Free Survival (PFS)
NCT00533702 (7) [back to overview]	Number of Participants With Adverse Events (AE)
NCT00597038 (4) [back to overview]	Phase II - Number of Participants With Overall Response (OR)
NCT00597038 (4) [back to overview]	Number of Participants With Progression Free Survival (PFS) at 6 Months
NCT00597038 (4) [back to overview]	Number of Participants With 12 Month Overall Survival (OS)
NCT00597038 (4) [back to overview]	Recommended Phase II Dose
NCT00654732 (1) [back to overview]	Event-free Survival (EFS) Rate
NCT00796991 (31) [back to overview]	Pharmacokinetic Parameter of Clearance (CLT) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
NCT00796991 (31) [back to overview]	Pharmacokinetic Parameter Maximum Observed Serum Concentration (Cmax) for Ipilimumab, Paclitaxel, Dacarbazine and the Active Metabolite for Dacarbazine, 5-aminoimidazole-4carboxamide (AIC)- Pharmacokinetic Analysis Population
NCT00796991 (31) [back to overview]	Number of Participants With Objective Response to Treatment and Disease Control Using mWHO Criteria - All Randomized Participants
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils Plus Bands - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Leukocytes - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Hemoglobin - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants in Best Overall Response Categories Based on Modified World Health Organization (mWHO) Criteria - All Treated Participants
NCT00796991 (31) [back to overview]	Number of Participants in Best Overall Response Categories Based on Immune Related (ir) Response Criteria (RC) - All Treated Participants
NCT00796991 (31) [back to overview]	Mean Change From Baseline in Respiration Rate at Weeks 16 and 48 - All Treated Population
NCT00796991 (31) [back to overview]	Mean Change From Baseline in Pulse Rate at Weeks 16 and 48 - All Treated Population
NCT00796991 (31) [back to overview]	Mean Change From Baseline at Weeks 16 and 48 in Diastolic and Systolic Blood Pressure - All Treated Population
NCT00796991 (31) [back to overview]	Mean Baseline Change in Body Temperature at Weeks 16 and 48 - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events, Deaths, and Discontinuation Due to Adverse Events From Day 1 to Week 48 - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Uric Acid - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Lipase - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Aspartate Aminotransferase (AST) - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Calcium (High) - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Bilirubin - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Amylase - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Serum Potassium (High) - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alkaline Phosphatase - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Albumin - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alanine Aminotransferase (ALT) - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Lymphocytes - All Treated Population
NCT00796991 (31) [back to overview]	Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Platelet Count - All Treated Population
NCT00796991 (31) [back to overview]	Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
NCT00796991 (31) [back to overview]	Pharmacokinetic Parameter of Time of Maximum Observed Concentration (Tmax) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
NCT00796991 (31) [back to overview]	Pharmacokinetic Parameter of Terminal Elimination Half Life (T-HALF) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
NCT00796991 (31) [back to overview]	Mean Absolute Lymphocyte Count (ALC) at Each Nominal Ipilimumab Induction Dose and at End of the Induction Period - Pharmacodynamic Population
NCT00796991 (31) [back to overview]	Area Under the Concentration Time Curve (AUC) From Time Zero to 21 Days [AUC(0-21d)] for Ipilimumab and AUC Time Zero Extrapolated to Infinity [AUC(INF)] for Paclitaxel, Dacarbazine and the Active Metabolite AIC - Pharmacokinetic Analysis Population
NCT00802880 (13) [back to overview]	Overall Tumor Metabolic Response
NCT00802880 (13) [back to overview]	Time to Progression (TTP)
NCT00802880 (13) [back to overview]	Overall Survival
NCT00802880 (13) [back to overview]	Rate of Nausea/Emesis (Any Grade)
NCT00802880 (13) [back to overview]	Rate of Neutropenia (Grade 3/4)
NCT00802880 (13) [back to overview]	Overall Disease Control Rate
NCT00802880 (13) [back to overview]	Correlate Time to Progression With Best Metabolic Response
NCT00802880 (13) [back to overview]	Correlate the Tumor Metabolic Response Rate With the Tumor Anatomic Response Rate
NCT00802880 (13) [back to overview]	Correlate the Time to Progression With Best Anatomic Response
NCT00802880 (13) [back to overview]	Correlate Overall Survival With Best Metabolic Response
NCT00802880 (13) [back to overview]	Correlate Overall Survival With Best Anatomic Response
NCT00802880 (13) [back to overview]	Comparison of the SUV at up to 3 Tumor Sites
NCT00802880 (13) [back to overview]	Best Anatomical Tumor Response
NCT00822120 (8) [back to overview]	Percentage of HIV-negative Patients Who Are PET-positive After 2 Cycles of ABVD With 2-year PFS
NCT00822120 (8) [back to overview]	Percentage of HIV-negative Patients With 2-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging
NCT00822120 (8) [back to overview]	Percentage of HIV-negative Patients With 2-year Progression-free Survival (PFS) Treated With 2 Initial Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging.
NCT00822120 (8) [back to overview]	Percentage of HIV-positive Patients With 2-year Progression-free Survival (PFS) Treated With Initial 2 Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging.
NCT00822120 (8) [back to overview]	Percentage of HIV-positive Patients With 5-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging.
NCT00822120 (8) [back to overview]	Number of HIV-negative Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00822120 (8) [back to overview]	Number of HIV-positive Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00822120 (8) [back to overview]	Complete and Partial Response Rates for HIV-negative Patients Treated With Response- Adapted Therapy Based on FDG-PET Imaging After 2 Cycles of ABVD
NCT00837148 (1) [back to overview]	Overall Objective Response
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Hypercalcemia (HCA) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Concentrations of Antibodies Against Protein D (Anti-PD)
NCT00849875 (37) [back to overview]	Anti-MAGE-A3 Antibody Concentrations
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Lymphopenia (LYM) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Bilirubine (BIL) Values by Maximum Grade.
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Creatinine (CREA) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Gamma-glutamyl Transpeptidase (GGT) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Hemoglobin (HGB) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Aspartate Aminotransferase (AST) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Hyperkalemia (HKA) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Hypernatremia (HNA) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Hypoalbuminemia(hAL) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Hypocalcemia(hCA) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Hypokalemia (hKA) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Hyponatremia (hNA) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Leukocytes (LEU) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Neutrophils (NEU) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Partial Thromboplastin Time (PTT) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Platelets(PLT) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Any Adverse Events (AEs) and With AEs by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Any Serious Adverse Events (SAEs) and With AEs by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Mixed Response (MxR) to MAGE-A3 ASCI Study Treatment
NCT00849875 (37) [back to overview]	Number of Patients With Objective Tumor Response (OR) to MAGE-A3 ASCI Study Treatment
NCT00849875 (37) [back to overview]	Number of Patients With Stable Disease (SD) Response to MAGE-A3 ASCI Study Treatment
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Alkaline Phosphatase (ALK) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients With Abnormal Alanine Aminotransferase (ALT) Values by Maximum Grade
NCT00849875 (37) [back to overview]	Number of Patients Reported With Unsolicited Adverse Events (AEs) That Were Causally Related to Treatment Administration by Maximum Grade.
NCT00849875 (37) [back to overview]	Time to Treatment Failure (TTF), by Gene Signature
NCT00849875 (37) [back to overview]	Progression-free Survival (PFS) for the Overall Population
NCT00849875 (37) [back to overview]	Progression-free Survival (PFS) by Gene Signature
NCT00849875 (37) [back to overview]	Progression-free Survival (PFS) After Slow Progressive Disease (SPD) by Gene Signature
NCT00849875 (37) [back to overview]	Overall Survival (OS) by Gene Signature
NCT00849875 (37) [back to overview]	Number of Seroconverted Patients for Melanoma Antigen (Anti-MAGE-A3)
NCT00849875 (37) [back to overview]	Number of Patients With Treatment Response for Anti-PD
NCT00849875 (37) [back to overview]	Number of Patients With Treatment Response for Anti-MAGE-A3 Antibodies
NCT00849875 (37) [back to overview]	Number of Patients Reported With Serious Adverse Events (SAEs)
NCT00849875 (37) [back to overview]	Duration of Stable Disease (SD) Response to MAGE-A3 ASCI Study Treatment
NCT00864253 (12) [back to overview]	Nadir for the Absolute Neutrophil Count (ANC) Measurements
NCT00864253 (12) [back to overview]	Nadir for the Hemoglobin Count Measurements
NCT00864253 (12) [back to overview]	Nadir for White Blood Cells (WBCs) Measurements
NCT00864253 (12) [back to overview]	Participant Survival
NCT00864253 (12) [back to overview]	Nadir for Platelet Count Measurements.
NCT00864253 (12) [back to overview]	Duration of Response (DOR) in Responding Participants
NCT00864253 (12) [back to overview]	Summary of Treatment-emergent Adverse Events (AEs)
NCT00864253 (12) [back to overview]	Percent of Participants Who Achieve an Objective Confirmed Complete or Partial Response Based on Blinded Radiology Assessment of Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0
NCT00864253 (12) [back to overview]	Number of Participants Experiencing Dose Reductions, or Dose Interruptions, or Dose Delays of Study Drug
NCT00864253 (12) [back to overview]	Progression-free Survival (PFS) Based on Investigator Assessment Using RECIST Response Guidelines
NCT00864253 (12) [back to overview]	Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines
NCT00864253 (12) [back to overview]	Percent of Participants With Stable Disease (SD) for ≥ 16 Weeks, or Confirmed Complete or Partial Response (i.e., Disease Control) Based on a Blinded Radiology Assessment of Response
NCT00911443 (3) [back to overview]	Overall Survival
NCT00911443 (3) [back to overview]	Progression Free Survival
NCT00911443 (3) [back to overview]	Overall Tumor Response
NCT00936221 (4) [back to overview]	Change in Target Lesion Tumour Size at Week 12
NCT00936221 (4) [back to overview]	Overall Survival
NCT00936221 (4) [back to overview]	Progression Free Survival
NCT00936221 (4) [back to overview]	Objective Response Rate
NCT01006980 (7) [back to overview]	Progression-free Survival
NCT01006980 (7) [back to overview]	Duration of Response
NCT01006980 (7) [back to overview]	Time to Confirmed Response
NCT01006980 (7) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01006980 (7) [back to overview]	Overall Survival
NCT01006980 (7) [back to overview]	Participants With a Best Overall Response (BOR) of Complete Response or Partial Response
NCT01006980 (7) [back to overview]	Pre and Post-dose Plasma Vemurafenib Concentration by Study Day
NCT01028222 (8) [back to overview]	PFS Rate
NCT01028222 (8) [back to overview]	Progression Free Survival (PFS)
NCT01028222 (8) [back to overview]	Time to Objective Response (TOR)
NCT01028222 (8) [back to overview]	Disease Control Rate (DCR)
NCT01028222 (8) [back to overview]	Durable Overall Response Rate (DORR)
NCT01028222 (8) [back to overview]	OS Rate
NCT01028222 (8) [back to overview]	Overall Response Rate (ORR)
NCT01028222 (8) [back to overview]	Overall Survival (OS)
NCT01100528 (2) [back to overview]	Number of Participants With Toxicity or Grade 4 Adverse Events Via CTCAE Version 3.0
NCT01100528 (2) [back to overview]	Number of Patients With Disease-free Survival (DFS)
NCT01132807 (3) [back to overview]	36 Month Progression Free Survival Rate of Patients Receiving 4 Cycles of ABVD Versus Patients Receiving 2 Cycles of ABVD and 2 Cycles of BEACOPP and Radiation.
NCT01132807 (3) [back to overview]	Progression-Free Survival (PFS) at 36-Months for Patients Who Received 4 Cycles of ABVD
NCT01132807 (3) [back to overview]	Complete Response Rate
NCT01133977 (3) [back to overview]	Progression Free Survival (PFS) (for Phase 2)
NCT01133977 (3) [back to overview]	Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b)
NCT01133977 (3) [back to overview]	Number of Participants With Adverse Events/Serious Adverse Events (AEs/SAEs)
NCT01143402 (2) [back to overview]	Median Overall Survival (Evaluable Randomized Patients)
NCT01143402 (2) [back to overview]	Progression-free Survival (PFS) (Evaluable Randomized Patients)
NCT01152788 (4) [back to overview]	Safety and Toxicity Profile (Participants With Grade 3 4 5 Adverse Event)
NCT01152788 (4) [back to overview]	Response Rate
NCT01152788 (4) [back to overview]	Progression Free Survival
NCT01152788 (4) [back to overview]	Overall Survival
NCT01164007 (11) [back to overview]	Overall Survival (OS)
NCT01164007 (11) [back to overview]	Duration of Response (DOR) With CR or PR According to RECIST
NCT01164007 (11) [back to overview]	DOR With CR, PR, or SD According to RECIST
NCT01164007 (11) [back to overview]	Percentage of Participants Who Discontinued Treatment
NCT01164007 (11) [back to overview]	Percentage of Participants With Death or Disease Progression Following a Previous Assessment of CR, PR, or Stable Disease (SD) According to RECIST
NCT01164007 (11) [back to overview]	Time to Treatment Failure (TTF)
NCT01164007 (11) [back to overview]	Time to Progression (TTP) According to RECIST
NCT01164007 (11) [back to overview]	Percentage of Participants With Death or Disease Progression Following a Previous Assessment of CR or PR According to RECIST
NCT01164007 (11) [back to overview]	Percentage of Participants With Death or Disease Progression According to RECIST
NCT01164007 (11) [back to overview]	Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST)
NCT01164007 (11) [back to overview]	Percentage of Participants Who Died
NCT01227889 (12) [back to overview]	Number of Participants With a Best Overall Response of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator: Randomized Phase
NCT01227889 (12) [back to overview]	Number of Participants With a Best Overall Response of Confirmed CR or PR as Assessed by an Independent Radiologist: Randomized Phase
NCT01227889 (12) [back to overview]	Number of Participants With Non-melanoma Skin Lesions: Randomized Phase
NCT01227889 (12) [back to overview]	Duration of Response as Assessed by an Independent Radiologist: Randomized Phase
NCT01227889 (12) [back to overview]	Duration of Response as Assessed by the Investigator: Crossover Phase
NCT01227889 (12) [back to overview]	Duration of Response as Assessed by the Investigator: Randomized Phase
NCT01227889 (12) [back to overview]	Overall Survival
NCT01227889 (12) [back to overview]	Progression-free Survival (PFS) as Assessed by an Independent Radiologist: Randomized Phase
NCT01227889 (12) [back to overview]	Progression-free Survival (PFS) as Assessed by the Investigator
NCT01227889 (12) [back to overview]	Progression-free Survival (PFS2) as Assessed by the Investigator: Crossover Phase
NCT01227889 (12) [back to overview]	Agreement Rate for V600E Mutation Validation of the BRAF Mutation Assay
NCT01227889 (12) [back to overview]	Number of Participants With a Best Overall Response of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator: Crossover Phase
NCT01327885 (4) [back to overview]	Progression-Free Survival (PFS)
NCT01327885 (4) [back to overview]	Progression-Free Rate at 12 Weeks (PFR12wks)
NCT01327885 (4) [back to overview]	Overall Survival (OS)
NCT01327885 (4) [back to overview]	Clinical Benefit Rate (CBR)
NCT01343277 (6) [back to overview]	Duration of Response
NCT01343277 (6) [back to overview]	Objective Response Rate
NCT01343277 (6) [back to overview]	Overall Survival (OS)
NCT01343277 (6) [back to overview]	Progression-Free Survival (PFS)
NCT01343277 (6) [back to overview]	Time to Progression
NCT01343277 (6) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01359956 (4) [back to overview]	Overall Survival (OS)
NCT01359956 (4) [back to overview]	Progression Free Survival (PFS)
NCT01359956 (4) [back to overview]	Treatment Related Toxicity
NCT01359956 (4) [back to overview]	Overall Response Rate (ORR)
NCT01390584 (5) [back to overview]	Progression-free Survival Rate
NCT01390584 (5) [back to overview]	Overall Survival
NCT01390584 (5) [back to overview]	Proportion of Patients Who Are PET Negative After Induction Treatment
NCT01390584 (5) [back to overview]	Complete Response (CR) Rate After Induction Treatment
NCT01390584 (5) [back to overview]	Progression-free Survival at 36 Months Among Patients Who Are PET Positive After Induction Treatment
NCT01404936 (1) [back to overview]	Participants' Response
NCT01534078 (4) [back to overview]	Overall Response Rate
NCT01534078 (4) [back to overview]	Complete Response Rate
NCT01534078 (4) [back to overview]	Overall Response Rate After One Cycle of Brentuximab
NCT01534078 (4) [back to overview]	Grade III or IV Adverse Events
NCT01542255 (1) [back to overview]	Progression Free Survival
NCT01681212 (3) [back to overview]	Percentage of Participants Surviving at 1 Year
NCT01681212 (3) [back to overview]	Number of Participants With Grade 3-4 Immune-related Adverse Events (irAEs)
NCT01681212 (3) [back to overview]	Number of Patients Who Died and Who Had Serious Adverse Events (SAEs), Treatment-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, Grade 3-4 AEs, and Related Grade 3-4 AEs
NCT01693068 (13) [back to overview]	Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)
NCT01693068 (13) [back to overview]	Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death
NCT01693068 (13) [back to overview]	Number of Subjects With Adverse Events (AEs) of Special Interest
NCT01693068 (13) [back to overview]	Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)
NCT01693068 (13) [back to overview]	Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)
NCT01693068 (13) [back to overview]	Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)
NCT01693068 (13) [back to overview]	Progression Free Survival (PFS)
NCT01693068 (13) [back to overview]	Percentage of Subjects With Progression-free Survival (PFS) at 6 Months
NCT01693068 (13) [back to overview]	Percentage of Subjects With Overall Survival (OS) at 12 Months
NCT01693068 (13) [back to overview]	Disease Control Rate (DCR)
NCT01693068 (13) [back to overview]	Overall Survival (OS)
NCT01693068 (13) [back to overview]	Objective Response Rate (ORR)
NCT01693068 (13) [back to overview]	Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings
NCT01704287 (10) [back to overview]	Final Overall Survival (OS) By Programmed Cell Death-Ligand 1 (PD-L1) Tumor Expression Status - Initial Treatment Period
NCT01704287 (10) [back to overview]	Final Overall Survival (OS) - Initial Treatment Period
NCT01704287 (10) [back to overview]	Duration of Response (DOR) - Initial Treatment Period
NCT01704287 (10) [back to overview]	Best Overall Response (BOR) - Switch-to-Pembrolizumab Treatment Period
NCT01704287 (10) [back to overview]	Progression-free Survival (PFS) - Initial Treatment Period
NCT01704287 (10) [back to overview]	Overall Response Rate (ORR) - Initial Treatment Period
NCT01704287 (10) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE) - Overall Study
NCT01704287 (10) [back to overview]	Number of Participants Who Discontinued Study Drug Due to an Adverse Event (AE) - Overall Study
NCT01704287 (10) [back to overview]	Best Overall Response (BOR) - Initial Treatment Period
NCT01704287 (10) [back to overview]	Interim Overall Survival (OS) - Initial Treatment Period
NCT01712490 (19) [back to overview]	Number of Participants With Abnormal Clinical Laboratory Values
NCT01712490 (19) [back to overview]	Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF)
NCT01712490 (19) [back to overview]	Event-free Survival (EFS) Per IRF
NCT01712490 (19) [back to overview]	Duration of Response (DOR) Per IRF
NCT01712490 (19) [back to overview]	Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
NCT01712490 (19) [back to overview]	Change From Baseline in Patient-Reported Outcome (PRO) Scores by mPFS Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30) at EOT
NCT01712490 (19) [back to overview]	Disease-free Survival (DFS) Per IRF
NCT01712490 (19) [back to overview]	Complete Remission (CR) Rate at the End of Randomized Regimen Per IRF
NCT01712490 (19) [back to overview]	Complete Remission (CR) Per IRF Rate at the End of Frontline Therapy
NCT01712490 (19) [back to overview]	A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin MMAE
NCT01712490 (19) [back to overview]	Positron Emission Tomography (PET) Negativity Rate Per IRF at Cycle 2
NCT01712490 (19) [back to overview]	Duration of Complete Remission (DOCR) Per IRF
NCT01712490 (19) [back to overview]	A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC and TAb
NCT01712490 (19) [back to overview]	A+AVD: Cmax: Maximum Observed Plasma Concentration for Brentuximab Vedotin Monomethyl Auristatin E (MMAE)
NCT01712490 (19) [back to overview]	A+AVD: Number of Participants With Antitherapeutic Antibody (ATA) and Neutralizing Antitherapeutic Antibody (nATA) Positive for Brentuximab Vedotin
NCT01712490 (19) [back to overview]	A+AVD: Cmax: Maximum Observed Serum Concentration for Brentuximab Vedotin Antibody-drug Conjugate (ADC) and Total Antibody (TAb)
NCT01712490 (19) [back to overview]	Overall Response Rate (ORR) Per IRF
NCT01712490 (19) [back to overview]	Overall Survival (OS)
NCT01712490 (19) [back to overview]	Percentage of Participants Not in CR Per IRF Who Received Subsequent Radiation After Completion of Frontline Therapy
NCT01721746 (7) [back to overview]	Overall Survival (OS) by PD-L1 Negative
NCT01721746 (7) [back to overview]	Overall Survival (OS) by PD-L1 Positive
NCT01721746 (7) [back to overview]	Progression Free Survival (PFS)
NCT01721746 (7) [back to overview]	Mean Change From Baseline in Health-related Quality of Life (HRQoL)
NCT01721746 (7) [back to overview]	Objective Response Rate (ORR) by Baseline PD-L1 Expression
NCT01721746 (7) [back to overview]	Overall Survival (OS)
NCT01721746 (7) [back to overview]	Objective Response Rate (ORR)
NCT01721772 (10) [back to overview]	Progression-free Survival (PFS) Rate
NCT01721772 (10) [back to overview]	Overall Survival (OS) Extended
NCT01721772 (10) [back to overview]	Overall Survival (OS)
NCT01721772 (10) [back to overview]	Objective Response Rate (ORR)
NCT01721772 (10) [back to overview]	Overall Survival by Programmed Cell Death Ligand 1 (PD-L1) Expression Level
NCT01721772 (10) [back to overview]	Overall Survival (OS) Rate Extended
NCT01721772 (10) [back to overview]	Overall Survival (OS) Rate
NCT01721772 (10) [back to overview]	Change From Baseline in Health-related Quality of Life (HRQoL) Scores
NCT01721772 (10) [back to overview]	Change From Baseline in Health-related Quality of Life (HRQoL) Scores
NCT01721772 (10) [back to overview]	Progression-free Survival (PFS)
NCT01763164 (23) [back to overview]	Change From Baseline in EuroQoL-5 Dimensions- 5 Levels (EQ-5D-5L) Index Score at Weeks 4, 7, 13, 19, 25, 34, 43, 52, 61, 70, End of Treatment, Safety Follow-up Visit, Post-treatment Follow-up Visit 1, 2, 3, 4, 5 and 6
NCT01763164 (23) [back to overview]	Time to Definitive 10% Deterioration in Global Health Status Score of European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)
NCT01763164 (23) [back to overview]	Time to Definitive 1 Point Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
NCT01763164 (23) [back to overview]	Time to Response (TTR)
NCT01763164 (23) [back to overview]	Change From Baseline in EuroQoL-5 Dimensions- 5 Levels (EQ-5D-5L) Index Score at Weeks 4, 7, 13, 19, 25, 34, 43, 52, 61, 70, End of Treatment, Safety Follow-up Visit, Post-treatment Follow-up Visit 1, 2, 3, 4, 5 and 6
NCT01763164 (23) [back to overview]	Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
NCT01763164 (23) [back to overview]	Change From Baseline in Global Health Status Score of EORTC QLQ-C30 at Weeks 4, 7, 13, 19, 25, 34, 43, 52, 61, 70, End of Treatment, Safety Follow-up Visit, Post-Treatment Follow-up Visit 1, 2, 3, 4, 5 and 6
NCT01763164 (23) [back to overview]	Change From Baseline in Global Health Status Score of EORTC QLQ-C30 at Weeks 4, 7, 13, 19, 25, 34, 43, 52, 61, 70, End of Treatment, Safety Follow-up Visit, Post-Treatment Follow-up Visit 1, 2, 3, 4, 5 and 6
NCT01763164 (23) [back to overview]	Disease Control Rate (DCR)
NCT01763164 (23) [back to overview]	Number of Participants With Clinically Notable Clinical Chemistry/Biochemistry Shifts Based on NCI-CTCAE Grade, Version 4.03
NCT01763164 (23) [back to overview]	Number of Participants With Clinically Notable Hematology Shifts Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Grade, Version 4.03
NCT01763164 (23) [back to overview]	Number of Participants With Clinically Notable Vital Signs
NCT01763164 (23) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01763164 (23) [back to overview]	Overall Response Rate (ORR)
NCT01763164 (23) [back to overview]	Plasma Concentration of Binimetinib
NCT01763164 (23) [back to overview]	Duration of Objective Response (DOR)
NCT01763164 (23) [back to overview]	Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
NCT01763164 (23) [back to overview]	Number of Participants With Neuroblastoma RAS Viral (V-ras) Oncogene Homolog (NRAS) Mutation Status at Baseline
NCT01763164 (23) [back to overview]	Number of Participants With Notable Electrocardiogram (ECG) Values
NCT01763164 (23) [back to overview]	Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
NCT01763164 (23) [back to overview]	Overall Survival (OS)
NCT01763164 (23) [back to overview]	Number of Participants With Adverse Events of Special Interest: Ocular Events
NCT01763164 (23) [back to overview]	Number of Participants With Adverse Events of Special Interest: Cardiac Events
NCT01771107 (12) [back to overview]	Partial Response Rate
NCT01771107 (12) [back to overview]	Maximal Tolerated Dose of Brentuximab Vedotin (Phase I)
NCT01771107 (12) [back to overview]	Incidence of Neurotoxicity
NCT01771107 (12) [back to overview]	Frequency of Adverse Events
NCT01771107 (12) [back to overview]	Event-free Survival
NCT01771107 (12) [back to overview]	Characterization of Histologic Subtypes in HIV-HL in the HAART Era
NCT01771107 (12) [back to overview]	CD8 Counts
NCT01771107 (12) [back to overview]	CD4 Counts
NCT01771107 (12) [back to overview]	Complete Response Rate
NCT01771107 (12) [back to overview]	Viral Load
NCT01771107 (12) [back to overview]	2-year Overall Survival
NCT01771107 (12) [back to overview]	2-year Progression-free Survival (PFS)
NCT01835145 (5) [back to overview]	Percentage of Patients Who Experienced Grade 3+ Adverse Events Regardless of Attribution
NCT01835145 (5) [back to overview]	Proportion of Patients Without a Progression Free Survival Event at 4 Months (PFS4)
NCT01835145 (5) [back to overview]	Confirmed Response Rate as Determined by the RECIST Criteria (Version 1.1)
NCT01835145 (5) [back to overview]	Overall Survival (OS)
NCT01835145 (5) [back to overview]	PFS
NCT01920932 (11) [back to overview]	Descriptive of Neuropathic Adverse Events
NCT01920932 (11) [back to overview]	To Assess the Patient Reported Symptoms and Health-related Quality of Life in Children With High Risk HL Compared to Those Treated on the Unfavorable HOD99 Treatment Arm (UR2) at Multiple Time Points. (PedsQL v.3.0)
NCT01920932 (11) [back to overview]	To Assess the Patient Reported Symptoms and Health-related Quality of Life in Children With High Risk HL Compared to Those Treated on the Unfavorable HOD99 Treatment Arm (UR2) at Multiple Time Points. (PedsQL v.3.0)
NCT01920932 (11) [back to overview]	To Assess the Patient Reported Symptoms and Health-related Quality of Life in Children With High Risk HL Compared to Those Treated on the Unfavorable HOD99 Treatment Arm (UR2) at Multiple Time Points. (PedsQL v.4.0)
NCT01920932 (11) [back to overview]	Percentage of Initially Enrolled Patients That Have a Complete Response at Early Response Assessment Compared to Historical Control
NCT01920932 (11) [back to overview]	Comparison of the Event-free (EFS) Survival in High Risk HL Patients Treated With AEPA/CAPDac to the Historical Control HOD99 Unfavorable Risk 2 Arm (UR2).
NCT01920932 (11) [back to overview]	Complete Response Rate Estimate for All Evaluable Participants
NCT01920932 (11) [back to overview]	Local Failure Rate in High Risk HL Patients Treated With AEPA/CAPDac.
NCT01920932 (11) [back to overview]	Percentage of Initially Enrolled Patients That Have a Complete Response at Early Response Assessment Compared to Historical Control
NCT01920932 (11) [back to overview]	Descriptive of Hematological Adverse Events
NCT01920932 (11) [back to overview]	Descriptive of Infectious Adverse Events
NCT01974752 (4) [back to overview]	Assessment of the Overall Survival (OS) in Patients Taking Selumetinib in Combination With Dacarbazine Compared With Those Taking Placebo in Combination With Dacarbazine
NCT01974752 (4) [back to overview]	Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine in Terms of Objective Response Rate (ORR) by BICR
NCT01974752 (4) [back to overview]	Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine Measured as Progression Free Survival (PFS) Using BICR According to RECIST 1.1.
NCT01974752 (4) [back to overview]	Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine in Terms of Change in Tumour Size at Week 6 by BICR
NCT02181738 (22) [back to overview]	Complete Remission (CR) Rate Based on IRRC Assessments in Cohorts A, B, and C
NCT02181738 (22) [back to overview]	Partial Remission (PR) Rate Based on IRRC Assessments in Cohorts A, B, and C
NCT02181738 (22) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) in Cohort D
NCT02181738 (22) [back to overview]	Number of Participants With Select AEs in Cohort D
NCT02181738 (22) [back to overview]	Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests in Cohort D Monotherapy Phase
NCT02181738 (22) [back to overview]	Number of Participants Laboratory Abnormalities in Specific Thyroid Tests in Cohort D Combination Therapy Phase
NCT02181738 (22) [back to overview]	Objective Response Rates (ORR) Based on Investigator Assessments for Cohorts A, B, and C
NCT02181738 (22) [back to overview]	Objective Response Rate (ORR) Based on IRRC Assessments in Cohorts A, B, and C Extended Collection
NCT02181738 (22) [back to overview]	Objective Response Rate (ORR) Based on IRRC Assessments in Cohorts A, B, and C
NCT02181738 (22) [back to overview]	Number of Participants With Laboratory Abnormalities in Specific Liver Tests in Cohort D Monotherapy Phase
NCT02181738 (22) [back to overview]	Duration of PR Based on IRRC Assessments in Cohorts A, B, and C
NCT02181738 (22) [back to overview]	Duration of Objective Response (DOR) Based on Investigator Assessments in Cohorts A, B, and C
NCT02181738 (22) [back to overview]	Treatment Discontinuation Rate in Cohort D
NCT02181738 (22) [back to overview]	Complete Response (CR) Rate at Planned End of Therapy Based on IRRC Assessments in Cohort D
NCT02181738 (22) [back to overview]	Duration of Complete Remission (CR) Based on IRRC Assessments for Cohorts A, B, and C
NCT02181738 (22) [back to overview]	Number of Participants With AEs Leading to Dose Delay in Cohort D
NCT02181738 (22) [back to overview]	Number of Participants With Laboratory Abnormalities in Specific Liver Tests in Cohort D Combination Therapy Phase
NCT02181738 (22) [back to overview]	Duration of Objective Response Based on IRRC Assessments in Cohorts A, B, and C
NCT02181738 (22) [back to overview]	Number of Participants With AEs Leading to Discontinuation in Cohort D
NCT02181738 (22) [back to overview]	Number of Participants With Adverse Events (AEs) in Cohort D
NCT02181738 (22) [back to overview]	Number of Participants Who Experienced at Least One Treatment Related Grade 3-5 AE in Cohort D
NCT02181738 (22) [back to overview]	Number of Participants Who Died in Cohort D
NCT02288897 (6) [back to overview]	Change in Domain Scores From Baseline Using the Patient Reported Skindex-16 Instrument
NCT02288897 (6) [back to overview]	Progression-free Survival (PFS)
NCT02288897 (6) [back to overview]	Overall Survival (OS)
NCT02288897 (6) [back to overview]	Complete Response Rate (CRR)
NCT02288897 (6) [back to overview]	Number of Participants With Adverse Events
NCT02288897 (6) [back to overview]	Duration of Complete Response (DCR)
NCT02505269 (3) [back to overview]	Complete Response Rate
NCT02505269 (3) [back to overview]	Number of Patients With Grade III and IV Adverse Events
NCT02505269 (3) [back to overview]	Overall Response Rate
NCT02545075 (8) [back to overview]	Two-Years Survival Rate
NCT02545075 (8) [back to overview]	Progression Free Survival ( PFS)
NCT02545075 (8) [back to overview]	Best Overall Response Rate ( BORR )
NCT02545075 (8) [back to overview]	Duration of Response ( DoR)
NCT02545075 (8) [back to overview]	Overall Survival (OS)
NCT02545075 (8) [back to overview]	One-Year Survival Rate
NCT02545075 (8) [back to overview]	Duration of Stable Disease ( DoSD )
NCT02545075 (8) [back to overview]	Disease Control Rate ( DCR )
NCT02979522 (57) [back to overview]	Phase 2: Progression-free Survival (PFS)
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF Assessment
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended Dose
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants Who Experienced SAEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants Who Experienced AEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT Visit
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants Receiving Irradiation for HL Following Study Treatment
NCT02979522 (57) [back to overview]	Phase 2: Overall Survival (OS)
NCT02979522 (57) [back to overview]	Phase 2: Event-free Survival (EFS)
NCT02979522 (57) [back to overview]	Phase 2: Duration of Response (DOR)
NCT02979522 (57) [back to overview]	Phase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric Population
NCT02979522 (57) [back to overview]	Phase 1: Percentage of Participants Whose Disease Was PET Positive After 6 Cycles of Protocol Therapy Per IRF Assessment
NCT02979522 (57) [back to overview]	Phase 1: Percentage of Participants Whose Disease Was PET Negative After 2 Cycles of Protocol Therapy Per IRF Assessment
NCT02979522 (57) [back to overview]	Phase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
NCT02979522 (57) [back to overview]	Phase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
NCT02979522 (57) [back to overview]	Phase 1: Percentage of Participants Who Achieved an ORR Per IRF Assessment Per IWG Criteria at EOT Visit
NCT02979522 (57) [back to overview]	Phase 1: Percentage of Participants Who Achieved a PR Per IRF Assessment Per IWG Criteria at EOT Visit
NCT02979522 (57) [back to overview]	Phase 1: Percentage of Participants Who Achieved a CR Per IRF Assessment Per IWG Criteria at EOT Visit
NCT02979522 (57) [back to overview]	Phase 1: Number of ATA Positive and ATA Negative Participants With AEs and SAEs
NCT02979522 (57) [back to overview]	Phase 2: Immune Reconstitution-Change From Baseline Total Immunoglobulin at EOT
NCT02979522 (57) [back to overview]	Phase 2: Immune Reconstitution-Change From Baseline Poliovirus Antibodies Ratio at EOT
NCT02979522 (57) [back to overview]	Phase 2: Immune Reconstitution-Change From Baseline in Total Lymphocyte Count at EOT
NCT02979522 (57) [back to overview]	Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD8+ (CD8+CD45RA-CD197- and CD8+CD45RA-CD197+) Subset of Cells at EOT
NCT02979522 (57) [back to overview]	Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD4+ (CD4+CD45RA-CD197- and CD4+CD45RA+CD197+) Subset of Cells at EOT
NCT02979522 (57) [back to overview]	Phase 2: Immune Reconstitution-Change From Baseline in Tetanus at EOT
NCT02979522 (57) [back to overview]	Phase 2: Immune Reconstitution-Change From Baseline in Peripheral Blood CD34+A at EOT
NCT02979522 (57) [back to overview]	Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin M at the End of Treatment (EOT)
NCT02979522 (57) [back to overview]	Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin A at EOT
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants Who Were ATA Positive, Persistently Positive, or Transiently Positive, and nATA Positive
NCT02979522 (57) [back to overview]	Phase 2: Immune Reconstitution-Change From Baseline in Haemophilus Influenzae B Antibody, IgG at EOT
NCT02979522 (57) [back to overview]	Phase 2: Immune Reconstitution-Change From Baseline Immunoglobulin G Levels at End of Treatment (EOT)
NCT02979522 (57) [back to overview]	Phase 1: Percentage of Participants With Low and High ATA Titer Values
NCT02979522 (57) [back to overview]	Phase 1: Percentage of Participants Who Were Antitherapeutic Antibody (ATA) Positive, Persistently Positive or Transiently Positive, and Neutralizing Antitherapeutic Antibody (nATA) Positive
NCT02979522 (57) [back to overview]	Phase 1: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants
NCT02979522 (57) [back to overview]	Phase 1: Median Time to Reach Cmax (Tmax) of MMAE in Plasma
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants With Low and High ATA Titer Values
NCT02979522 (57) [back to overview]	Phase 2: Time to Onset and Resolution for All Peripheral Neuropathy Events
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants
NCT02979522 (57) [back to overview]	Phase 1: Median Time to Reach Cmax (Tmax) of Brentuximab Vedotin and TAb in Serum
NCT02979522 (57) [back to overview]	Phase 1: Mean Maximum Observed Serum Concentration (Cmax) of Brentuximab Vedotin Total Conjugated and Therapeutic Antibody (TAb)
NCT02979522 (57) [back to overview]	Phase 1: Mean Maximum Observed Plasma Concentration (Cmax) of Monomethyl Auristatin E (MMAE)
NCT02979522 (57) [back to overview]	Phase 2: Number of ATA Positive and ATA Negative Participants With AEs and SAEs
NCT02979522 (57) [back to overview]	Phase 2: Percentage of Participants Who Experienced Peripheral Neuropathy, Regardless of Seriousness, From the First Dose of Protocol Therapy
NCT02979522 (57) [back to overview]	Phase 2: Median Tmax of MMAE in Plasma
NCT02979522 (57) [back to overview]	Phase 2: Median Tmax of Brentuximab Vedotin and TAb in Serum
NCT02979522 (57) [back to overview]	Phase 2: Mean Serum Cmax of Brentuximab Vedotin and TAb
NCT02979522 (57) [back to overview]	Phase 2: Mean Serum AUC0-15d of Brentuximab Vedotin and TAb
NCT02979522 (57) [back to overview]	Phase 2: Mean AUC 0-15 of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
NCT02979522 (57) [back to overview]	Phase 1: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
NCT02979522 (57) [back to overview]	Phase 1: Mean AUC 0-15d of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
NCT02979522 (57) [back to overview]	Phase 1: Mean Area Under the Serum Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of Brentuximab Vedotin and TAb
NCT02979522 (57) [back to overview]	Phase 1: Mean Area Under the Plasma Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of MMAE
NCT02979522 (57) [back to overview]	Phase 2: Mean Plasma Cmax of MMAE
NCT02979522 (57) [back to overview]	Phase 2: Mean Plasma AUC0-15 of MMAE
NCT02979522 (57) [back to overview]	Phase 2: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
NCT03070392 (7) [back to overview]	Quality-of-Life: Change From Baseline in EORTC QLQ-C30 Global Health Status
NCT03070392 (7) [back to overview]	Quality-of-Life: Change From Baseline in EQ-5D,5L Domain Scores
NCT03070392 (7) [back to overview]	Safety: Number of Participants With Treatment Emergent Adverse Events
NCT03070392 (7) [back to overview]	Pharmacokinetics (PK): Tebentafusp Concentration
NCT03070392 (7) [back to overview]	Efficacy: Progression Free Survival (PFS)
NCT03070392 (7) [back to overview]	Efficacy: Overall Survival
NCT03070392 (7) [back to overview]	Quality-of-life: Change From Baseline in EQ-5D Visual Analogue Score (VAS)
NCT03226249 (3) [back to overview]	Complete Response (CR) With Pembrolizumab Treatment Alone
NCT03226249 (3) [back to overview]	Overall Survival at Treatment Completion
NCT03226249 (3) [back to overview]	Progression Free Survival (PFS) at Treatment Completion
NCT03646123 (16) [back to overview]	Subsequent Anticancer Therapy Utilization Rate (Part A)
NCT03646123 (16) [back to overview]	Relative Dose Intensity (Part A)
NCT03646123 (16) [back to overview]	Rate of Dose Reduction and Delays: Vinblastine (Part A)
NCT03646123 (16) [back to overview]	Rate of Dose Reduction and Delays: Doxorubicin (Part A)
NCT03646123 (16) [back to overview]	Rate of Dose Reduction and Delays: Dacarbazine (Part A)
NCT03646123 (16) [back to overview]	Rate of Dose Reduction and Delays: Brentuximab Vedotin (Part A)
NCT03646123 (16) [back to overview]	Incidence of Laboratory Abnormalities (Parts B and C)
NCT03646123 (16) [back to overview]	Febrile Neutropenia (FN) Rate (Part A)
NCT03646123 (16) [back to overview]	Actual Dose Intensity: Doxorubicin, Vinblastine, Dacarbazine (Part A)
NCT03646123 (16) [back to overview]	Primary Refractory Disease Rate (Part A)
NCT03646123 (16) [back to overview]	Physician-reported Progression Free Survival (PFS) (Part A)
NCT03646123 (16) [back to overview]	Overall Response Rate (ORR) at EOT (Parts B and C)
NCT03646123 (16) [back to overview]	Complete Response Rate (Part A)
NCT03646123 (16) [back to overview]	Complete Response (CR) Rate (Parts B and C)
NCT03646123 (16) [back to overview]	Actual Dose Intensity: Brentuximab Vedotin (Part A)
NCT03646123 (16) [back to overview]	Incidence of Adverse Events (Parts B and C)

Failure-free Survival at 5 Years

"Failure-free survival is defined as the time from randomization to the earlier of progression/relapse or death. The 5-year failure-free survival is the probability a patient is failure-free and survives 5 years.~Progression is defined as an increase in size of 25% of the sum of the products of the pretreatment measurements or appearance of new lesions. Significant enlargement of the liver or spleen is evidence of progression. A significant increase in size is defined as > 2.0 cm in distance between costal margin and the inferior margin of either organ.~Relapse is defined as the re-appearance of any clinical evidence of Hodgkin's disease in a patient who has had a complete response. Relapse for partial responders is defined as progressive disease relative to disease status during the partial remission." (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5

Intervention	Proportion of patients (Number)
Arm A (ABVD)	0.74
Arm B (Stanford V)	0.71

Intervention	Participants (Number)
	Abdominal pain/cramping	Acidosis	Acute vascular leak syndrome	Alkaline phosphatase increase	Allergic reaction	Anal incontinence	Anemia	Anorexia	Anxiety/agitation	Apnea	Arrhythmia, NOS	Arthralgia	Bilirubin increase	Bone pain	CPK increase	Cardiovascular-other	Catheter related infection	Cerebrovascular ischemia	Colitis	Confusion	Constipation/bowel obstruction	Cranial neuropathy	Creatinine increase	Dehydration	Delusions	Depression	Diarrhea without colostomy	Dizziness/light headedness	Dizziness/vertigo, NOS	Double vision	Dyspnea	Eryth/rash/eruption/desq, NOS	Esophagitis/dysphagia	Eye-other	Fatigue/malaise/lethargy	Febrile neutropenia	Fever without neutropenia	Fever, NOS	Hallucinations	Headache	Hemorrhage w/ 3-4 thrombocyt	Hyperglycemia	Hyperkalemia	Hypermagnesemia	Hypertension	Hypertriglyceridemia	Hypocalcemia	Hypokalemia	Hypomagnesemia	Hyponatremia	Hypophosphatemia	Hypotension	Hypoxia	Infection w/o 3-4 neutropenia	Infection with 3-4 neutropenia	Infection, unk ANC	Insomnia	Leukopenia	Lipase increase	Local injection site reaction	Lymphopenia	Mood/consciousness change, NOS	Muscle weakness (not neuro)	Myalgia	Nausea	Neutropenia/granulocytopenia	PRBC transfusion	Pancreatitis	Personality/behavioral change	Petechiae/purpura	Platelet transfusion	Pruritus	Rash/desquamation	Renal failure	Reportable adverse event, NOS	Respiratory infect w/ neutrop	Rigors/chills	SGOT (AST) increase	SGPT (ALT) increase	Seizures	Sensory neuropathy	Stomatitis/pharyngitis	Surgery-wound infection	Syncope	Thrombocytopenia	Thrombosis/embolism	Typhlitis	Vertigo	Vomiting	Weakness (motor neuropathy)	Weight loss
Biochemotherapy	1	1	1	3	0	1	8	9	5	0	0	3	1	4	1	0	2	0	2	3	4	0	4	7	1	4	6	1	1	1	2	3	2	0	22	9	5	1	1	5	1	3	1	1	1	0	18	7	5	6	4	16	1	3	9	2	1	38	2	0	2	1	1	4	51	61	3	1	0	1	5	3	10	1	1	2	1	7	8	2	2	1	0	0	50	1	1	0	37	2	0
Interferon	1	0	0	0	1	0	0	1	4	1	2	4	0	0	0	1	0	1	0	2	0	1	0	1	0	14	2	2	0	0	1	1	0	1	38	1	1	0	1	9	0	2	0	1	0	1	0	1	0	0	0	0	0	0	0	1	1	12	1	1	0	0	0	7	10	25	0	0	1	0	0	1	4	0	1	0	2	18	32	0	0	0	3	2	1	1	0	1	9	1	3

Intervention	participants (Number)
	Not Compliant	Compliant
Cohort A (Chemotherapy, Radiation, Thalidomide, Surgery)	5	10
Cohort B (Thalidomide, Radiation, Surgery)	2	5

Intervention	participants (Number)
	CR	PR	SD	PD	Not Evaluated
Placebo + Dacarbazine	0	6	22	21	1
Sorafenib (Nexavar, BAY43-9006) + Dacarbazine	0	12	24	15	0

Intervention	participants (Number)
	missing	better	no change	worse
Placebo + Dacarbazine	1	2	34	13
Sorafenib (Nexavar, BAY43-9006) + Dacarbazine	1	1	34	15

Intervention	scores on a scale (Mean)
Sorafenib (Nexavar, BAY43-9006) + Dacarbazine	0.558
Placebo + Dacarbazine	-4.425

Intervention	scores on a scale (Mean)
Sorafenib (Nexavar, BAY43-9006) + Dacarbazine	-2.00
Placebo + Dacarbazine	-8.146

Intervention	scores on a scale (Mean)
Sorafenib (Nexavar, BAY43-9006) + Dacarbazine	-0.015
Placebo + Dacarbazine	-0.019

Intervention	scores on a scale (Mean)
Sorafenib (Nexavar, BAY43-9006) + Dacarbazine	-0.004
Placebo + Dacarbazine	-0.008

Intervention	days (Mean)
Arm 1- PI-88 Plus Dacarbazine	117.0
Arm 2- Dacarbazine Alone	140.6

Intervention	Participants (Count of Participants)
	End of cycle 2_Non-progressed	End of cycle 2_progressed	End of cycle 4_Non-progressed	End of cycle 4_progressed
Arm 1- PI-88 Plus Dacarbazine	33	32	24	41
Arm 2- Dacarbazine Alone	35	30	31	33

Intervention	days (Median)
Arm 1- PI-88 Plus Dacarbazine	304.00
Arm 2- Dacarbazine Alone	416.00

Intervention	mL/day/kg (Mean)
Intetumumab 3 mg/kg [Phase 1 (Part 1)]	11.85
Intetumumab 5 mg/kg [Phase 1 (Part 1)]	9.96
Intetumumab 10 mg/kg [Phase 1 (Part 1)]	6.79

Intervention	Days (Median)
Dacarbazine + Placebo [Phase 2]	135.0
Intetumumab 5 mg/kg [Phase 2]	226.0
Intetumumab 10 mg/kg [Phase 2]	194.0
Dacarbazine + Intetumumab 10 mg/kg [Phase 2]	170.0

Intervention	Days (Median)
Dacarbazine + Placebo [Phase 2]	54.0
Intetumumab 5 mg/kg [Phase 2]	42.0
Intetumumab 10 mg/kg [Phase 2]	42.0
Dacarbazine + Intetumumab 10 mg/kg [Phase 2]	75.0

Intervention	Percentage of Participants (Number)
Dacarbazine + Placebo [Phase 2]	32.3
Intetumumab 5 mg/kg [Phase 2]	25.8
Intetumumab 10 mg/kg [Phase 2]	24.2
Dacarbazine + Intetumumab 10 mg/kg [Phase 2]	53.3

Intervention	Percentage of Participants (Number)
Dacarbazine + Placebo [Phase 2]	41.9
Intetumumab 5 mg/kg [Phase 2]	25.8
Intetumumab 10 mg/kg [Phase 2]	30.3
Dacarbazine + Intetumumab 10 mg/kg [Phase 2]	56.7

Intervention	Days (Median)
Dacarbazine + Placebo [Phase 2]	233.0
Intetumumab 5 mg/kg [Phase 2]	298.0
Intetumumab 10 mg/kg [Phase 2]	426.0
Dacarbazine + Intetumumab 10 mg/kg [Phase 2]	333.5

Intervention	mcg/mL (Mean)
Dacarbazine + Placebo [Phase 2]	NA
Intetumumab 5 mg/kg [Phase 2]	131.18
Intetumumab 10 mg/kg [Phase 2]	240.81
Dacarbazine + Intetumumab 10 mg/kg [Phase 2]	219.47

Intervention	Microgram per milliliter (mcg/mL) (Mean)
Dacarbazine + Intetumumab 5 mg/kg [Phase 1 (Part 2)]	118.47
Dacarbazine + Intetumumab 10 mg/kg [Phase 1 (Part 2)]	220.87

Intervention	Microgram per milliliter (mcg/mL) (Mean)
Intetumumab 3 mg/kg [Phase 1 (Part 1)]	94.44
Intetumumab 5 mg/kg [Phase 1 (Part 1)]	199.45
Intetumumab 10 mg/kg [Phase 1 (Part 1)]	306.86

dacarbazine

Description

Cross-References

Synonyms (238)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (4)

Protein Targets (35)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (71)

Molecular Functions (32)

Ceullar Components (22)

Bioassays (257)

Research

Studies (7,211)

Market Indicators

Research Demand Index: 65.30

Study Types

Clinical Trials (175)

Trial Overview

Trial Outcomes

Failure-free Survival at 5 Years

5-year Overall Survival

Incidence of Second Cancers

5-year Overall Survival

5-year Relapse-Free Survival

Toxicity

Treatment Delivery With Compliance Defined as Receiving at Least 95% of the Pre-operative Protocol Dose of RT, All 3 Cycles of MAID (if Applicable), and Receive Thalidomide on 75% of the Days During Radiation

Duration of Objective Response

Objective Response Rate in Subjects With Measurable Lesions

Overall Survival

Progression Free Survival

Number of Participants in Tumor Response Categories

Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to the Visit When the Best Tumor Response Was Noted

Time to Progression (TTP)

Progression Free Survival (PFS)

Overall Survival (OS)

Duration of Response (DOR)

Change of European Quality of Life Visual Analogue Scale (EQ-VAS) Score From Baseline to the Visit at Which Best Response Was First Noted

Change of European Quality of Life Visual Analogue Scale (EQ-VAS) Score From Baseline to the End of Treatment

Change of European Quality of Life 5-dimensional (EQ-5D) Questionnaire Index Score From Baseline to the End of Treatment

Change of European Quality of Life 5-dimensional (EQ-5D) Questionnaire Index Score From Baseline to the Visit at Which Best Response Was First Noted

Duration of Response

Non-progression Rate

Time to Progression

Survival

Total Clearance (CL) of Intetumumab After Intravenous Administration - Phase 1 (Part 1)

Time to Worsening in Eastern Cooperative Oncology Group (ECOG) Performance Status - Phase 2

Progression-Free Survival (PFS) - Phase 2

Percentage of Participants Who Achieved Stable Disease (SD) - Phase 2

Percentage of Participants Who Achieved CR - Phase 2

Percentage of Participants Who Achieved a Best Overall Tumor Response as Complete Response (CR) or Partial Response (PR) - Phase 2

Percentage of Participants Who Achieved a Best Overall Response as CR, PR, or SD - Phase 2

Overall Survival (OS) - Phase 2

Number of Participants With Dose Limiting Toxicities (DLTs) - Phase 1

Maximum Observed Serum Concentration (Cmax) of Intetumumab - Phase 2

Maximum Observed Serum Concentration (Cmax) of Intetumumab - Phase 1 (Part 2)

Maximum Observed Serum Concentration (Cmax) of Intetumumab - Phase 1 (Part 1)

Half-life of Intetumumab - Phase 1 (Part 2)

Half-life of Intetumumab - Phase 1 (Part 1)

Area Under the Serum Concentration Versus Time Curve (AUC) of Intetumumab - Phase 1 (Part 2)

Area Under the Serum Concentration Versus Time Curve (AUC) of Intetumumab - Phase 1 (Part 1)

Area Under the Concentration Versus Time Curve Between Zero to Infinite Time (AUCinf) of Intetumumab - Phase 1 (Part 1)

Change From Baseline in Functional Assessment of Cancer Therapy-Melanoma Subscale (FACT-MS) Score - Phase 2

Volume of Distribution (Vz) of Intetumumab - Phase 1 (Part 1)

Change From Baseline in Brief Pain Inventory (BPI) Score - Phase 2

Volume of Distribution (Vz) of Intetumumab - Phase 1 (Part 2)

Total Clearance (CL) of Intetumumab After Intravenous Administration - Phase 1 (Part 2)

Number of Participants With Grade 2-3 and Grade 3-4 Immune-related Adverse Events (irAEs) With Resolution Resolved

Time to Resolution of Grade 2-3, Grade 3-4 Immune-related Adverse Events (irAEs)

Survival Rate at 1 Year, 18 Months, 2 Years, and 3 Years

Progression-free Survival (PFS) Rate Truncated at Week 12

Number of Participants With Adverse Events (AEs), Drug-related AEs, AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Hypersensitivity, Immune-related AEs/SAEs, and Inflammatory AEs/SAEs

Intervention	Days (Mean)
Dacarbazine + Intetumumab 5 mg/kg [Phase 1 (Part 2)]	2.41
Dacarbazine + Intetumumab 10 mg/kg [Phase 1 (Part 2)]	2.36

Intervention	Days (Mean)
Intetumumab 3 mg/kg [Phase 1 (Part 1)]	2.03
Intetumumab 5 mg/kg [Phase 1 (Part 1)]	2.13
Intetumumab 10 mg/kg [Phase 1 (Part 1)]	5.33

Intervention	mcg*day/mL (Mean)
Dacarbazine + Intetumumab 5 mg/kg [Phase 1 (Part 2)]	368.74
Dacarbazine + Intetumumab 10 mg/kg [Phase 1 (Part 2)]	963.17

Intervention	mcg*day/mL (Mean)
Intetumumab 3 mg/kg [Phase 1 (Part 1)]	257.55
Intetumumab 5 mg/kg [Phase 1 (Part 1)]	503.71
Intetumumab 10 mg/kg [Phase 1 (Part 1)]	1479.07

Intervention	mcg*day/mL (Mean)
Intetumumab 3 mg/kg [Phase 1 (Part 1)]	257.80
Intetumumab 5 mg/kg [Phase 1 (Part 1)]	503.88
Intetumumab 10 mg/kg [Phase 1 (Part 1)]	1591.54

Intervention	Units on a scale (Mean)
	Baseline (Cycle 1) (n=23, 24, 26, 26)	Change at Cycle 2 (pre-dose) (n=20, 24, 22, 23)	Change at Cycle 3 (pre-dose) (n = 19, 11, 5, 14)	Change at final visit (n = 15, 20, 20, 17)
Dacarbazine + Intetumumab 10 mg/kg [Phase 2]	53.3	-2.0	-0.1	-3.2
Dacarbazine + Placebo [Phase 2]	53.8	-2.2	-2.6	-5.7
Intetumumab 10 mg/kg [Phase 2]	55.3	-2.9	0.2	-2.2
Intetumumab 5 mg/kg [Phase 2]	55.6	-1.9	-1.3	-5.5

Intervention	mL/kg (Mean)
Intetumumab 3 mg/kg [Phase 1 (Part 1)]	34.69
Intetumumab 5 mg/kg [Phase 1 (Part 1)]	30.63
Intetumumab 10 mg/kg [Phase 1 (Part 1)]	50.80

Intervention	Units on a scale (Mean)
	Baseline (Cycle 1) (n=23, 23, 27, 25)	Change at Cycle 2 (pre-dose) (n=20, 22, 22, 22)	Change at Cycle 3 (pre-dose) (n = 19, 10, 6, 14)	Change at final visit (n = 15, 20, 20, 16)
Dacarbazine + Intetumumab 10 mg/kg [Phase 2]	2.2	-0.3	-0.8	0.3
Dacarbazine + Placebo [Phase 2]	1.3	0.9	0.5	1.4
Intetumumab 10 mg/kg [Phase 2]	0.9	0.5	0.0	1.0
Intetumumab 5 mg/kg [Phase 2]	2.0	0.0	0.5	0.8

Intervention	mL/kg (Mean)
Dacarbazine + Intetumumab 5 mg/kg [Phase 1 (Part 2)]	47.38
Dacarbazine + Intetumumab 10 mg/kg [Phase 1 (Part 2)]	35.18

Intervention	mL/day/kg (Mean)
Dacarbazine + Intetumumab 5 mg/kg [Phase 1 (Part 2)]	13.44
Dacarbazine + Intetumumab 10 mg/kg [Phase 1 (Part 2)]	10.34